Methylpyrazole derivatives as RET inhibitors

By developing methylpyrazole derivative compounds, the problems of low selectivity and drug resistance mutations of existing RET inhibitors in clinical applications have been solved, and high selectivity inhibition and drug resistance to RET have been achieved, which has improved RET Drive the therapeutic effect of cancer.

CN113135896BActive Publication Date: 2024-12-06CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110061785.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-01-18
Filing Date
2021-01-18
Publication Date
2024-12-06
Estimated Expiration
2041-01-18

AI Technical Summary

Technical Problem

Existing RET inhibitors have low selectivity and drug resistance mutation problems in clinical applications, resulting in poor efficacy in RET-driven cancer treatment, and side effects and drug resistance reduce the effectiveness of the drug.

Method used

A new class of methylpyrazole derivative compounds and their stereoisomers and their pharmaceutically acceptable salts were developed as RET inhibitors designed to improve affinity for RET and overcome drug resistance by specific chemical structures. mutation.

Benefits of technology

These compounds show high selectivity inhibitory effects on RET, effectively overcoming the drug resistance problems caused by mutations in RET gatekeeper and solvent front-domain, and improving the therapeutic effect and drug tolerance of RET-driven cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113135896B_ABST
    Figure CN113135896B_ABST
Patent Text Reader

Abstract

The present application relates to methylpyrazole derivatives as RET inhibitors, and specifically to compounds represented by formula (I), stereoisomers thereof, and pharmaceutically acceptable salts thereof, preparation methods thereof, and pharmaceutical compositions thereof. The compounds of formula (I) described in the present application can be used to prevent or treat diseases mediated by abnormal RET activity. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to methylpyrazole derivatives as RET inhibitors, and specifically to compounds represented by formula (I), stereoisomers thereof and pharmaceutically acceptable salts thereof, preparation methods thereof, pharmaceutical compositions thereof and use thereof in the preparation of drugs for preventing or treating diseases mediated by abnormal RET activity. Background Art

[0002] RET (Rearranged during Transfection) is a membrane receptor tyrosine kinase encoded by the proto-oncogene RET gene located on chromosome 10. Its ligands are GNDF family proteins (GFLs), such as GDNF, NTRN, ARTN and PSPN. However, unlike other receptor tyrosine kinases, RET does not bind directly to its ligands. GDNF, NTRN, ARTN and PSPN bind to the co-receptor GFRα of RET to form the GFL-GFRα complex, which mediates the dimerization of RET and the autophosphorylation of tyrosine residues in the intracellular domain of RET, activates the cascade reaction of downstream pathways such as MAPK, PI3K, JAK-STAT, PKA and PKC, and ultimately regulates the proliferation and differentiation levels of cells. Therefore, abnormal upregulation of RET activity will cause diseases such as cancer.

[0003] RET can be abnormally activated through two pathways: point mutation and gene fusion. Point mutations at the kinase end of the RET intracellular domain increase the catalytic phosphorylation activity of RET, such as E768D, L790F, V804M, etc.; point mutations in the extracellular domain can promote the formation of intermolecular disulfide bonds, causing ligand-independent dimerization of RET, thereby leading to autophosphorylation of RET. Gene fusion of RET can easily lead to the fusion of the RET kinase end with the partner protein with a dimer end to form a hybrid protein with RET catalytic activity, leading to RET ligand-independent dimerization and stimulating RET catalytic activity. RET fusion genes that have been discovered so far include RET-CCDC6, RET-PRKAR1A, RET-GOLGA5, and RET-RFG9. Clinical studies have shown that many cancers, such as thyroid cancer, non-small cell lung cancer, colon cancer and breast cancer, are driven by RET. Among them, RET-driven papillary thyroid cancer, medullary thyroid cancer and non-small cell lung cancer account for a relatively high proportion, accounting for 11%, 60% and 2% respectively.

[0004] Although first-generation RET inhibitors such as vandetanib and cabozantinib can inhibit RET activity at low nM concentrations, they can also effectively inhibit a variety of non-RET kinases, and their inhibitory activity on non-RET kinases is better than that on RET. Therefore, this type of drug exhibits dose-dependent off-target-related side effects in clinical trials, such as hypertension, hand-foot syndrome, and proteinuria associated with VEGFR inhibition; rash associated with BRAF inhibition; hypopigmentation associated with KIT inhibition; diarrhea associated with EGFR inhibition, etc. The incidence of reduced doses due to dose tolerance issues for this type of drug is 23%-79%, and the incidence of treatment discontinuation is 6%-21%. In addition, when the first-generation RET inhibitors are used to treat RET-driven NSCLC, there are still problems with low overall response rate and short median progression-free survival, and the benefits of patients are far less than those of NSCLC patients with EGFR mutations, ALK and ROS1 gene fusions, etc. Like other targeted drugs, the emergence of drug-resistant mutations greatly reduces the efficacy of first-generation RET inhibitors, leading to rapid progression of cancer. Mutations in the RET gatekeeper (such as V804L and V804M) are the most important drug-resistant mutations. The mutation of Val to Leu or Met with a larger side chain increases the steric hindrance of the hydrophobic fragment of the RET inhibitor extending into the hydrophobic pocket behind the ATP binding site, reducing the affinity with the inhibitor, thus leading to the generation of drug resistance. Another major type of drug-resistant mutation is the solvent-front mutation G810R and G810A. This type of mutation is similar to ALKG1202R, ROS1G2032R, NTRK1G595R and NTRK3G623R. The mutation of Gl810 in the solvent region of RET is a larger amino acid residue, which produces a steric hindrance with the solvent region fragment of the drug and reduces affinity.

[0005] Therefore, the clinical use of first-generation RET inhibitors is subject to certain restrictions. However, no second-generation RET inhibitors with high selectivity and effectiveness against drug-resistant mutations have been approved for marketing, so there is still a need to develop excellent second-generation RET inhibitors with high selectivity and effectiveness against drug-resistant mutations. Summary of the invention

[0006] The compound represented by formula (I), its stereoisomers and pharmaceutically acceptable salts thereof,

[0007]

[0008] in,

[0009] X is selected from NH;

[0010] U, V, and W are each independently selected from C(R 1 ) or N;

[0011] Q is selected from C(R 2 ) or N;

[0012] Ring A is a 6- to 8-membered monocyclic heterocyclic ring, a 6- to 10-membered bridged heterocyclic ring, a benzene ring, a naphthalene ring, a 7- to 12-membered fused ring or fused heterocyclic ring, or a 7- to 12-membered fused heteroaromatic ring, wherein the monocyclic heterocyclic ring contains at least one N atom;

[0013] Ring B is a benzene ring, a naphthalene ring, a 5-6 membered heteroaromatic ring, a 7-12 membered fused heteroaromatic ring or a 7-12 membered fused heteroaromatic ring;

[0014] -L 1 - is selected from a single bond, -O-, -S-, -C(O)-, -C(S)-, -S(O)2- or -N(R A0 )-;

[0015] -L 2 -Selected from -O-, -S-, -C(S)-, -S(O)2-, -(CR A2 R B2 ) q -、-N(R A1 )-、-C(O)-N(R A1 )-、-N(R A1 )-C(S)-、-(CR A2 R B2 ) q -C(S)-、-(CR A2 R B2 ) q -S(O)2-、-C(O)-N(R A1 )-(CR A2 R B2 ) q -、-N(R A1 )-C(O)-(CR A2 R B2 ) q -、-C(S)-N(R A1 )-(CR A2 R B2 ) q -、-N(R A1 )-C(S)-(CR A2 R B2 ) q -、-S(O)2-N(R A1 )-(CR A2 R B2 ) q -、-N(R A1 )-S(O)2-(CR A2 R B2 ) q -、-C(O)-N(RA1 )-C(O)-, -N(R A1 )-C(O)-N(R A1 )-, -N(R A1 )-C(O)-N(R A1 )-(CR A2 R B2 ) q -, -N(R A1 )-C(O)-(CR A2 R B2 ) q -N(R A1 )-, -N(R A1 )-C(O)-(CR A2 R B2 ) q -C(O)-, -N(R A1 )-C(O)-N(R A1 )-C(O)-, -C(O)-N(R A1 )-C(O)-(CR A2 R B2 ) q -, -C(S)-N(R A1 )-C(O)-(CR A2 R B2 ) q -, -C(O)-N(R A1 )-(CR A2 R B2 ) q -C(O)-, -C(S)-N(R A1 )-(CR A2 R B2 ) q -C(O)-, -N(R A1 )-C(O)-(CR A2 R B2 ) q -C(O)-N(R A1 )-, -C(O)-N(R A1 )-(CR A2 R B2 ) q -C(O)-N(R A1 )- or -C(O)-N(R A1 )-(CR A2 R B2 ) q -N(R A1 )-C(O)-;

[0016] R A0 is selected from C 1-6 alkyl, C3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocycloalkyl may be optionally substituted by one, two or three substituents selected from halogen, hydroxy, cyano or amino;

[0017] R A1 Selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocycloalkyl may be optionally substituted by one, two or three substituents selected from halogen, hydroxy, cyano or amino;

[0018] R A2 and R B2 Each is independently selected from H, halogen, hydroxyl, cyano, amino, COOH, nitro, C 1-6 Alkyl, C 1-6 Alkyl-NH-, C 1-6 Alkoxy, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl and 3-6 membered heterocycloalkyl may be optionally substituted by one, two or three substituents selected from halogen, hydroxy, cyano or amino; or R A2 , R B2 Together with the C to which it is attached, it forms a three-membered, four-membered or five-membered saturated monocyclic or heterocyclic ring without or with a substituent, wherein the heterocyclic ring includes 1 or 2 heteroatoms selected from O or N;

[0019] R 1 , R 2 and R 5 Each is independently selected from H, halogen, hydroxyl, amino, cyano, COOH, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, methoxy, C 3-6 Alkoxy, 3- to 6-membered cycloalkyl or 3- to 6-membered heterocycloalkyl; or R 1 , R 2 The C atoms connected thereto together form a 3- to 6-membered monocyclic ring or a 3- to 6-membered heterocyclic ring; the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, methoxy, C 3-6Alkoxy, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, 3-6 membered monocyclic ring and 3-6 membered monocyclic heterocyclic ring may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino;

[0020] R 3 Selected from halogen, hydroxyl, amino, cyano, COOH, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, 3-6 membered cycloalkyl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 The alkoxy and 3-6 membered cycloalkyl groups may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino;

[0021] R 4 Selected from H, halogen, hydroxyl, amino, cyano, COOH, nitro, C 2-6 Alkenyl, C 2-6 Alkynyl, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, pyrazolyl, 6-10 membered bridged heterocycle, 3-6 membered heterocycloalkyl-C 1-6 Alkylene; said C 2-6 Alkenyl, C 2-6 Alkynyl, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, 6-10 membered bridged heterocycle, 3-6 membered heterocycloalkyl-C 1-6 The alkylene group may be optionally replaced by one, two or three selected from R 6 The pyrazolyl group is substituted by one, two or three substituents selected from halogen, hydroxyl, amino, cyano, COOH, nitro;

[0022] R 6 independently halogen, hydroxyl, amino, cyano, COOH, nitro, C 1-6 Alkyl, C 2-6 Alkynyl, C 1-6 Alkyl-NH-, N,N-di(C 1-6 Alkyl)-N-, C 1-6 Alkyl-O-, C 1-6 Alkyl-S-, C 1-6 Alkyl-C(O)-, the C 1-6 Alkyl, C 2-6 Alkynyl, C 1-6 Alkyl-NH-, N,N-di(C 1-6 Alkyl)-N-, C 1-6 Alkyl-O-, C 1-6 Alkyl-S- and C 1-6Alkyl-C(O)- may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino;

[0023] n is 0 or 1;

[0024] p is 1, 2, or 3;

[0025] q is 1, 2, 3, 4, or 5;

[0026] When ring A is a piperidine ring, L 2 Not -C(O)-N(R A1 )-(CR A2 R B2 ) q - and -N(R A1 )-C(O)-(CR A2 R B2 ) q -;

[0027] When only one of U, V, and W is N, Q is C(CH3), and ring A is a piperazine ring, n is not 0;

[0028] And this application does not include the following specific compounds, their stereoisomers and pharmaceutically acceptable salts:

[0029]

[0030] In some embodiments, R 1 Each is independently selected from H, halogen, hydroxyl, amino, cyano, COOH, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, methoxy, C 3-6 Alkoxy, 3-6 membered cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, methoxy, C 3-6 The alkoxy, 3- to 6-membered cycloalkyl and 3- to 6-membered heterocycloalkyl groups may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0031] In some embodiments, R 1 are each independently selected from H, halogen or C 1-6 Alkyl, the C 1-6 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino; in some embodiments, R 1 are each independently selected from H, halogen or C 1-4 Alkyl, the C 1-4The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0032] In some embodiments, R 1 Each is independently selected from H or halogen.

[0033] In some embodiments, R 1 For H.

[0034] In some embodiments, U, V, and W are all CH.

[0035] In some embodiments, at least one of U, V, and W is selected from N.

[0036] In some embodiments, U is CH, V is N, and W is N.

[0037] In some embodiments, U is CH, V is CH, and W is N.

[0038] In some embodiments, U is CH, V is N, and W is CH.

[0039] In some embodiments, U is N, V ​​is CH, and W is N.

[0040] In some embodiments, Q is C(R 2 ).

[0041] In some embodiments, R 2 Selected from H, halogen, hydroxyl, amino, cyano, COOH, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, methoxy, C 3-6 Alkoxy, 3-6 membered cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, methoxy, C 3-6 The alkoxy, 3- to 6-membered cycloalkyl and 3- to 6-membered heterocycloalkyl groups may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0042] In some embodiments, R 2 Select from H or C 1-6 Alkyl, the C 1-6 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino; in some embodiments, R 2 Select from H or C 1-4 Alkyl, the C 1-4 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0043] In some embodiments, R 2 is selected from H, methyl, ethyl, isopropyl or tert-butyl, said methyl, ethyl, isopropyl or tert-butyl being optionally substituted with one, two or three substituents selected from halogen.

[0044] In some embodiments, R 2 is selected from H or methyl, said methyl being optionally substituted with one, two or three substituents selected from halogen.

[0045] In some embodiments, R 2 is selected from H, methyl, difluoromethyl or trifluoromethyl.

[0046] In some embodiments, R 2 Selected from methyl.

[0047] In some embodiments, U is CH, V is N, W is N, and Q is C(R 2 ).

[0048] In some embodiments, U is CH, V is N, W is N, and Q is C(CH3).

[0049] In some embodiments, U is CH, V is CH, W is N, and Q is N.

[0050] In some embodiments, R 1 , R 2 The C atoms connected to it together form a 5-membered monocyclic ring.

[0051] In some embodiments, R A0 Independently selected from C 1-6 Alkyl, the C 1-6 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino; in some embodiments, R A0 Independently selected from C 1-4 Alkyl, the C 1-4 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0052] In some embodiments, R A0 Independently selected from methyl, ethyl, isopropyl or tert-butyl.

[0053] In some embodiments, R A0 are independently selected from methyl.

[0054] In some embodiments, L 1 is selected from a single bond, -O-, -S-, -C(O)- or -N(R A0)-; In some embodiments, L 1 Selected from a single bond, -C(O)- or -N(R A0 )-.

[0055] In some embodiments, L 1 is selected from a single bond, -C(O)-, -N(CH3)-, -N(CH2CH3)- or -N(CH(CH3)2)-.

[0056] In some embodiments, L 1 Selected from a single bond, -C(O)- or -N(CH3)-.

[0057] In some embodiments, L 1 Select from single bonds.

[0058] In some embodiments, ring A is a 6-8 membered monocyclic heterocycle, a 6-10 membered bridged heterocycle, a benzene ring, an 8-10 membered fused ring or a fused heterocycle, and the monocyclic heterocycle contains at least one N atom; in some embodiments, ring A is a 6-8 membered saturated monocyclic heterocycle, a 6-10 membered saturated bridged heterocycle, an 8-10 membered fused ring or a fused heterocycle, a benzene ring, and the monocyclic heterocycle contains at least one N atom.

[0059] In some embodiments, Ring A is In some embodiments, Ring A is

[0060] In some embodiments, Ring A is

[0061] In some embodiments, for

[0062] In some embodiments, for

[0063] In some embodiments, for

[0064] In some embodiments, R 3 Independently selected from halogen, hydroxy, amino, or C 1-6 Alkyl, the C 1-6 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino; in some embodiments, R 3 independently selected from halogen, or C 1-4 Alkyl, the C 1-4 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0065] In some embodiments, R 3 Independently selected from F, methyl, ethyl, isopropyl or tert-butyl.

[0066] In some embodiments, R 3 Independently selected from F, or methyl.

[0067] In some embodiments, n is 0.

[0068] In some embodiments, -L 2 -Selected from -O-, -S-, -C(S)-, -S(O)2-, -(CR A2 R B2 ) q -、-N(R A1 )-、-C(O)-N(R A1 )-、-N(R A1 )-C(S)-、-(CR A2 R B2 ) q -C(S)-、-(CR A2 R B2 ) q -S(O)2-、-C(O)-N(R A1 )-(CR A2 R B2 ) q -、-N(R A1 )-C(O)-(CR A2 R B2 ) q -、-C(S)-N(R A1 )-(CR A2 R B2 ) q -、-N(R A1 )-C(S)-(CR A2 R B2 ) q -、-S(O)2-N(R A1 )-(CR A2 R B2 ) q -、-N(R A1 )-S(O)2-(CR A2 R B2 ) q-, -C(O)-N(R A1 )-C(O)-, -N(R A1 )-C(O)-N(R A1 )-(CR A2 R B2 ) q -, -N(R A1 )-C(O)-(CR A2 R B2 ) q -N(R A1 )-, -N(R A1 )-C(O)-(CR A2 R B2 ) q -C(O)-, -N(R A1 )-C(O)-N(R A1 )-C(O)-, -C(O)-N(R A1 )-C(O)-(CR A2 R B2 ) q -, -C(S)-N(R A1 )-C(O)-(CR A2 R B2 ) q -, -C(O)-N(R A1 )-(CR A2 R B2 ) q -C(O)-, -C(S)-N(R A1 )-(CR A2 R B2 ) q -C(O)-, -N(R A1 )-C(O)-(CR A2 R B2 ) q -C(O)-N(R A1 )-, -C(O)-N(R A1 )-(CR A2 R B2 ) q -C(O)-N(R A1 )- or -C(O)-N(R A1 )-(CR A2 R B2 ) q -N(R A1 )-C(O)-.

[0069] In some embodiments, L 2 is selected from -O-, -S-, -(CR A2 R B2 )q -, -N(R A1 )-, -C(O)-N(R A1 )-, -C(S)-N(R A1 )-(CR A2 R B2 ) q -, -N(R A1 )-C(S)-(CR A2 R B2 ) q -, -C(O)-N(R A1 )-(CR A2 R B2 ) q -, -N(R A1 )-C(O)-(CR A2 R B2 ) q -, -S(O)2-N(R A1 )-(CR A2 R B2 ) q -, -N(R A1 )-S(O)2-(CR A2 R B2 ) q -, -N(R A1 )-C(O)-N(R A1 )-, -N(R A1 )-C(O)-N(R A1 )-(CR A2 R B2 ) q - or -N(R A1 )-C(O)-(CR A2 R B2 ) q -C(O)-N(R A1 )-;

[0070] In some embodiments, L 2 is selected from -O-, -C(O)-N(R A1 )-, -C(O)-N(R A1 )-(CR A2 R B2 ) q -, -S(O)2-N(R A1 )-(CR A2 R B2 ) q -, -N(R A1 )-C(O)-(CR A2 R B2 ) q-、-C(S)-N(R A1 )-(CR A2 R B2 ) q -、-N(R A1 )-C(O)-N(R A1 )-、-N(R A1 )-C(O)-N(R A1 )-(CR A2 R B2 ) q -or-N(R A1 )-C(O)-(CR A2 R B2 ) q -C(O)-N(R A1 )-;

[0071] In some embodiments, L 2 Selected from -O-, -C(O)-N(R A1 )-、-C(O)-N(R A1 )-(CR A2 R B2 )-、-S(O)2-N(R A1 )-(CR A2 R B2 )-、-N(R A1 )-C(O)-(CR A2 R B2 )-、-C(S)-N(R A1 )-(CR A2 R B2 )-、-N(R A1 )-C(O)-N(R A1 )-(CR A2 R B2 )-or-N(R A1 )-C(O)-(CR A2 R B2 )-C(O)-N(R A1 )-.

[0072] In some embodiments, R A1 Independently selected from H or C 1-6 Alkyl, the C 1-6 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino; in some embodiments, R A1 Independently selected from H or C 1-4 Alkyl, the C 1-4 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0073] In some embodiments, R A1 Independently selected from H, methyl, ethyl, isopropyl or tert-butyl.

[0074] In some embodiments, R A1 Independently selected from H or methyl.

[0075] In some embodiments, R A1 Independently selected from H.

[0076] In some embodiments, R A2 and R B2 Each is independently selected from H, halogen, hydroxyl, C 1-6 Alkyl or C 1-6 Alkyl-NH-, the C 1-6 Alkyl and C 1-6 The alkyl-NH- may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino, or R A2 , R B2 Together with the C to which it is connected, it forms a three-membered, four-membered or five-membered saturated monocyclic or heterocyclic ring without or with a substituent, wherein the heterocyclic ring includes 1 or 2 heteroatoms selected from O or N; in some embodiments, R A2 and R B2 Each independently selected from H, C 1-4 Alkyl or C 1-4 Alkyl-NH-, the C 1-4 Alkyl and C 1-4 The alkyl-NH- may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino, or R A2 , R B2 Together with the C to which it is attached, it forms a three-membered saturated monocyclic or heterocyclic ring without or with a substituent, wherein the heterocyclic ring includes 1 or 2 heteroatoms selected from O or N.

[0077] In some embodiments, R A2 and R B2 Each is independently selected from H, methyl, ethyl or methyl-NH-.

[0078] In some embodiments, R A2 and R B2 Each is independently selected from H or methyl.

[0079] In some embodiments, R A2 and R B2 Both are H.

[0080] In some embodiments, R A2 Selected from methyl, R B2 is selected from methyl, or RA2 , R B2 Together with the C to which it is attached, it forms a cyclopropane ring.

[0081] In some embodiments, R A2 Selected from H, R B2 is selected from methyl; or, R A2 Selected from methyl, R B2 Selected from H.

[0082] In some embodiments, L 2 Selected from -O-, -CH2-, -C(O)-NH-, -C(O)-NH-CH(CH3)-, -C(O)-NH-CH2-, -NH-C(O)-NH-, -S(O)2-NH-CH(CH3)-, -NH-C(O)-CH(CH3)-, -C(S)-NH-CH(CH3)-, -NH-C(O)-NH-CH(CH3)-, -N(CH3)-C(O)-NH-CH(CH3)- or

[0083] In some embodiments, L 2 Selected from -O-, -C(O)-NH-, -C(O)-NH-CH(CH3)-, -C(O)-NH-CH2-, -NH-C(O)-NH-, -S(O)2-NH-CH(CH3)-, -NH-C(O)-CH(CH3)-, -C(S)-NH-CH(CH3)-, -NH-C(O)-NH-CH(CH3)-, -N(CH3)-C(O)-NH-CH(CH3)- or

[0084] In some embodiments, L 2 Selected from -C(O)-NH- or -C(O)-NH-CH(CH3)-.

[0085] In some embodiments, L 2 Selected from -C(O)-NH-CH(CH3)-.

[0086] In some embodiments, ring B is a benzene ring, a 5-6 membered heteroaromatic ring, a 7-10 membered fused heterocyclic ring or a 7-10 membered fused heteroaromatic ring, wherein the heteroaromatic ring, fused heterocyclic ring or fused heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from O, N and S; in some embodiments, ring B is a benzene ring, a 5-6 membered heteroaromatic ring, a 9-10 membered fused heterocyclic ring or a 9-10 membered fused heteroaromatic ring, wherein the heteroaromatic ring, fused heterocyclic ring or fused heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from O, N and S.

[0087] In some embodiments, ring B is a furan ring, a pyrrole ring, a pyrazole ring, an imidazole ring, an oxazole ring, an isoxazole ring, a thiophene ring, a thiazole ring, an isothiazole ring, a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring, a pyridazine ring, an indole ring, a benzimidazole ring, a benzothiazole ring, a benzoxazole ring, a quinoline ring, an isoquinoline ring, a quinazoline ring, In some embodiments, Ring B is a benzene ring, a pyridine ring, a benzimidazole ring, or a benzothiazole ring.

[0088] In some embodiments, Ring B is

[0089] In some embodiments, Ring B is

[0090] In some embodiments, Ring B is

[0091] In some embodiments, for

[0092] In some embodiments, for

[0093] In some embodiments, for

[0094] In some embodiments, R 5 are independently selected from H, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, methoxy or C 3-6 Alkoxy, the C 1-6 Alkyl, methoxy or C 3-6 The alkoxy group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0095] In some embodiments, R 5 are independently selected from H, halogen, hydroxy, amino, cyano or C 1-6 Alkyl, the C 1-6 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0096] In some embodiments, R 5 are independently selected from H, halogen, hydroxyl, C 1-4 Alkyl, methoxy or C 3-6 Alkoxy, the C 1-4 Alkyl, methoxy or C 3-6The alkoxy group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0097] In some embodiments, R 5 are independently selected from H, halogen, hydroxyl or C 1-4 Alkyl, the C 1-4 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0098] In some embodiments, R 5 independently selected from H, halogen, hydroxy, methyl, ethyl, isopropyl, tert-butyl, methoxy, propoxy, isopropoxy, butyl-2-oxy, tert-butyloxy or pentan-2-yloxy, wherein the methyl, ethyl, isopropyl, tert-butyl, methoxy, propoxy, isopropoxy, butyl-2-oxy, tert-butyloxy or pentan-2-yloxy group may be optionally substituted with one, two or three substituents selected from halogen or cyano.

[0099] In some embodiments, R 5 Independently selected from H, halogen, hydroxy, methyl, ethyl, isopropyl or tert-butyl, said methyl, ethyl, isopropyl or tert-butyl may be substituted with one, two or three substituents selected from halogen.

[0100] In some embodiments, R 5 Independently selected from H, F, hydroxy, trifluoromethyl, methoxy, trifluoromethyloxy, isopropyloxy, butyl-2-oxy, pentan-2-yloxy.

[0101] In some embodiments, R 5 Independently selected from H, F, hydroxy, trifluoromethyl.

[0102] In some embodiments, p is 1 or 2.

[0103] In some embodiments, R 5 Independently selected from H.

[0104] In some embodiments, R 4 Selected from H, halogen, hydroxyl, amino, cyano, C 2-6 Alkynyl, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, pyrazolyl, 6-8 membered bridged heterocyclic ring or 3-6 membered heterocycloalkyl-C 1-6 Alkylene, the C 2-6 Alkynyl, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, 6-8 membered bridged heterocyclic or 3-6 membered heterocycloalkyl-C 1-6 The alkylene group may be optionally replaced by one, two or three selected from R 6The pyrazolyl group is substituted by one, two or three substituents selected from halogen, hydroxy, amino, cyano, COOH, and nitro.

[0105] In some embodiments, R 4 Selected from H, halogen, cyano, C 2-4 Alkynyl, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, pyrazolyl, 6-7 membered bridged heterocyclic or 5-6 membered heterocycloalkyl-C 1-4 Alkylene, the C 2-4 Alkynyl, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, 6-7 membered bridged heterocyclic or 5-6 membered heterocycloalkyl-C 1-4 The alkylene group may be optionally replaced by one, two or three selected from R 6 The pyrazolyl group is substituted by one, two or three substituents selected from halogen, hydroxy, amino, cyano, COOH, and nitro.

[0106] In some embodiments, R 4 is selected from H, halogen, cyano, ethynyl, 1-propynyl, 2-propynyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, pyrazolyl, tetrahydropyrrolyl-1-methylene, tetrahydropyrrolyl-2-methylene, tetrahydropyrrolyl-3-methylene, piperidinyl-1-methylene, piperidinyl-2-methylene, piperidinyl-3-methylene, piperidinyl-4-methylene, piperazinyl-1-methylene or piperazinyl-2-methylene, the ethynyl, 1-propynyl, 2-propynyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, Tetrahydropyrrolyl-1-methylene, tetrahydropyrrolyl-2-methylene, tetrahydropyrrolyl-3-methylene, piperidinyl-1-methylene, piperidinyl-2-methylene, piperidinyl-3-methylene, piperidinyl-4-methylene, piperazinyl-1-methylene or piperazinyl-2-methylene may be optionally substituted by one, two or three selected from R 6 The pyrazolyl group is substituted by one, two or three substituents selected from halogen, hydroxy, amino, cyano, COOH, and nitro.

[0107] In some embodiments, R 4 is selected from H, F, cyano, ethynyl, cyclopropyl, cyclopentyl, azetidinyl, tetrahydropyrrolyl, pyrazolyl, Tetrahydropyrrolyl-1-methylene or piperazinyl-1-methylene, the ethynyl, cyclopropyl, cyclopentyl, azetidinyl, tetrahydropyrrolyl, The tetrahydropyrrolyl-1-methylene or piperazinyl-1-methylene may be optionally substituted by one, two or three selected from R 6 The pyrazolyl group is substituted by one, two or three substituents selected from halogen.

[0108] In some embodiments, R 6 are independently selected from halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 2-6 Alkynyl, C 1-6 Alkyl-NH-, N,N-di(C 1-6 Alkyl)-N-, the C 1-6 Alkyl, C 2-6 Alkynyl, C 1-6 Alkyl-NH- and N,N-di(C 1-6 alkyl)-N- may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino; in some embodiments, R 6 are independently selected from halogen, cyano, C 1-4 Alkyl, C 2-4 Alkynyl or N,N-di(C 1-4 Alkyl)-N-, the C 1-4 Alkyl, C 2-4 Alkynyl and N,N-di(C 1-4 The (alkyl)-N- may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino.

[0109] In some embodiments, R 6 Independently selected from halogen, cyano, methyl, ethynyl or N,N-dimethylamino.

[0110] In some embodiments, R 6 Independently selected from F.

[0111] In some embodiments, R 4 Selected from H, F, cyano, ethynyl,

[0112] In some embodiments, R 4 Selected from

[0113] In some embodiments, the compound of the aforementioned formula (I) has the structure shown in formula (II),

[0114]

[0115] Among them, R 2 , R 3 , R 4 , R5 , Ring A, Ring B, L 2 , n, and p are as defined above in the compound of formula (I).

[0116] In some embodiments, the compound of the aforementioned formula (I) has a structure shown in formula (III),

[0117]

[0118] Among them, R 3 , R 4 , R 5 , Ring A, Ring B, L 2 , n, and p are as defined above in the compound of formula (I).

[0119] In some embodiments, the compound of the aforementioned formula (I) has a structure shown in formula (IV),

[0120]

[0121] Among them, R 3 , R 4 , R 5 , Ring A, Ring B, n, and p are as defined in the compound of formula (I) above, and Ring A is not a piperidine ring.

[0122] In some embodiments, the compound of the aforementioned formula (I) has a structure shown in formula (IV-a),

[0123]

[0124] Among them, R 3 , R 4 , R 5 , Ring A, Ring B, n, and p are as defined in the compound of formula (I) above, and Ring A is not a piperidine ring.

[0125] In some embodiments, the compound of the aforementioned formula (I) has a structure shown in formula (V),

[0126]

[0127] Among them, R 3 , R 4 , R 5 , Ring A, L 2 , n, and p are as defined above in the compound of formula (I).

[0128] In some embodiments, the compound of the aforementioned formula (I) has a structure shown in formula (VII),

[0129]

[0130] Among them, R3 , R 5 , Ring A, L 2 , n, and p are as defined above in the compound of formula (I).

[0131] In some embodiments, the compound of the aforementioned formula (I) has a structure shown in formula (VIII),

[0132]

[0133] Among them, R 3 , R 5 , Ring A, n, and p are as defined in the compound of formula (I) above, and Ring A is not a piperidine ring.

[0134] In some embodiments, the compound of the aforementioned formula (I) has a structure shown in formula (VIII-a),

[0135]

[0136] Among them, R 3 , R 5 , Ring A, n, and p are as defined in the compound of formula (I) above, and Ring A is not a piperidine ring.

[0137] In some embodiments, the present application is selected from the following compounds, their stereoisomers and pharmaceutically acceptable salts thereof:

[0138]

[0139]

[0140]

[0141]

[0142]

[0143]

[0144]

[0145]

[0146]

[0147]

[0148]

[0149]

[0150]

[0151]

[0152]

[0153] On the other hand, the present application relates to a pharmaceutical composition comprising the compound of formula (I) of the present application, its stereoisomers and pharmaceutically acceptable salts thereof.

[0154] In some embodiments, the pharmaceutical composition of the present application comprises a therapeutically effective amount of the compound of formula (I) of the present application, its stereoisomers and pharmaceutically acceptable salts thereof.

[0155] In some embodiments, the pharmaceutical composition of the present application further comprises a pharmaceutically acceptable excipient.

[0156] The pharmaceutical composition of the present application can be prepared by combining the compound of the present application with suitable pharmaceutically acceptable excipients, for example, it can be formulated into solid, semi-solid, liquid or gaseous preparations, such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols, etc.

[0157] Typical routes of administration of the compounds of the present application or their pharmaceutically acceptable salts or their pharmaceutical compositions include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, vaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration.

[0158] The pharmaceutical composition of the present application can be manufactured by methods well known in the art, such as conventional mixing methods, dissolution methods, granulation methods, sugar-coated pill making methods, grinding methods, emulsification methods, freeze-drying methods, etc.

[0159] In some embodiments, the pharmaceutical composition is in oral form. For oral administration, the pharmaceutical composition can be prepared by mixing the active compound with pharmaceutically acceptable excipients well known in the art. These excipients enable the compounds of the present application to be formulated into tablets, pills, lozenges, dragees, capsules, liquids, gels, slurries, suspensions, etc., for oral administration to patients.

[0160] Solid oral compositions can be prepared by conventional mixing, filling or tableting methods. For example, they can be obtained by mixing the active compound with a solid excipient, optionally grinding the resulting mixture, adding other suitable excipients if necessary, and then processing the mixture into particles to obtain a tablet or dragee core. Suitable excipients include, but are not limited to, adhesives, diluents, disintegrants, lubricants, glidants, sweeteners or flavoring agents, etc.

[0161] On the other hand, the present application relates to a method for treating a disease mediated by abnormal RET activity in a mammal, comprising administering a therapeutically effective amount of a compound of formula (I) of the present application, its stereoisomers and pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof to a mammal, preferably a human, in need of such treatment.

[0162] In all administration methods of the compound of formula (I) of the present application, its stereoisomers or pharmaceutically acceptable salts thereof, the daily dosage is 0.01 to 100 mg / kg body weight, preferably 0.05 to 50 mg / kg body weight, more preferably 0.1 to 5 mg / kg body weight, in the form of a single or divided dose.

[0163] On the other hand, the present application relates to the use of the compound of formula (I), its stereoisomers and pharmaceutically acceptable salts thereof, or its pharmaceutical composition in the preparation of drugs for preventing or treating diseases mediated by abnormal RET activity.

[0164] On the other hand, the present application relates to the use of the compound of formula (I), its stereoisomers and pharmaceutically acceptable salts thereof, or its pharmaceutical composition in preventing or treating diseases mediated by abnormal RET activity.

[0165] On the other hand, the present application relates to compounds of formula (I), stereoisomers thereof and pharmaceutically acceptable salts thereof for preventing or treating diseases mediated by abnormal RET activity.

[0166] The diseases mediated by abnormal RET activity described in the present application include cancer.

[0167] In some embodiments, the cancer described in the present application is selected from papillary thyroid carcinoma (PTC), medullary thyroid carcinoma (MTC), pheochromocytoma (PC), pancreatic cancer, multiple endocrine neoplasia (MEN2A and MEN2B), breast cancer, testicular cancer, small cell lung cancer, non-small cell lung cancer, blood tumors, colorectal cancer, ovarian cancer, cervical cancer, gastric cancer, prostate cancer, salivary gland cancer.

[0168] definition

[0169] Unless otherwise specified, the following terms used in this application have the following meanings. A particular term should not be considered to be uncertain or unclear in the absence of a special definition, but should be understood according to the common meaning in the art. When a trade name appears in this article, it is intended to refer to the corresponding commodity or its active ingredient.

[0170] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0171] The term "pharmaceutically acceptable salt" refers to salts of compounds of the present application, prepared from compounds with specific substituents found in the present application and relatively non-toxic acids or bases. When the compounds of the present application contain relatively acidic functional groups, base addition salts can be obtained by contacting a neutral form of such compounds with a suitable base. When the compounds of the present application contain relatively basic functional groups, acid addition salts can be obtained by contacting a neutral form of such compounds with a suitable acid. Certain specific compounds of the present application contain basic and acidic functional groups, and thus can be converted into either base or acid addition salts.

[0172] Certain compounds of the present application may have asymmetric carbon atoms (optical centers) or double bonds. Racemates, diastereomers, geometric isomers and individual isomers are all included within the scope of the present application.

[0173] When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless specified otherwise, they include E and Z geometric isomers. Likewise, all tautomeric forms are included within the scope of this application, for example, and It is a tautomeric form.

[0174] The compounds of the present application may exist in specific geometric or stereoisomeric forms. The present application contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as mixtures enriched in enantiomers or diastereomers, all of which are within the scope of the present application. Additional asymmetric carbon atoms may be present in substituents such as alkyl. All of these isomers and their mixtures are included within the scope of the present application. For example, the compound structure contains are diastereoisomers; for example, There are (R)- and (S)-enantiomers.

[0175] Optically active (R)- and (S)-isomers and D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present application is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a diastereomeric salt is formed with an appropriate optically active acid or base, and then the diastereoisomers are separated by conventional methods known in the art, and then the pure enantiomer is recovered. In addition, the separation of enantiomers and diastereomers is usually accomplished by using chromatography, which uses a chiral stationary phase and is optionally combined with a chemical derivatization method (e.g., carbamate is generated from an amine).

[0176] The compounds of the present application may contain unnatural proportions of atomic isotopes on one or more of the atoms constituting the compound. For example, the compounds may be labeled with radioactive isotopes, such as deuterium ( 2 H), tritium ( 3 H), iodine-125( 125 I) or C-14( 14 C) All isotopic variations of the compounds of the present application, whether radioactive or not, are included within the scope of the present application.

[0177] The term "pharmaceutically acceptable excipients" refers to those excipients that have no significant irritation to the organism and do not impair the biological activity and performance of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.

[0178] The term "effective amount" or "therapeutically effective amount" refers to a sufficient amount of a drug or pharmaceutical agent to achieve the desired effect. The determination of the effective amount varies from person to person, depending on the age and general condition of the recipient, and also on the specific active substance. The appropriate effective amount in each case can be determined by a person skilled in the art based on routine experiments.

[0179] The terms "active ingredient," "therapeutic agent," "active substance," or "active agent" refer to a chemical entity that is effective in treating a target disorder, disease, or condition.

[0180] The word "comprise" or "comprises" and its English variations such as comprises or comprising should be construed in an open and non-exclusive sense, ie, "including but not limited to".

[0181] The term "optional" or "optionally" means that the event or situation described subsequently may or may not occur, and the description includes the occurrence of the event or situation and the non-occurrence of the event or situation. For example, an ethyl group is "optionally" substituted with a halogen, meaning that the ethyl group may be unsubstituted (CH2CH3), monosubstituted (such as CH2CH2F), polysubstituted (such as CHFCH2F, CH2CHF2, etc.) or fully substituted (CF2CF3). It will be appreciated by those skilled in the art that for any group comprising one or more substituents, no substitution or substitution pattern that is sterically impossible to exist and / or cannot be synthesized will be introduced.

[0182] The C used in this paper m-n means that there are mn carbon atoms in the part. For example, "C 3-10 "Cycloalkyl" means that the cycloalkyl group has 3 to 10 carbon atoms. 0-6 "Alkylene" means that the alkylene has 0 to 6 carbon atoms, and when the alkylene has 0 carbon atoms, the group is a bond.

[0183] The numerical ranges herein refer to each integer in the given range. For example, "C 1-10 ” means that the group can have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, 6 carbon atoms, 7 carbon atoms, 8 carbon atoms, 9 carbon atoms, or 10 carbon atoms.

[0184] The term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, as long as the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is a keto group (i.e., =O) (also known as an oxo group), it means that two hydrogen atoms are replaced, and keto substitution does not occur on an aromatic group.

[0185] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 0-2 Rs, the group may be optionally substituted with up to two Rs, and each occurrence of R is an independent choice. In addition, combinations of substituents and / or variants thereof are permitted only if such combinations result in stable compounds.

[0186] When one of the variables is selected from a bond, it means that the two groups it connects are directly connected. For example, when L in ALZ represents a bond, it means that the structure is actually AZ.

[0187] When a substituent is vacant, it means that the substituent does not exist, for example, when X in AX is vacant, it means that the structure is actually A. When a substituent's bond can cross-link to two atoms on a ring, this substituent can be bonded to any atom on this ring. When the listed substituent does not indicate which atom it is connected to the compound included but not specifically mentioned in the chemical formula, this substituent can be bonded through any atom. Combinations of substituents and / or their variants are allowed only if such combinations will produce stable compounds. For example, the structural unit It means that it can be substituted at any position on the cyclohexyl group or cyclohexadiene. For example, the structural unit express

[0188] The term "halogen" or "halo" refers to fluorine, chlorine, bromine or iodine.

[0189] The term "hydroxy" refers to -OH.

[0190] The term "cyano" refers to -CN.

[0191] The term "amino" refers to -NH2.

[0192] The term "nitro" refers to -NO2.

[0193] The term "alkyl" refers to a straight or branched saturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc. The specific alkyl group includes all isomeric forms thereof, such as propyl includes -CH2CH2CH3, -CH(CH3)2, and butyl includes -CH2CH2CH2CH3, -CH(CH3)(CH2CH3), -C(CH3)3, -CH2CH(CH3)2. The term "C 1-6 "Alkyl" refers to an alkyl group having 1 to 6 carbon atoms. The term "C 1-4 "Alkyl" refers to an alkyl group having 1 to 4 carbon atoms. The term "C 1-3 "Alkyl" refers to an alkyl group having 1 to 3 carbon atoms. 1-8 Alkyl", "C 1-6 Alkyl" or "C 1-3 The "alkyl" group may be unsubstituted or substituted by one or more substituents selected from hydroxy, halogen or amino.

[0194] The term "alkylene" means that one hydrogen atom of an alkyl group is further substituted, for example: "methylene" means -CH2-, "ethylene" means -CH2-CH2-, "propylene" means -CH2-CH2-CH2-, "butylene" means -CH2-CH2-CH2-CH2-, and the like.

[0195] The term "alkoxy" refers to an alkyl group as defined above having the specified number of carbon atoms attached through an oxygen bridge. 1-6 Alkoxy groups include C1, C2, C3, C4, C5 and C6 alkoxy groups. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy and S-pentoxy.

[0196] The term "alkyleneoxy" refers to an alkoxy group in which one hydrogen atom is further substituted.

[0197] The term "alkenyl" refers to a straight or branched hydrocarbon chain containing 2 to 12 carbon atoms and having one or more double bonds. Examples of alkenyl groups include, but are not limited to, allyl, propenyl, 2-butenyl, and 3-hexenyl. One of the double bond carbons may optionally be the point of attachment for the alkenyl substituent.

[0198] The term "alkynyl" refers to a straight or branched hydrocarbon chain containing 2 to 12 carbon atoms and characterized by having one or more triple bonds. Examples of alkynyl groups include, but are not limited to, ethynyl, propynyl, propargyl, and 3-hexynyl. One of the triple bond carbons may optionally be the point of attachment for the alkynyl substituent.

[0199] Unless otherwise specified, the term "hetero" means a heteroatom or heteroatom group (i.e., an atom group containing heteroatoms), including atoms other than carbon (C) and hydrogen (H) and atom groups containing these heteroatoms, for example, including oxygen (O), nitrogen (N), sulfur (S), silicon (Si), germanium (Ge), aluminum (Al), boron (B), -O-, -S-, =O, =S, -C(=O)O-, -C(=O)-, -C(=S)-, -S(=O), -S(=O)2-, and -C(=O)N(H)-, -N(H)-, -C(=NH)-, -S(=O)2N(H)- or -S(=O)N(H)-.

[0200] Unless otherwise specified, the term "monocyclic ring" means a saturated or partially saturated monocyclic cyclic hydrocarbon, the monocyclic ring containing 3 to 12 carbon atoms, preferably 3 to 8 carbon atoms, more preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic rings include cyclopropyl ring, cyclobutyl ring, cyclopentyl ring, cyclopentene ring, cyclohexyl ring, cyclohexene ring, cyclohexadiene ring, cycloheptyl ring, cycloheptatriene ring, cyclooctane ring, etc.

[0201] The term "cycloalkyl" refers to a saturated monocyclic ring.

[0202] The term "monocyclic heterocycle" refers to a monocyclic ring having 3 to 12 ring atoms, wherein 1 or 2 ring atoms are selected from N, O, S(O) n(where n is 0, 1 or 2) with the remaining ring atoms being C. Such rings may be saturated or unsaturated (e.g., have one or more double bonds), but do not have a completely conjugated π-electron system. Examples of 3-membered saturated monocyclic heterocycles include, but are not limited to Examples of 4-membered saturated monocyclic heterocycles include, but are not limited to Examples of 5-membered saturated monocyclic heterocycles include, but are not limited to Examples of 6-membered saturated monocyclic heterocycles include, but are not limited to Examples of 7-membered saturated monocyclic heterocycles include, but are not limited to Examples of 5-membered unsaturated monocyclic heterocycles include, but are not limited to Examples of 6-membered unsaturated monocyclic heterocycles include, but are not limited to

[0203] The term "heterocycloalkyl" refers to a saturated monocyclic heterocyclic ring.

[0204] The term "bridged heterocycle" refers to a polycyclic ring with 5 to 14 members, two rings sharing two or more atoms, which may contain one or more double bonds, but none of the rings has a completely conjugated π electron system, wherein one or more ring atoms are selected from N, O, S(O) n (where n is 0, 1 or 2) heteroatom, and the remaining ring atoms are carbon. Preferably, it is 6 to 14 members, and more preferably, it is 6 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocycles, preferably bicyclic or tricyclic, and more preferably bicyclic. Non-limiting examples of bridged heterocycles include:

[0205] The term "condensed ring" refers to a 7-20-membered, all-carbon polycyclic ring in which two rings share two adjacent carbon atoms, and at least one ring has a completely conjugated π electron system. Preferably, it is 6-14 members, and more preferably 6-10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic condensed heterocyclic ring, preferably a bicyclic or tricyclic ring, and more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic ring. Non-limiting examples of condensed rings include:

[0206] The term "fused heterocycle" refers to a polycyclic ring of 5 to 20 members, in which two rings share two adjacent ring atoms, at least one of which has a completely conjugated π electron system, and one or more of the ring atoms are selected from N, O, S(O) n(where n is 0, 1 or 2) heteroatom, and the remaining ring atoms are carbon. Preferably 6 to 14 members, more preferably 6 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic condensed heterocyclic rings, preferably bicyclic or tricyclic, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic rings. Non-limiting examples of condensed heterocyclic rings include:

[0207] The term "fused heteroaromatic ring" refers to a fused heterocyclic ring having a completely conjugated π electron system. Non-limiting examples of fused heteroaromatic rings include:

[0208] The term "heteroaromatic ring" or "heteroaryl" refers to a monocyclic ring with a conjugated π electron system containing 1 to 4 heteroatoms, 5 to 8 ring atoms, wherein the heteroatoms are selected from O, N, S, and the remaining ring atoms are C. The heteroaryl group is preferably 5-6 members, containing 1 to 3 heteroatoms; more preferably 5- or 6-membered, containing 1 to 2 heteroatoms; preferably, for example, imidazolyl, furanyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridinyl, pyrimidinyl, thiadiazolyl, pyrazinyl, etc., preferably imidazolyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl or pyrazinyl.

[0209] In this application, L 1 , L 2 The connection method with ring A and ring B indicates the connection from left to right. For example, -L 2 -Selected from -N(R A1 )-C(O)-(CR A2 R B2 ) q -, only represents the ring AN(R A1 )-C(O)-(CR A2 R B2 ) q -Ring B.

[0210] "EA" means ethyl acetate.

[0211] "TFA" refers to trifluoroacetic acid.

[0212] "DCM" means dichloromethane.

[0213] "DMF" refers to N,N-dimethylformamide.

[0214] "HATU" refers to 2-(7-oxybenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate.

[0215] "DMSO" means dimethyl sulfoxide.

[0216] "EDTA" refers to ethylenediaminetetraacetic acid.

[0217] "BINAP" refers to 1,1'-binaphthyl-2,2'-diphenylphosphine.

[0218] "Dioxane" means dioxane.

[0219] "Pd2dba3" refers to tris(dibenzylideneacetone)dipalladium.

[0220] "DavePhos" refers to 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)-biphenyl.

[0221] "LiHMDS" refers to lithium hexamethyldisilazide.

[0222] "THF" means tetrahydrofuran.

[0223] "DIPEA" refers to N,N'-diisopropylethylamine.

[0224] "Triphosgene" refers to triphosgene.

[0225] "CDI" refers to N'N-carbonyldiimidazole.

[0226] “Room temperature” is 20~30℃.

[0227] Specific embodiment

[0228] The present application is described in detail below by way of examples, but this does not mean any adverse limitation to the present application. The present disclosure has been described in detail herein, and its specific embodiments are also disclosed therein. It will be apparent to those skilled in the art that various changes and modifications will be made to the specific embodiments of the present disclosure without departing from the spirit and scope of the present application.

[0229] Example 1: Preparation of (S)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide)

[0230] Reaction process:

[0231]

[0232] Step A: Preparation of 1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethanone

[0233] Add 10g (71.88mmol) of 2-fluoro-5-acetylpyridine, 100mL of DMF, 6.18g (71.88mmol) of 4-fluoro-1H-pyrazole and 9.93g (71.88mmol) of potassium carbonate to a 250mL sealed tube, heat to 100℃ and stir for 10h. Turn off the heating, cool the reaction solution to room temperature, pour it into 400mL of water, and stir for 30min. Filter, wash the filter cake with water, collect the filter cake and dry it to obtain 13.7g of beige target product. The crude product is used directly in the next step without purification.

[0234] Step B: Preparation of (R)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide

[0235] 150 mL of anhydrous tetrahydrofuran, 13.7 g (66.7 mmol) of 1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethanone, 8.09 g (66.7 mmol) of R-tert-butylsulfenamide, 17.92 g (133.4 mmol) of diethylene glycol dimethyl ether and 30.46 g (133.4 mmol) of tetraethyl titanate were added to a 500 mL three-necked round-bottom flask, and the reaction solution was heated to reflux for 5 h. The reaction solution was cooled to -78 ° C, and 200.3 mL of 1M tetrahydrofuran solution of lithium tri-sec-butyl borohydride was slowly added dropwise under nitrogen protection. After the addition was completed, the reaction was continued to stir at -78 ° C for 40 min. 20 mL of methanol was added dropwise to quench the reaction, and the reaction solution was naturally heated to 0 ° C, poured into 500 mL of water and stirred. Filter, and wash the filter cake with ethyl acetate. Separate the organic phase, and extract the aqueous phase with ethyl acetate. The organic phases were combined and dried over anhydrous sodium sulfate, and concentrated to obtain a yellow oily crude product. 150 mL of petroleum ether was added to the crude product, and the mixture was stirred at room temperature for 2 h, filtered, and the filter cake was washed with petroleum ether to obtain 12.1 g of an off-white target product. The product was used directly in the next step without purification.

[0236] Step C: Preparation of (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethylamine dihydrochloride

[0237] Add 12.1 g of (R)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide and 50 mL of methanol to a 250 mL round-bottom flask. After stirring and dissolving, add 100 mL of 1M hydrogen chloride solution in 1,4-dioxane under the same conditions and stir at room temperature overnight. After the reaction is completed, concentrate the reaction solution to obtain a pale yellow oily crude product. Add 30 mL of ethyl acetate to the crude product and stir at room temperature for 1.5 hours. Filter, wash the filter cake with a small amount of ethyl acetate, collect the filter cake and dry it to obtain 9.4 g of pale yellow target product.

[0238] MS (ESI, [M+H] + )m / z:207.1.

[0239] Step D: Preparation of 2-chloro-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine

[0240] 12 g (73.6 mmol) of 2,4-dichloro-6-methylpyridine, 50 mL of DMSO, 7.86 g (73.6 mmol) of 5-methyl-1H-pyrazole-3-amine and 14.2 g (1 10 mmol) of diisopropylethylamine were added to a 100 mL round-bottom flask, and the reaction solution was heated to 60 °C for overnight reaction. The reaction solution was cooled to room temperature and poured into 400 mL of water, extracted with methyl tert-butyl ether, and the combined organic phases were washed with saturated aqueous NaCl solution and dried. The organic phase was concentrated, and the obtained crude product was added to 50 mL of dichloromethane and stirred overnight. Filter, wash the filter cake with a small amount of dichloromethane, collect the filter cake and dry it to obtain 9.9 g of white target.

[0241] MS (ESI, [M+H] + )m / z:224.1.

[0242] Step E: Preparation of tert-butyl 4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxylate

[0243] In a 100mL round-bottom flask, 0.5g (2.235mmol) of 2-chloro-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-4-amine, 5ml of DMF and 0.833g (4.47mmol) of tert-butyl piperazine-1-carboxylate were added in sequence. Under N2 protection, the mixture was heated to 100°C for 7h. The reaction solution was directly poured into 50mL of ice water and extracted with ethyl acetate. The organic phase was collected and dried over anhydrous sodium sulfate. Filtered and concentrated to obtain 1.5g of colorless oil. Purified by column chromatography to obtain 0.8g of off-white powdery solid.

[0244] MS (ESI, [M+H] + )m / z:374.4.

[0245] Step F: Preparation of 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-(piperazin-1-yl)pyrimidin-4-amine trifluoroacetate

[0246] In a 50 mL round-bottom flask, 0.78 g (1.938 mmol) of tert-butyl 4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxylate, 10 ml of DCM and 1.105 g (9.69 mmol) of trifluoroacetic acid were added in sequence and stirred at room temperature overnight. After the reaction was completed, the reaction solution was concentrated to obtain 0.8 g of a white solid product, which was directly used in the next step without purification.

[0247] 1 H-NMR (500MHz, DMSO-d6): δ10.85(s,1H),9.31(s,2H),6.38(s,1H),6.24(s,1H),3.99(s,4H),3.29(s,4H),2.33(s,3H),2.35(s,3H);

[0248] MS (ESI, [M+H] + )m / z:274.4.

[0249] Step G: Preparation of (S)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide)

[0250] Dissolve 0.011g (0.037mmol) of triphosgene in 3mL of dichloromethane, cool to 0°C under N2 protection, and add 2mL of dichloromethane solution containing 0.030g (0.107mmol) of (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl-1-amine dihydrochloride and 0.086g (0.852mmol) of triethylamine. After the reaction solution was stirred at 0°C for 5min, 0.05g (0.107mmol) of 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-(piperazine-1-yl)pyrimidin-4-amine trifluoroacetate and triethylamine were added, and stirred at room temperature for 20min. After the reaction was completed, 50mL of dichloromethane was added to the reaction solution for dilution, and washed with 10mL of saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and the obtained crude product was purified by column chromatography to obtain 32 mg of the target compound as a white powdery solid.

[0251] 1H NMR (500MHz, DMSO-d6): δ11.82(s,1H),9.25(s,1H),8.66(d,J=4.5Hz,1H),8.42(s,1H),7.96(d,J=8.5Hz,1H),7.89(m,2H),6.97(d ,J=7.5Hz,1H),6.22(br,1H),6.14(br,1H),4.94(m,1H),3.68(s,4H),3.40(s,4H),2.21(s,3H),2.13(s,3H),1.45(d,J=7.0Hz,3H);

[0252] MS (ESI, [M+H] + )m / z:506.5.

[0253] Example 2: Preparation of (1S,4S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-5-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxamide

[0254] Reaction process:

[0255]

[0256] The synthesis method is as in Example 1.

[0257] 1 H NMR (500MHz, DMSO-d6): δ11.88(s,1H),9.30(br,1H),8.63(s,1H),8.39(s,1H),7.89(m,3H),6.74(s,1H),6.23(br, 2H), 4.86 (m, 1H), 3.65 (m, 3H), 3.07 (m, 3H), 2.21 (s, 3H), 2.12 (s, 3H), 1.40 (d, J = 7.0Hz, 3H), 1.26 (t, J = 7.0Hz, 2H);

[0258] MS (ESI, [M+H] + )m / z:518.34.

[0259] Example 3: Preparation of (1R, 4R)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-5-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxamide

[0260] Reaction process:

[0261]

[0262] The synthesis method is as in Example 1.

[0263] 1 H-NMR (500MHz, DMSO-d6): δ11.88(s,1H),9.97(s,1H),8.64(d,J=5.0Hz,1H),8.37(d,J=5.0Hz,1H),7.85(m,3H),6.73(s, 1H),6.23(br,2H),4.89(m,1H),3.43(m,2H),3.07(m,4H),2.19(s,3H),2.13(s,3H),1.42(d,J=10.0Hz,3H),1.24(s,2H);

[0264] MS (ESI, [M+H] + )m / z:518.29.

[0265] Example 4: Preparation of N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-6-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide

[0266] Reaction process:

[0267]

[0268] The synthesis method is as in Example 1.

[0269] 1 H NMR (500MHz, DMSO-d6): δ12.30(s,1H),10.51(s,1H),8.64(d,J=3.5Hz,1H),8.35(s,1H),7.90(d,J=4.5Hz,2H),7.81(d,J=8.5Hz,1H ),6.76(s,1H),6.31(m,2H),4.88(m,1H),3.90(m,2H),3.46(m,2H),3.05(m,2H),2.37(s,3H),2.29(s,3H),1.59(s,2H),1.40(m,3H);

[0270] MS (ESI, [M+H] + )m / z:518.5.

[0271] Example 5: Preparation of N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxamide

[0272] Reaction process:

[0273]

[0274] The synthesis method is as in Example 1.

[0275] 1 H NMR (500MHz, DMSO-d6): δ11.92(s,1H),10.45(s,1H),8.55(m,1H),8.29(s,1H),7.88(m,1H),7.79(d,J=8Hz,1H),7.66(d,J=9Hz,1H),7.22 (m,1H),6.31(s,1H),6.18(s,1H),4.82(m,1H),4.31(m,2H),4.10(m, 2H),3.48(m,2H),2.21(s,3H),2.15(s,3H),1.43(m,3H),1.36(m,2H);

[0276] MS (ESI, [M+H] + )m / z:518.5.

[0277] Example 6: Preparation of N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-8-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxamide

[0278] Reaction process:

[0279]

[0280] The synthesis method is as in Example 1.

[0281] 1H-NMR (500MHz, DMSO-d6): δ11.87(s,1H),9.32(s,1H),8.67(d,J=5.0Hz,1 H),8.39(s,1H),7.90(m,3H),6.77(d,J=5.0Hz,1H),6.15(m,2H),4.91(m,1 H),4.66(s,2H),3.74(d,J=10.0Hz,2H),3.00(d,J=10.0Hz,2H),2.21(s,3H ),2.14(s,3H),1.84(s,2H),1.69(d,J=5.0Hz,2H),1.42(d,J=10.0Hz,3H);

[0282] MS (ESI, [M+H] + )m / z:532.30.

[0283] Example 7: Preparation of N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide

[0284] Reaction process:

[0285]

[0286] The synthesis method is as in Example 1.

[0287] 1 H-NMR (500MHz, DMSO-d6): δ11.88(s,1H),9.90(s,1H),8.67(d,J=5.0Hz,1H) ,8.42(s,1H),7.92(m,3H),7.13(d,J=5.0Hz,1H),6.15(m,2H),4.96(m,1H), 4.42(d,J=5.0Hz,2H),4.29(d,J=5.0Hz,2H),3.08(d,J=5.0Hz,2H),2.21(s, 3H), 2.13 (s, 3H), 1.75 (s, 2H), 1.59 (d, J = 10.0Hz, 2H), 1.46 (d, J = 5.0Hz, 3H);

[0288] MS (ESI, [M+H] + )m / z:532.30.

[0289] Example 8: Preparation of (R)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0290] Reaction process:

[0291]

[0292] The synthesis method is as in Example 1.

[0293] 1 H NMR (500MHz, CDCl3) δ8.37–8.38(m,2H),7.89(d,J=8.5Hz,1H),7.77(d,J=7.7Hz,1H),7.56(d,J =4.0Hz,1H),7.19(s,1H),6.06(d,J=21.0Hz,2H),5.06–5.11(m,1H),4.75(d,J=6.0Hz,1H),4.5 4(d,J=12.5Hz,1H),4.45(d,J=13.0Hz,1H),4.15(s,1H),3.76(d,J=12.5Hz,1H),3.20–3.27(m, 2H),3.05–3.11(m,1H),2.29(s,3H),2.23(s,3H),1.54(d,J=7.0Hz,3H),1.19(d,J=6.5Hz,3H);

[0294] MS (ESI, [M+H] + )m / z:520.27.

[0295] Example 9: Preparation of (S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0296] Reaction process:

[0297]

[0298] The synthesis method is as in Example 1.

[0299] 1H NMR (500MHz, CDCl3) δ8.38–8.40(m,2H),7.90(d,J=8.5Hz,1H),7.79(dd,J=8.5,2.5Hz,1H),7.58( d,J=4.0Hz,1H),7.31(s,1H),6.07(d,J=17.0Hz,2H),5.08–5.18(m,1H),4.81(d,J=7.0Hz,1H),4.5 5(d,J=12.5Hz,1H),4.47(d,J=13.0Hz,1H),4.13–4.18(m,1H),3.80(d,J=13.0Hz,1H),3.21–3.27 (m,2H),3.07–3.13(m,1H),2.30(s,3H),2.24(s,3H),1.56(d,J=7.0Hz,3H),1.21(d,J=7.0Hz,3H);

[0300] MS (ESI, [M+H] + )m / z:520.25.

[0301] Example 10: (S)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-7-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-4,7-diazaspiro[2.5]octane-4-carboxamide

[0302] Reaction process:

[0303]

[0304] The synthesis method is as in Example 1.

[0305] 1 H NMR (500MHz, CDCl3) δ8.36–8.37(m,2H),7.88(d,J=8.5Hz,1H),7.75(d,J=8.5Hz,1H),7.56(d,J=4.5Hz,2H),6.03(s,2H),5. 66(d,J=7.0Hz,1H),5.07–5.20(m,1H),3.67(s,6H),2.26(s,3H),2.19(s,3H),1.56(d,J=7.0Hz,3H),1.01(d,J=15.5Hz,4H);

[0306] MS (ESI, [M+H] + )m / z:532.28.

[0307] Example 11: Preparation of (S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0308] Reaction process:

[0309]

[0310] The synthesis method is as in Example 1.

[0311] 1 H NMR (500MHz, CDCl3) δ8.39–8.40(m,2H),7.90(d,J=8.5Hz,1H),7.79(d,J=8.5Hz,1H),7.58(d,J =4.5Hz,1H),7.18(s,1H),6.07(d,J=18.0Hz,2H),5.07–5.14(m,1H),4.87(s,1H),4.77(d,J=6. 5Hz,1H),4.46(d,J=13.5Hz,1H),3.90(d,J=12.0Hz,1H),3.69(d,J=13.0Hz,1H),3.29–3.35(m, 2H),3.05–3.11(m,1H),2.30(s,3H),2.25(s,3H),1.57(d,J=7.0Hz,3H),1.23(d,J=6.5Hz,3H);

[0312] MS (ESI, [M+H] + )m / z:520.5.

[0313] Example 12: Preparation of (R)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0314] Reaction process:

[0315]

[0316] The synthesis method is as in Example 1.

[0317] 1H NMR (500MHz, CDCl3) δ8.40–8.41(m,2H),7.92(d,J=8.5Hz,1H),7.81(d,J=8.5Hz,1H),7.59(d ,J=4.0Hz,1H),6.97(s,1H),6.09(d,J=25.0Hz,2H),5.10–5.15(m,1H),4.88(s,1H),4.68(d, J=6.6Hz,1H),4.50(d,J=13.3Hz,1H),3.89(d,J=12.0Hz,1H),3.69(d,J=13.0Hz,1H),3.30–3 .38(m,2H),3.07–3.13(m,1H),2.33(s,3H),2.27(s,3H),1.57(d,J=7.0Hz,3H),1.25(s,3H).

[0318] MS (ESI, [M+H] + )m / z:520.5.

[0319] Example 13: 4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-N-phenylpiperazine-1-carboxamide

[0320] Reaction process:

[0321]

[0322] The synthesis method is as in Example 1.

[0323] 1 H NMR (500MHz, CDCl3) δ7.39(d,J=8.0Hz,2H),7.29(t,J=8.0Hz,2H),7.04(t,J=7.5Hz,1H),6.96(s ,1H),6.50(s,1H),6.14(s,1H),6.02(s,1H),3.87(s,4H),3.58(s,4H),2.31(s,3H),2.25(s,3H).

[0324] MS (ESI, [M+H] + )m / z:393.3.

[0325] Example 14: (S)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-N-(1-(pyridin-3-yl)ethyl)-1-carboxamide

[0326]

[0327] The synthesis method is as in Example 1.

[0328] 1 H NMR (500MHz, CDCl3) δ8.63(s,1H),8.50(s,1H),7.66(d,J=10.0Hz,1H),6.84(s,1H),6.15(s,1H),6.01(s,1H),5.34( s,1H),5.08(m,1H),4.72(d,J=7.0Hz,1H),3.82(s,4H),3.57(s,4H),2.31(s,3H),2.26(s,3H),1.54(d,J=7.0Hz,3H).

[0329] MS (ESI, [M+H] + )m / z:422.4.

[0330] Example 15: Preparation of (S)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-2-aza-spiro[3.3]heptane-6-carboxamide

[0331] Reaction process:

[0332]

[0333] Step A: Preparation of (S)-6-((1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)carbamoyl)-2-azaspiro[3.3]heptane-2-tert-butylcarboxylate

[0334] In a 50 mL round-bottom flask, 0.4 g (1.658 mmol) of 2-(tert-butoxycarbonyl)-2-azaspiro[3.3]heptane-6-carboxylic acid, 5 mL of tetrahydrofuran, 0.463 g (1.658 mmol) of (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethylamine dihydrochloride, 0.693 g (1.824 mmol) of HATU and 0.857 g (6.63 mmol) of N,N-diisopropylethylamine were added in sequence, and the mixture was stirred at room temperature for reaction. After the reaction was completed, stirring was stopped, and 100 mL of ethyl acetate and 20 mL of water were added to the reaction system. The organic phase was collected, washed with saturated brine, and dried over anhydrous sodium sulfate. Filtered, the filtrate was concentrated, and the crude product was purified by column chromatography to obtain 0.7 g of a white powdery solid product.

[0335] MS (ESI, [M+Na] + )m / z:452.4.

[0336] Step B: Preparation of (S)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-aza-spiro[3.3]heptane-6-carboxamide

[0337] In a 50 mL round-bottom flask, 0.27 g (0.624 mmol) of (S)-6-((1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)carbamoyl)-2-azaspiro[3.3]heptane-2-tert-butylcarboxylate, 5 ml of acetonitrile and 0.764 g (4.99 mmol) of trimethylsilyl bromide were added in sequence and stirred at room temperature for 3 h. After the reaction was completed, 20 mL of water was added to the reaction system and extracted with ethyl acetate. The organic phases were combined and dried over anhydrous sodium sulfate. Filtered and the filtrate was concentrated to obtain 0.13 g of a gray oily substance. It was used directly in the next step without further purification.

[0338] MS (ESI, [M+H] + )m / z:330.2.

[0339] Step C: Preparation of (S)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-2-aza-spiro[3.3]heptane-6-carboxamide

[0340] In a 35 mL microwave tube, 0.12 g (0.364 mmol) of (S)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-aza-spiro[3.3]heptane-6-carboxamide, 10 mL of isopropanol, 0.147 g (1.457 mmol) of triethylamine, and 0.081 g (0.364 mmol) of 2-chloro-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine were added in sequence, and the mixture was heated at 120° C. in a microwave reactor for 2 h. After the reaction was completed, the reaction solution was poured into 50 mL of water, extracted twice with ethyl acetate, and the organic phases were combined. The organic phase was washed three times with saturated brine and dried over anhydrous sodium sulfate. The filtrate was filtered and concentrated, and the crude product was subjected to column chromatography to obtain 82 mg of the target substance as a white powdery solid.

[0341] 1H NMR (500MHz, DMSO-d6): δ12.04(s,1H),8.67(d,J=4.5Hz,1H),8.36(m,2H),7.95(m,3H),6.25(m,2H),4.99(t,J=7.5 Hz,1H),4.11(s,2H),3.99(s,2H),2.98(t,J=8.0Hz,1H),2.36(d,J=8.0Hz,3H),2.19(m,7H),1.40(d,J=7.0Hz,3H);

[0342] MS (ESI, [M+H] + )m / z:517.5.

[0343] Example 16: Preparation of (1R, 5S, 6R)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide

[0344] Reaction process:

[0345]

[0346] The synthesis method is similar to that of Example 15.

[0347] 1 H NMR (500MHz, DMSO-d6): δ12.00(s,1H),8.67(s,1H),8.59(d,J=6.5Hz,1H),8.40(s,1H),7.90(m,4H),6.25(m,2H), 5.00(d,J=6.0Hz,1H),3.91(s,2H),3.56(s,2H),3.10(s,1H),2.21(m,3H),2.03(m,3H),1.42(s,2H),1.24(s,3H);

[0348] MS (ESI, [M+H] + )m / z:503.4.

[0349] Example 17: Preparation of (1R, 3R, 5S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-8-(4-methyl-6-(5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-8-azabicyclo[3.2.1]octane-3-carboxamide

[0350] Reaction process:

[0351]

[0352] The synthesis method is similar to that of Example 15.

[0353] 1 H-NMR (500MHz, DMSO-d6): δ11.83(s,1H),9.22(br,1H),8.65(d,J=4.5Hz,1H),8.33(m,2H),7.91-7.85(m.3H),6.15(br,2H),4.90 (t,J=7.5Hz,1H),4.60(m,2H),2.88(m,1H),2.18(s,3H),2.11(s,3H),1.37(d,J=7Hz,3H),1.97(m,2H),1.78(m,2H),1.51(m,3H);

[0354] MS (ESI, [M+H] + )m / z:531.4.

[0355] Example 18: Preparation of (S)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperidine-4-sulfonamide

[0356] Reaction process:

[0357]

[0358] Step A: Preparation of (S)-tert-butyl 4-(N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)sulfonyl)piperidine-1-carboxylate

[0359] In a 25 mL round-bottom flask, 0.17 g (0.71 mmol) of (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethylamine dihydrochloride, 5 mL of dichloromethane, 0.14 g (1.41 mmol) of triethylamine, and 0.2 g (0.71 mmol) of N-tert-butyloxycarbonyl-4-chlorosulfonylpiperidine were added in sequence, and the mixture was stirred at room temperature overnight. After the reaction was completed, 50 mL of dichloromethane was added to dilute the mixture, and the mixture was washed with saturated brine. The organic phase was dried over anhydrous sodium sulfate and then filtered. The filtrate was collected and concentrated, and the crude product was purified by column chromatography to obtain 0.36 g of an off-white solid.

[0360] 1H-NMR (500MHz, DMSO-d6): δ8.68(d,J=4.5Hz,1H),8.46(d,J=1Hz,1H),8.02(dd,J=1.5Hz,8.5Hz,1H),7 .93-7.88(m,3H),4.62(m,1H),4.00(m,2H),3.07(m,1H),2.03-1.94(m,2H),1.46(m,4H),1.36(m,12H);

[0361] MS (ESI, [M+Na] + )m / z:476.5.

[0362] Step B: Preparation of (S)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethylpiperidine-4-sulfonamide hydrochloride

[0363] 0.36 g (0.81 mmol) of (S)-tert-butyl 4-(N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)sulfonyl)piperidine-1-carboxylate was dissolved in 10 mL of 1 mol / L HCl methanol solution and stirred at room temperature for 2 h. After the reaction was completed, the reaction solution was concentrated to obtain 0.27 g of crude product. The obtained product was directly used in the next step without purification.

[0364] Step C: Preparation of (S)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperidine-4-sulfonamide

[0365] In a 35 mL microwave tube, 0.13 g (0.33 mmol) of (S)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethylpiperidine-4-sulfonamide hydrochloride, 10 mL of isopropanol, 0.14 g (1.33 mmol) of triethylamine, and 0.075 g (0.33 mmol) of 2-chloro-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine were added in sequence, and the reaction was heated at 120° C. in a microwave reactor for 5 h. After the reaction was completed, the reaction solution was poured into 50 mL of water, extracted twice with ethyl acetate, and the organic phases were combined. The organic phase was washed three times with saturated brine and dried over anhydrous sodium sulfate. Filtered, the filtrate was concentrated, and the crude product was subjected to column chromatography to obtain 43 mg of the target product as a white powder solid.

[0366] 1H-NMR (500MHz, DMSO-d6): δ11.85(s,1H),9.20(s,1H),8.67(d,J=4.5Hz,1H),8.47(s,1H),8 .01(d,J=8.5Hz,1H),7.92-7.85(m,3H),6.22(br,1H),6.09(br,1H),4.71(t,J=8.5Hz,1H),4 .63(t,J=7Hz,1H),3.14(t,J=8.5Hz,1H),2.81(t,1H),2.81(t,J=12Hz,1H),2.71(t,J=12Hz ,1H),2.20(s,3H),2.10(s,3H),2.00(d,J=12.5Hz,1H),1.90(d,J=12.5Hz,1H),1.46(m,4H);

[0367] MS (ESI, [M+H] + )m / z:541.4.

[0368] Example 19: Preparation of (S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0369] Reaction process:

[0370]

[0371] Step A: Preparation of tert-butyl (S)-4-(6-chloro-4-methylpyridin-2-yl)-2-methylpiperazine-1-carboxylate

[0372] 2,6-dichloro-4-methylpyridine (1 g, 6.17 mmol), tert-butyl (S)-2-methylpiperazine-1-carboxylate (1.236 g, 6.17 mmol), palladium acetate (0.069 g, 0.309 mmol), BINAP (0.384 g, 0.617 mmol), cesium carbonate (3.02 g, 9.26 mmol) and Dioxane were added to a 30 mL sealed tube in sequence. After nitrogen was purged, the mixture was placed in a microwave reactor and heated to 120°C at 100 W for 2 h. The mixture was filtered, the filtrate was collected and concentrated, and the crude product was purified by column chromatography to obtain 0.44 g of a brown solid target.

[0373] MS (ESI, [M+H] + )m / z:326.1.

[0374] Step B: Preparation of tert-butyl (S)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)piperazine-1-carboxylate

[0375] Tert-butyl (S)-4-(6-chloro-4-methylpyridin-2-yl)-2-methylpiperazine-1-carboxylate (439 mg, 1.349 mmol), 5-methyl-1H-pyrazole-3-amine (131 mg, 1.349 mmol), Pd2dba3 (61.8 mg, 0.067 mmol), DavePhos (53.1 mg, 0.135 mmol), LiHMDS (564 mg, 3.37 mmol) and THF (3 ml) were added to a 20 mL sealed tube in sequence. The air was purged with nitrogen and placed in a microwave reactor. The reaction was heated to 130 ° C at 100 W for 30 minutes. 2 mL of 1M saturated ammonium chloride solution was added dropwise under ice bath conditions to quench the reaction, and 20 mL of ethyl acetate was used for dilution. The organic phase was washed with saturated sodium chloride aqueous solution and dried over anhydrous sodium sulfate. The organic phase was concentrated and the resulting crude product was purified by column chromatography to obtain 0.320 g of the target compound as a yellow solid.

[0376] MS (ESI, [M+H] + )m / z:387.2.

[0377] Step C: Preparation of (S)-4-methyl-N-(5-methyl-1H-pyrazol-3-yl)-6-(3-methylpiperazin-1-yl)pyridin-2-amine trifluoroacetate

[0378] In a 50 mL round-bottom flask, 0.320 g (0.83 mmol) of tert-butyl (S)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)piperazine-1-carboxylate, 10 ml of DCM and 0.473 g (4.15 mmol) of trifluoroacetic acid were added in sequence and stirred at room temperature overnight. After the reaction was completed, the reaction solution was concentrated to obtain 0.31 g of a white solid product, which was directly used in the next step without purification.

[0379] MS (ESI, [M+H] + )m / z:287.1.

[0380] Step D: Preparation of (S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0381] Dissolve 0.011 g (0.037 mmol) of triphosgene in 5 mL of dichloromethane, cool to 0°C under nitrogen protection in an ice-salt bath, and drop 2 mL of a dichloromethane solution containing 0.226 g (0.807 mmol) of (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethylamine dihydrochloride and 0.716 g (6.456 mmol) of triethylamine. Stir the reaction solution at 0°C for 5 min, then add 0.31 g (0.807 mmol) of (S)-4-methyl-N-(5-methyl-1H-pyrazol-3-yl)-6-(3-methylpiperazin-1-yl)pyridin-2-amine trifluoroacetate and triethylamine, and stir at room temperature for 20 min. After the reaction is complete, add 50 mL of dichloromethane to dilute the reaction solution, and wash with 20 mL of saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and the obtained crude product was purified by column chromatography to obtain 131 mg of the target compound as a white powdery solid.

[0382] 1 H-NMR(500MHz,DMSO-d6):8.39(d,J=12.5Hz,2H),7.84(d,J=30.1Hz,2H),7. 57(s,1H),7.38(s,1H),6.92(s,2H),6.07(s,1H),5.88(d,J=17.4Hz,2H),5. 17(s,1H),4.18(s,1H),3.97-3.99(m,1H),3.78-3.89(m,2H),3.19–3.29(m, 2H),2.99–3.03(m,1H),2.26(s,3H),2.18(s,3H),1.56(s,3H),1.23(s,3H);

[0383] MS (ESI, [M+H] + )m / z:519.3.

[0384] Example 20: Preparation of (S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-methyl-4-(6-methyl-4-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0385] Reaction process:

[0386]

[0387] Step A: Preparation of tert-butyl (S)-4-(4-chloro-6-methylpyridin-2-yl)-2-methylpiperazine-1-carboxylate

[0388] In a 25mL single-mouth bottle, 2,4-dichloro-6-methylpyridine (2g, 12.34mmol), tert-butyl (S)-2-methylpiperazine-1-carboxylate (2.72g, 13.58mmol), Et3N (1.499g, 2.065ml, 14.81mmol) and DMSO (20mL) were added in sequence, and the mixture was heated to 100°C under nitrogen protection for 16h. 10mL of water was added to the reaction solution, and extracted with ethyl acetate, and the organic phase was collected, dried with anhydrous sodium sulfate, filtered, and concentrated to obtain a brown oil, which was purified by column chromatography to obtain 1.24g of a brown solid target.

[0389] MS (ESI, [M+H] + )m / z:326.3.

[0390] Step B: Preparation of tert-butyl (S)-2-methyl-4-(6-methyl-4-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)piperazine-1-carboxylate

[0391] Tert-butyl (S)-4-(6-chloro-4-methylpyridin-2-yl)-2-methylpiperazine-1-carboxylate (439 mg, 1.349 mmol), 5-methyl-1H-pyrazole-3-amine (131 mg, 1.349 mmol), Pd2dba3 (61.8 mg, 0.067 mmol), DavePhos (53.1 mg, 0.135 mmol), LiHMDS (564 mg, 3.37 mmol) and THF (3 mL) were added to a 20 mL sealed tube in sequence. The air was purged with nitrogen and placed in a microwave reactor. The reaction was heated to 130 ° C at 100 W for 30 minutes. 2 mL of 1M saturated ammonium chloride solution was added dropwise under ice bath conditions to quench the reaction, and 20 mL of ethyl acetate was used for dilution. The organic phase was washed with saturated sodium chloride aqueous solution and dried over anhydrous sodium sulfate. The organic phase was concentrated and the resulting crude product was purified by column chromatography to obtain 0.309 g of the target compound as a yellow solid.

[0392] MS (ESI, [M+H] + )m / z:387.4.

[0393] Step C: Preparation of (S)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-6-(3-methylpiperazin-1-yl)pyridin-4-amine

[0394] In a 50 mL round-bottom flask, 0.309 g (0.801 mmol) of tert-butyl (S)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)piperazine-1-carboxylate, 10 mL of DCM and 0.456 g (4.01 mmol) of trifluoroacetic acid were added in sequence and stirred at room temperature overnight. After the reaction was completed, the reaction solution was concentrated to obtain 0.30 g of a white solid product, which was directly used in the next step without purification.

[0395] MS (ESI, [M+H] + )m / z:287.1.

[0396] Step D: Preparation of (S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-methyl-4-(6-methyl-4-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0397] Dissolve 0.011 g (0.037 mmol) of triphosgene in 5 mL of dichloromethane, cool to 0°C under nitrogen protection in an ice-salt bath, and drop 2 mL of a dichloromethane solution containing 0.218 g (0.807 mmol) of (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl-1-amine dihydrochloride and 0.717 g (6.456 mmol) of triethylamine. Stir the reaction solution at 0°C for 5 min, then add 0.30 g (0.780 mmol) of (S)-4-methyl-N-(5-methyl-1H-pyrazol-3-yl)-6-(3-methylpiperazin-1-yl)pyridin-2-amine trifluoroacetate and triethylamine, and stir at room temperature for 20 min. After the reaction is complete, add 50 mL of dichloromethane to dilute the reaction solution, and wash with 20 mL of saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and the obtained crude product was purified by column chromatography to obtain 120 mg of the target compound as a white powdery solid.

[0398] 1H-NMR (500MHz, CDCl3) δ12.05 (s, 1H), 8.35 (d, J = 20.2Hz, 2H), 7.80 (s, 2H), 7.5 4(s,1H),6.88(s,1H),5.89(s,1H),5.84(s,1H),5.80(s,1H),5.05(s,1H),4.2 8(s,1H),3.83–3.85(m,1H),3.62–3.64(m,1H),3.51–3.53(m,1H),3.25–3.33( m,2H),3.13–3.15(m,1H),2.32(s,3H),2.17(s,3H),1.53(s,3H),1.13(s,3H);

[0399] MS (ESI, [M+H] + )m / z:519.6.

[0400] Example 21: Preparation of (1R,5S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carbothioamide

[0401] Reaction process:

[0402]

[0403] Step A: Preparation of (1R,5S)-3-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester

[0404] Add 0.3 g (1.341 mmol) of 2-chloro-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine, 5 mL of DMF, and 0.43 g (2.012 mmol) of tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate to a 100 mL single-mouth bottle. React at 100 ° C for 10 h under nitrogen protection. After the reaction is completed, add 50 ml of water to the reaction solution to dilute it and extract it with ethyl acetate. Combine the organic phases, dry them with anhydrous sodium sulfate, filter, concentrate, and purify them by column chromatography to obtain 380 mg of transparent granular solid.

[0405] MS (ESI, [M+H] + )m / z:400.5.

[0406] Step B: Preparation of 2-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine trifluoroacetate

[0407] In a 100mL single-mouth bottle, add (1R, 5S)-3-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester 0.38g (0.951mmol), dichloromethane 10mL, trifluoroacetic acid 0.868g (7.61mmol). React at room temperature for 12h. After the reaction is completed, the reaction solution is directly concentrated to obtain a white oil, and ethyl acetate is added for pulping and filtered to obtain 0.52g of a white powdery solid.

[0408] MS (ESI, [M+H] + )m / z:300.4.

[0409] Step C: Preparation of (1R,5S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carbothioamide

[0410] In a 50 mL single-necked bottle, add (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethan-1-amine dihydrochloride 0.16 g (0.573 mmol), chloroform 5 mL, triethylamine 0.23 g (2.293 mmol) and thiophosgene 0.079 g (0.688 mmol). Then add 2 mL of water to cover the reaction liquid surface. React at room temperature for 20 min. Remove the water layer, then add 2-((1R, 5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine trifluoroacetate 0.302 g (0.573 mmol), triethylamine 0.23 g (2.293 mmol) in 4 mL of chloroform solution. React at room temperature for 2 h. After the reaction was completed, 50 mL of dichloromethane was added to the reaction solution, and the organic phase was collected after washing with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain 140 mg of a yellow solid.

[0411] 1H-NMR (500MHz, CDCl3): δ12.10(s,1H),8.45(s,1H),8.36(d,J=4.5Hz,1H),7.87(s,2H),7.56(d,J=4.2Hz,1H),6.45(s,1H),6.11(s,1H),6.04 (s,1H),5.89(p,J=7.2Hz,1H),3.14(q,J=7.3Hz,4H),2.27(m,6H),1.65(d,J=7.0Hz,3H),1.34(t,J=7.3Hz,6H),0.89(dd,J=12.7,9.5Hz,1H);

[0412] MS (ESI, [M+H] + )m / z:548.2.

[0413] Example 22: Preparation of (S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-thiocarboxamide

[0414] Reaction process:

[0415]

[0416] Synthesis method: see Example 21

[0417] 1 H NMR (500MHz, CDCl3): δ8.44(s,1H),8.39(d,J=4.5Hz,1H),7.91(d,J=8.5Hz,1H),7.84(d,J=8.0Hz,1H),7.58(d,J=8.5Hz,1H),7.22(s,1H),6.10(s ,1H),6.04(s,1H),5.93(m,1H),5.86(s,1H),4.79(s,1H),4.38(m,3H),3 .49(m,4H),2.32(s,3H),2.25(s,3H),1.67(d,J=8.0Hz,3H),1.29(m,3H);

[0418] MS (ESI, [M+H] + )m / z:536.2.

[0419] Example 23: Preparation of (1R, 5S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-(4-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-amide

[0420] Reaction process:

[0421]

[0422] Step A: Preparation of (1R,5S)-3-(4-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester

[0423] Add 0.3 g (1.431 mmol) of 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine, 5 mL of DMF, and 0.456 g (2.147 mmol) of tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate to a 100 mL single-mouth bottle. React at 100 ° C for 10 h under nitrogen protection. After the reaction is completed, add 50 mL of water to dilute the reaction solution and extract with ethyl acetate. Combine the organic phases, dry with anhydrous sodium sulfate, filter, concentrate, and purify by column chromatography to obtain 0.52 g of brown solid.

[0424] MS (ESI, [M+H] + )m / z:386.5.

[0425] Step B: Preparation of 2-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl)-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine trifluoroacetate

[0426] In a 100 ml single-mouth bottle, add 0.52 g (1.341 mmol) of (1R, 5S)-3-(4-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 10 ml of dichloromethane, and 1.223 g (10.73 mmol) of trifluoroacetic acid. React at room temperature for 12 h. After the reaction is completed, the reaction solution is directly concentrated to obtain a white oil, and 20 ml of ethyl acetate is added to pulp and filtered to obtain 0.76 g of a yellow-white powdery solid.

[0427] MS (ESI, [M+H] + )m / z:286.4.

[0428] Step C: Preparation of (1R,5S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-(4-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-amide

[0429] Dissolve 0.064 g (0.217 mol) of triphosgene in 3 mL of dichloromethane in a 50 mL three-necked flask, and cool to 0°C in an ice-salt bath under nitrogen protection. Add 3 mL of dichloromethane solution containing 0.055 g (0.197 mmol) of (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethan-1-amine dihydrochloride and 0.160 g (1.576 mmol) of triethylamine dropwise. Stir the reaction solution at 0°C for 5 min. Add 0.100 g (0.197 mmol) of 2-((1R, 5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-4-amine trifluoroacetate and 3 mL of dichloromethane solution of 0.160 g (1.576 mmol) of triethylamine. React at room temperature for 30 min. After the reaction is completed, add 50 mL of dichloromethane to the reaction solution to dilute it, wash it with saturated brine, and collect the organic phase. The organic phase is dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain 54 mg of a yellow solid.

[0430] 1 H-NMR (500MHz, CDCl3): δ12.05(s,1H),11.21(s,4H),8.43(s,1H),8.36(d,J=4.7Hz,1H),7.88(m, 3H),7.55(d,J=4.4Hz,1H),3.67(m,7H),3.37–3.17(m,3H),2.32(s,3H),1.92(s,2H),1.72(s,2H);

[0431] MS (ESI, [M+H] + )m / z:518.3.

[0432] Example 24: Preparation of N-(4-fluorophenyl)-N-(1-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperidin-4-yl)cyclopropane-1,1-dicarboxamide

[0433] Reaction process:

[0434]

[0435] Step A: Preparation of methyl 1-((4-fluorophenyl)amidomethyl)cyclopropyl-1-carboxylate

[0436] In a 100mL three-necked flask, add 20mL toluene, 2.22g (19.98mmol) of 4-fluoroaniline, and 4.32g (19.98mmol) of sodium methoxide in sequence. React at 100℃ for 30min under nitrogen protection, then cool to 66℃ and evaporate the methanol in the reaction system under nitrogen flow. After the methanol is completely evaporated, add 3.79g (23.97mmol) of dimethyl 1,1-cyclopropanedicarboxylate. React at 66℃ under nitrogen protection, and evaporate the methanol with nitrogen flow every 1h until the reaction is complete. Concentrate the reaction solution to obtain an oily substance, add 100mL of water and adjust the pH of the system to weak acidity with 1.2M dilute hydrochloric acid. Extract with dichloromethane. Combine the organic phases, dry them over anhydrous sodium sulfate, filter, concentrate and purify by column chromatography to obtain 2.07g of yellow-green solid.

[0437] MS (ESI, [MH] - )m / z:236.2.

[0438] Step B: Preparation of 1-((4-fluorophenyl)amidomethyl)cyclopropyl-1-carboxylic acid.

[0439] Add 5 mL of methanol, 0.13 g (0.548 mmol) of methyl 1-((4-fluorophenyl)amidomethyl)cyclopropyl-1-carboxylate and 1.1 mL of 1N sodium hydroxide aqueous solution into a 50 mL single-mouth bottle. React overnight at room temperature. Pour 50 mL of ice water into the reaction solution and then drop 1 M dilute hydrochloric acid to adjust the pH of the system to weak acidity. Extract with dichloromethane, combine the organic phases, dry over anhydrous sodium sulfate, filter and concentrate to obtain 0.12 g of a white powdery solid.

[0440] MS (ESI, [MH] - )m / z:222.2.

[0441] Step C: Preparation of tert-butyl (1-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperidin-4-yl)aminocarboxylate

[0442] In a 100mL single-mouth bottle, add 1g (4.47mmol) of 2-chloro-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine, 10mL of DMF and 0.985g (4.92mmol) of 4-tert-butyloxycarbonylaminopiperidine. React at 100℃ for 8h under nitrogen protection. Pour 80mL of water into the reaction solution to dilute it, extract it with dichloromethane, combine the organic phases, dry them with anhydrous sodium sulfate, filter, concentrate and purify them by column chromatography to obtain 1.54g of white powdery solid.

[0443] MS (ESI, [M+H] +)m / z:388.5.

[0444] Step D: Preparation of 2-(4-aminopiperidin-1-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-4-aminotrifluoroacetate

[0445] In a 100mL single-mouth bottle, add tert-butyl (1-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperidin-4-yl)carbamate 1.54g (3.97mmol), dichloromethane 20ml and trifluoroacetic acid 4.53g (39.7mmol). React at room temperature for 12h. After the reaction is completed, directly concentrate the reaction solution, add 20mL of ethyl acetate to pulp, and filter to obtain 2.1g of white powdery solid.

[0446] MS (ESI, [M+H] + )m / z:288.3.

[0447] Step E: Preparation of N-(4-fluorophenyl)-N-(1-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperidin-4-yl)cyclopropane-1,1-dicarboxamide

[0448] In a 100mL single-mouth bottle, add 0.12g (0.538mmol) of 1-((4-fluorophenyl)amidomethyl)cyclopropyl-1-carboxylic acid, 5mL of DMF, and 0.307g (0.645mmol) of HATU. Dissolve 0.33g (0.645mmol) of 2-(4-aminopiperidin-1-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-4-aminotrifluoroacetate and 0.556g (4.3mmol) of DIPEA in 5mL of DMF and add to the above reaction system. React at room temperature for 4h. After the reaction is completed. Pour 80ml of purified water into the reaction solution and extract with ethyl acetate. Combine the organic phases, dry them over anhydrous sodium sulfate, filter, concentrate, and purify by column chromatography to obtain 0.15g of white solid.

[0449] 1H-NMR (500MHz, CDCl3): δ10.43 (s, 1H), 7.52 (dd, J = 8.8, 4.8Hz, 2H), 7.12 (s, 1 H),7.02(t,J=8.5Hz,2H),6.10(s,1H),6.03(d,J=8.2Hz,2H),4.66(dd,J=13.8 ,3.9Hz,2H),4.05(m,1H),3.11–2.99(m,2H),2.31(s,3H),2.24(s,3H),1.98(d ,J=15Hz,2H),1.70(q,J=4.7Hz,2H),1.46–1.39(m,3H),1.32(q,J=4.6Hz,2H);

[0450] MS (ESI, [M+H] + )m / z:493.2.

[0451] Example 25: Preparation of (1R, 5S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)oxy)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide

[0452] Reaction process:

[0453]

[0454] Step A: Preparation of 2-chloro-4-methyl-6-((5-methyl-1H-pyrazol-3-yl)oxy)pyrimidine

[0455] 1.309 g (8.03 mmol) of 2,4-dichloro-6-methylpyrimidine, 20 mL of DMF, 0.876 g (8.93 mmol) of 5-methyl-1H-pyrazole-3-ol and 1.315 g (10.17 mmol) of DIPEA were added to a 100 mL round-bottom flask in sequence, stirred evenly, and heated to 85 °C for 20 h. Heating was stopped, the temperature was cooled to room temperature, 50 mL of water was added to the reaction solution for dilution, and extracted with ethyl acetate, and the organic phases were combined and washed with saturated sodium chloride aqueous solution. The organic phase was dried over anhydrous sodium sulfate and concentrated, and the crude product was purified by column chromatography to obtain 0.718 g of a white solid.

[0456] MS (ESI, [M+Na] + )m / z:247.1.

[0457] Step B: Preparation of tert-butyl (1R,5S)-3-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)oxy)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8carboxylate

[0458] 0.2 g (0.890 mmol) of 2-chloro-4-methyl-6-((5-methyl-1H-pyrazol-3-yl)oxy)pyrimidine, 10 mL of DMF, 0.227 g (1.068 mmol) of (1R, 5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester and 0.246 g (1.781 mmol) of potassium carbonate were added to a 100 mL single-mouth bottle in sequence. Under N2 protection, the mixture was heated to 100 ° C for 7 h. The reaction solution was directly poured into 50 mL of ice water and extracted with ethyl acetate. The organic phase was collected and dried over anhydrous sodium sulfate. Filtered, concentrated, and purified by column chromatography to obtain 0.26 g of off-white powdery solid.

[0459] MS (ESI, [M+H] + )m / z:401.4.

[0460] Step C: Preparation of trifluoroacetic acid salt of (1R,5S)-3-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)oxy)-6-pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane

[0461] 0.39 g (0.974 mmol) of (1R, 5S)-3-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)oxy)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8carboxylic acid tert-butyl ester, 10 mL of DCM and 1.105 g (0.746 mL, 9.69 mmol) of trifluoroacetic acid were added to a 100 mL single-mouth bottle and stirred at room temperature overnight. The reaction solution was concentrated to obtain a colorless oil, 10 mL of ethyl acetate was added and stirred at room temperature for 30 min. Filtered to obtain 0.32 g of a white powdery solid.

[0462] MS (ESI, [M+H] + )m / z:301.3.

[0463] Step D: Preparation of (1R,5S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)oxy)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide

[0464] Triphosgene 179mg (0.602mmol) and dichloromethane 5mL were added to a 50mL three-necked flask in sequence. The temperature was lowered to 0℃ under N2 protection in an ice-salt bath, and a dichloromethane solution 5mL containing (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethan-1-amine dihydrochloride 210mg (0.753mmol) and triethylamine 0.4mL was added dropwise. After the reaction solution was stirred at 0℃ for 5min, 10mL of DCM containing trifluoroacetate 300mg (0.753mmol) of (1R,5S)-3-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)oxy)-6-pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane and triethylamine 0.8mL was added to the above reaction solution. The reaction solution was stirred at low temperature for 5-10 minutes, and then transferred to room temperature and stirred for 20 minutes. 50 mL of dichloromethane was added to the reaction solution for dilution, and then washed with a saturated sodium chloride aqueous solution. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by column chromatography to obtain 250 mg of a white powdery solid.

[0465] 1 H-NMR (500MHz, DMSO-d6): δ12.17(s,1H),8.66(d,J=5Hz,1H),8.41(s,1H),7.91(m,3H),7.08(d,J=10.0Hz,1H),6.01(s,1H),5.83(s, 1H), 4.95 (m, 1H), 4.30 (m, 4H), 2.97 (d, J = 10.0Hz, 2H), 2.23 (d, J = 5Hz, 6H), 1.75 (s, 2H), 1.54 (d, J = 10.0Hz, 2H), 1.45 (d, J = 5.0Hz, 3H).

[0466] MS (ESI, [M+H] + )m / z:533.4.

[0467] Example 26: Preparation of (1R,5S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-(6-methyl-2-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide

[0468] Reaction process:

[0469]

[0470] Step A: Preparation of tert-butyl (1R, 5S)-3-(2-chloro-6-methylpyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0471] In a 50mL single-mouth bottle, add 90mg (0.552mmol) of 2,4-dichloro-6-methylpyrimidine, 10mL of n-butanol, 129mg (0.607mmol) of tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate and 107mg (0.145ml, 0.828mmol) of diisopropylethylamine, and heat the mixture to 100℃ for 15h. After the reaction is complete, add 50mL of ethyl acetate to the reaction system and wash twice with 20mL of water. Collect the organic phase, dry it with anhydrous sodium sulfate, filter it, and concentrate it. The crude product is purified by column chromatography to obtain 154mg of the target beige solid.

[0472] MS (ESI, [M+H] + )m / z:339.4.

[0473] Step B: Preparation of (1R,5S)-3-(6-methyl-2-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]]octane-8-carboxylic acid tert-butyl ester

[0474] In a 50mL single-mouth bottle, add (1R, 5S)-3-(2-chloro-6-methylpyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester 122mg (0.360mmol), isopropanol 5mL and 5-methyl-1H-pyrazole-3-amine 175mg (1.800mmol) in sequence. Under nitrogen protection, heat the mixture to 100℃ and react for 36h. Concentrate to remove the solvent, add 5mL of a mixed solution of ethanol and water (ethanol: water = 1:3) to the reaction system. Add potassium carbonate 59.7mg (0.432mmol) to the reaction system and stir at room temperature for 1.5h. Add 50mL of ethyl acetate and 20mL of water to the reaction system. Separate the organic phase, collect the organic phase, dry it with anhydrous sodium sulfate, filter it, and concentrate it to obtain a light yellow oil. Purify it by column chromatography to obtain a colorless oil totaling 0.2g.

[0475] MS (ESI, [M+H] + )m / z:400.4.

[0476] Step C: Preparation of 4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-2-amine trifluoroacetate

[0477] In a 100mL single-mouth bottle, add 0.2g (0.5mmol) of (1R, 5S)-3-(6-methyl-2-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]]octane-8-carboxylic acid tert-butyl ester, 5mL of dichloromethane, and 0.868g (2.50mmol) of trifluoroacetic acid. React at room temperature for 12h. After the reaction is completed, the reaction solution is directly concentrated to obtain a white oil, which is then slurried with ethyl acetate and filtered to obtain 0.218g of a white powdery solid.

[0478] MS (ESI, [M+H] + )m / z:300.4.

[0479] Step D: Preparation of (1R,5S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-(6-methyl-2-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide

[0480] In a 50mL three-necked flask, 0.043g (0.145mmol) of triphosgene was dissolved in 3mL of dichloromethane. Under nitrogen protection, the temperature was cooled to about 0°C in an ice-salt bath. In another 35mL microwave tube, 0.090g (0.440mmol) of (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl-1-amine dihydrochloride was dissolved in 2mL of dichloromethane, and 0.137g (1.23mmol) of triethylamine was added. The neutralized raw materials were slowly added dropwise to the dichloromethane solution of triphosgene, and the addition was completed after about 2 minutes. The reaction solution was stirred at 0°C for 5min. Add 3 mL of dichloromethane solution containing 0.09 g (0.44 mmol) of 4-((1R, 5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2-amine trifluoroacetate and 0.08 g (0.72 mmol) of triethylamine. Stir the reaction solution at 0°C for 5 min, then warm to room temperature and stir for 20 min. Add 50 mL of dichloromethane to the reaction solution to dilute it and wash it with saturated brine. Collect the organic phase, dry it over anhydrous sodium sulfate, filter it, and concentrate it. The crude product obtained is purified by column chromatography to obtain 49 mg of a white powdery solid.

[0481] 1H-NMR (500MHz, DMSO-d6): δ12.23(s,1H),10.34(s,1H),8.66(d,J=3.5Hz,1 H),8.43(s,1H),7.91(m,3H),7.31(d,J=7.5Hz,1H),6.35(s,1H),6.09(s,1 H),4.95(d,J=7.0Hz,1H),4.49(m,2H),4.43(m,2H),3.01(m,2H),2.28(s,3 H),2.22(s,3H),1.80(s,2H),1.57(d,J=3.0Hz,2H),1.46(d,J=6.5Hz,3H);

[0482] MS (ESI, [M+H] + )m / z:532.5.

[0483] Example 27: Preparation of (1R,5S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide

[0484] Reaction process:

[0485]

[0486] The synthesis method is similar to that of Example 19.

[0487] 1 H NMR (500MHz, CDCl3): δ11.64(s,1H),8.61(m,2H),8.42(s,1H),7.88(m,3H),7.13(d,J=7.5Hz,1H),6.33(s,1H),6.23(s,1H),5.86(s,1H),4. 95(m,1H),4.44(m,2H),3.84(m,2H),2.89(m,2H),2.18(s,3H),2.11(s ,3H),1.77(d,J=3.5Hz,2H),1.67(d,J=7.5Hz,2H),1.45(d,J=7Hz,3H).

[0488] MS (ESI, [M+H] + )m / z:531.3.

[0489] Example 28: Preparation of (S)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-4-(3-methyl-5-((5-methyl-1H-pyrazol-3-yl)amino)phenyl)piperazine-1-carboxamide

[0490] Reaction process:

[0491]

[0492] The synthesis method is similar to that of Example 19.

[0493] 1 H NMR (500MHz, DMSO-d6): δ11.60(s,1H),10.27(s,1H),8.66(d,J=4.5Hz,1H),8.41(m,1H),7.93(m,4H),7.04(d,J=7.5Hz,1H) ,6.78(s,1H),6.16(s,1H),5.58(s,1H),4.93(m,1H),3.47(d,J=4.5Hz,4H),3.33(s,4H),2.17(s,6H),1.44(d,J=7.0Hz,3H).

[0494] MS (ESI, [M+H] + )m / z:504.3.

[0495] Example 29: Preparation of N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)cyclopropyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0496] Reaction process:

[0497]

[0498] Step A: Preparation of 1-(6-bromopyridin-3-yl)cyclopropane-1-amine

[0499] In a 25mL three-necked flask, add 6.99g (24.59mmol) of tetraisopropyl titanate and THF (3mL) in sequence, and heat the mixture to 50°C under N2 protection. Then add 3g (16.39mmol) of 2-bromo-5-cyanopyridine, and slowly add 5.46g (41.0mmol) of ethylmagnesium bromide at 50°C. Heat at 50°C for 4h. After the reaction is completed, concentrate the reaction solution and purify it by column chromatography to obtain 0.8g of a yellow solid product.

[0500] MS (ESI, [M+H] + )m / z:213.0,215.0.

[0501] Step B: Preparation of N-(1-(6-bromopyridin-3-yl)cyclopropyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0502] The synthesis method is similar to that of step G in Example 1.

[0503] MS (ESI, [M+H] + )m / z:512.1,514.1.

[0504] Step C: Preparation of N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)cyclopropyl)-(S)-4-(4-methyl-6-((methyl-1H-pyrazol-3-yl)yl)-2-yl)-N-(1-(6-((trimethylsilyl)ethynyl)pyrimidin-3-yl)ethyl)piperazine-1-carboxylic acid tert-butyl ester-1-carboxamide

[0505] In a 30 mL microwave tube, 300 mg (0.585 mmol) of N-(1-(6-bromopyridin-3-yl)cyclopropyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide, 252 mg (2.93 mmol) of 4-fluoro-1H-pyrazole, 572 mg (1.756 mmol) of cesium carbonate, 112 mg (0.585 mmol) of trans-(1R,2R)-N,N'-dimethyl1,2-cyclohexanediamine, 83 mg (0.585 mmol) of cuprous iodide and N,N-dimethylformamide (10 ml) were added in sequence, and the air was purged with N2, and the mixture was placed in a microwave reactor, heated to 120°C at 200 watts for 60 minutes. The reaction solution was directly poured into 50 mL of ice water and extracted with ethyl acetate. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by column chromatography to obtain 36 mg of the target product.

[0506] 1 H NMR(500MHz,Chloroform-d)δ8.38(s,2H),7.87(d,J=8.5Hz,1H),7.78(d,J=10.4Hz,1H),7.58(d,J=4.0Hz,1H),6.85(s, 1H),6.16(s,1H),6.04(s,1H),5.35(s,1H),3.85(s,4H),3.48(s,4H),2.33(s,3H),2.28(s,3H),1.32(d,J=14.6Hz,4H).

[0507] MS (ESI, [M+H] +)m / z:518.5.

[0508] Example 30: Preparation of (S)-N-(1-(6-(4-methyl-1H-imidazol-1-yl)pyridin-3-yl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0509] Reaction process:

[0510]

[0511] Step A: Preparation of (R)-N-((S)-1-(6-bromopyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide

[0512] The synthesis method is similar to that of step B in Example 1.

[0513] MS (ESI, [M+H] + )m / z:306.3.

[0514] Step B: Preparation of (R)-2-methyl-N-((S)-1-(6-(4-methyl-1H-imidazol-1-yl)pyridin-3-yl)ethyl)propane-2-sulfenamide Under nitrogen protection, (R)-N-((S)-1-(6-bromopyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide (350 mg, 1.147 mmol), DMF (10 mL) were added in sequence in a 30 mL sealed tube. ), 4-methylimidazole (284 mg, 3.46 mmol), cesium carbonate (1120 mg, 3.44 mmol), trans-(1R,2R)-N,N'-dimethyl-1,2-cyclohexanediamine (163 mg, 1.147 mmol), cuprous iodide (219 mg, 1.147 mmol), nitrogen was purged to remove air, placed in a microwave reactor, heated to 120°C at 100 W for 60 min.

[0515] Filter, collect and concentrate the filtrate, add 40 mL EA and 60 mL H2O, shake well to separate the liquids, dry over anhydrous sodium sulfate, filter, and concentrate. The crude product is purified by column chromatography to obtain 140 mg of a white solid.

[0516] MS (ESI, [M+H] + )m / z:307.1.

[0517] Step C: Preparation of (S)-1-(6-(4-(4-methyl-1H-imidazol-1-yl)pyridin-3-yl)ethan-1-amine hydrochloride

[0518] The synthesis method is similar to that of step C in Example 1.

[0519] MS (ESI, [M+H] + )m / z:203.2.

[0520] Step D: Preparation of (S)-N-(1-(6-(4-methyl-1H-imidazol-1-yl)pyridin-3-yl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0521] The synthesis method is similar to that of step G in Example 1.

[0522] 1 H NMR (500MHz, DMSO-d6) δ11.86 (s, 1H), 9.25 (s, 1H), 8.41 (d, J = 2.3Hz, 1H), 8. 36(d,J=1.3Hz,1H),7.91(dd,J=8.5,2.3Hz,1H),7.67(d,J=8.4Hz,1H),7.61 (s,1H),6.95(d,J=7.6Hz,1H),6.54–5.98(m,2H),4.92(p,J=7.1Hz,1H),3.7 4–3.59(m,4H),3.44–3.37(m,4H),2.22–2.10(m,9H),1.43(d,J=7.1Hz,3H).

[0523] MS (ESI, [M+H] + )m / z:502.3.

[0524] Example 31: Preparation of (S)-N-(1-(6-cyanopyridin-3-yl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0525] Reaction process:

[0526]

[0527] Step A: Preparation of (R)-N-((S)-1-(6-bromopyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide

[0528] The synthesis method is similar to that of step B in Example 1.

[0529] MS (ESI, [M+H] + )m / z:306.3.

[0530] Step B: Preparation of (R)-N-((S)-1-(6-cyanopyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide

[0531] Under nitrogen protection, (R)-N-((S)-1-(6-bromopyridin-3-yl)ethyl)-2-methylpropane-2-sulfinamide (1000 mg, 3.28 mmol), DMA (10 mL), dppf (150 mg, 0.271 mmol), zinc powder (80 mg, 1.224 mmol), zinc cyanide (300 mg, 2.56 mmol), Pd2(dba)3 (150 mg, 0.164 mmol) were added to a 30 mL sealed tube in sequence, and the air was purged with nitrogen. The mixture was placed in a microwave reactor and heated to 100°C at 100 W for 120 min. The mixture was filtered, the filtrate was collected and concentrated, 30 mL EA and 50 mL H2O were added, the liquid was separated by shaking, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography to obtain 700 mg of a yellow solid.

[0532] MS (ESI, [M+H] + )m / z:252.1.

[0533] Step C: Preparation of (S)-5-(1-aminoethyl)pyridinium hydrochloride

[0534] The synthesis method is similar to that of step C in Example 1.

[0535] MS (ESI, [M+H] + )m / z:148.0.

[0536] Step D: Preparation of (S)-N-(1-(6-cyanopyridin-3-yl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0537] The synthesis method is similar to that of step G in Example 1.

[0538] 1 H NMR (500MHz, DMSO-d6) δ11.86(s,1H),9.26(s,1H),8.76–8.70(m,1H),7.98(qd,J=8.1,1.4Hz,2H),7.04(d,J=7.3Hz,1H),6.18( d,J=41.0Hz,2H),4.95(p,J=7.1Hz,1H),3.73–3.63(m,4H),3.44–3.36(m,4H),2.21(s,3H),2.13(s,3H),1.43(d,J=7.1Hz,3H).

[0539] MS (ESI, [M+H] + )m / z:447.3.

[0540] Example 32: Preparation of (S)-N-(1-(6-ethynylpyridin-3-yl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)yl)pyridin-2-yl)piperazine-1-carboxamide

[0541] Reaction process:

[0542]

[0543] Step A: Preparation of (R)-N-((S)-1-(6-bromopyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide

[0544] The synthesis method is similar to that of step B in Example 1.

[0545] MS (ESI, [M+H] + )m / z:305.0

[0546] Step B: Preparation of (R)-2-methyl-N-((S)-1-(6-((trimethylsilyl)ethynyl)pyrimidin-3-yl)ethyl)propane-2-sulfenamide

[0547] In a 30mL microwave tube, 404mg (1.324mmol) of (R)-N-((S)-1-(6-bromopyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide, 260mg (2.65mmol) of trimethylethynylsilane, 46.5mg (0.066mmol) of bistriphenylphosphine palladium dichloride, 25mg (0.132mmol) of cuprous iodide and 670mg (6.62mmol) of triethylamine were added in sequence, and acetonitrile (10ml) was added. Under the protection of N2, the mixture was heated to 120°C for 10min. After the reaction was completed, the reaction solution was concentrated and purified by column chromatography to obtain 0.38g of a yellow solid product.

[0548] MS (ESI, [M+H] + )m / z:323.1.

[0549] Step C: Preparation of (S)-1-(6-((trimethylsilyl)ethynyl)pyrimidin-3-yl)ethane-1-amine

[0550] The synthesis method is similar to that of step C in Example 1.

[0551] MS (ESI, [M+H] + )m / z:219.2.

[0552] Step D: Preparation of (S)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-N-(1-(6-((trimethylsilyl)ethynyl)pyridin-3-yl)ethyl)piperazine-1-carboxamide

[0553] The synthesis method is similar to that of step G in Example 1.

[0554] MS (ESI, [M+H] + )m / z:518.4.

[0555] Step E: Preparation of (S)-N-(1-(6-ethynylpyridin-3-yl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0556] In a 50 mL eggplant-shaped bottle, 660 mg (1.275 mmol) of (S)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-N-(1-(6-((trimethylsilyl)ethynyl)pyridin-3-yl)ethyl)piperazine-1-carboxamide, 2 ml of dichloromethane and 3 ml of methanol were added in sequence, followed by 881 mg (6.37 mmol) of potassium carbonate. The mixture was reacted at room temperature for 3 h under N2 protection. After the reaction was completed, the reaction solution was concentrated and purified by column chromatography to obtain 58 mg of the target product.

[0557] 1 H NMR(500MHz,Chloroform-d)δ8.61(s,1H),7.66(d,J=7.8Hz,1H),7.46(d,J=7.7Hz,1H),7.29(s,1H),7.12(s,1H),6.09(d ,J=55.0Hz,2H),5.07-5.10(m,1H),4.88(d,J=6.2Hz,1H),3.83(s,4H),3.48(s,4H),2.29(d,J=27.2Hz,6H),1.55(s,3H).

[0558] MS (ESI, [M+H] + )m / z:446.2.

[0559] Example 33: Preparation of (S)-N-(1-(2-cyanopropane-2-yl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0560] Reaction process:

[0561]

[0562] Step A: Preparation of 2-(5-bromopyridin-2-yl)-2-methylpropionitrile

[0563] In a 25mL three-necked flask, 2g (10.15mmol) of 2-(5-bromopyridin-2-yl)acetonitrile, 2.285g (25.4mmol) of potassium tert-butoxide, 402mg (1.523mmol) of 18-crown ether-6 and tetrahydrofuran (10ml) were added in sequence, and stirred at room temperature under N2 protection. Subsequently, 11.53g (81mmol) of iodomethane was added, and the reaction was allowed to proceed overnight at room temperature. The reaction solution was evaporated under reduced pressure on a rotary evaporator to remove the solvent, and purified by column chromatography to obtain 1.66g of a white solid product.

[0564] MS (ESI, [M+H] + )m / z:225.0

[0565] Step B: Preparation of 2-(5-acetylpyridin-2-yl)-2-methylpropionitrile

[0566] Take a 25ml three-necked flask, add 1.2g (5.33mmol) of 2-(5-bromopyridin-2-yl)-2-methylpropionitrile and 10ml of tetrahydrofuran, and cool to -78°C under nitrogen protection. Use a syringe to add 0.41g (6.4mmol) of n-butyl lithium dropwise to the reaction liquid system, keeping the internal temperature below -65°C. After the addition, stir at low temperature for 15min. Dissolve 0.715g (6.93mmol) of N,N-dimethylacetamide in 5ml of THF, and add dropwise to the reaction system with a syringe, keeping the internal temperature below -65°C. After the addition, stir at low temperature for 2h. The reaction solution is evaporated under reduced pressure by a rotary evaporator to remove the solvent, and purified by column chromatography to obtain 1.66g of white solid product.

[0567] MS (ESI, [M+H] + )m / z:189.3.

[0568] Step C: Preparation of (R)-N-((S)-2-(5-(1-aminoethyl)pyridin-2-yl)-2-methylpropionitrile)-2-methylpropane-2-sulfenamide

[0569] The synthesis method is similar to that of step B in Example 1.

[0570] MS (ESI, [M+H] + )m / z:294.3.

[0571] Step D: Preparation of (S)-2-(5-(1-aminoethyl)pyridin-2-yl)-2-methylpropionitrile

[0572] The synthesis method is similar to that of step C in Example 1.

[0573] MS (ESI, [M+H] + )m / z:190.2.

[0574] Step E: Preparation of (S)-N-(1-(2-cyanopropane-2-yl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0575] The synthesis method is similar to that of step G in Example 1.

[0576] 1 H NMR(500MHz,Chloroform-d)δ10.98(s,1H),8.60(s,1H),8.27(s,1H),7.70(s,1H),7.51(s,1H),6.10(d,J=26.0Hz,2H) ,5.21(s,1H),5.04-5.06(m,1H),3.81(s,4H),3.50(s,4H),2.27(d,J=19.5Hz,6H),1.75(s,6H),1.52(d,J=6.8Hz,3H).

[0577] MS (ESI, [M+H] + )m / z:489.3.

[0578] Example 34: Preparation of (S)-N-(1-(6-cyclopropylpyridin-3-yl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0579] Reaction process:

[0580]

[0581] Step A: Preparation of (R)-N-((S)-1-(6-bromopyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide

[0582] The synthesis method is similar to that of step B in Example 1.

[0583] MS (ESI, [MH] - )m / z: 303.0. Step B: Preparation of (R)-N-((S)-1-(6-cyclopropylpyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide

[0584] In a 50 mL eggplant-shaped bottle, 405 mg (1.327 mmol) of (R)-N-((S)-1-(6-bromopyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide, 228 mg (2.65 mmol) of cyclopropylboric acid, 74 mg (0.265 mmol) of tricyclohexylphosphine, 925 mg (5.31 mmol) of potassium phosphate and 30 mg (0.133 mmol) of palladium acetate were added in sequence, and water (1 mL) and toluene (5 mL) were added. Under the protection of N2, the mixture was heated to 110°C for 6 h. Stirring was stopped, the reaction solution was cooled to room temperature, the solvent was evaporated under reduced pressure by a rotary evaporator, and 220 mg of brown oil was obtained by column chromatography purification.

[0585] MS (ESI, [M+H] + )m / z:267.1

[0586] Step C: Preparation of (S)-1-(6-cyclopropylpyridin-3-yl)ethane-1-amine

[0587] The synthesis method is similar to that of step C in Example 1.

[0588] MS (ESI, [M+H] + )m / z:163.1.

[0589] Step D: Preparation of (S)-N-(1-(6-cyclopropylpyridin-3-yl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0590] The synthesis method is similar to that of step G in Example 1.

[0591] 1 H NMR(500MHz,Chloroform-d)δ8.46(s,1H),7.53(d,J=10.1Hz,1H),7.10(d,J=8.1Hz,1H),7.05(s,1H),6.13(s,1H),6.04(s,1H),5.01-5.06(m,1H), 4.73(d,J=6.8Hz,1H),3.81-3.83(m,4H),3.45-3.50(m,4H),2.32(s,3H), 2.26(s,3H),2.01-2.06(m,1H),1.52(d,J=6.9Hz,3H),0.98-1.01(m,4H).

[0592] MS (ESI, [M+H] + )m / z:462.3.

[0593] Example 35: Preparation of (S)-N-(1-(6-(methoxypyridin-3-yl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0594]

[0595] The synthesis method is as in Example 1.

[0596] 1 H NMR (500MHz, DMSO-d6) δ11.84(s,1H),9.24(s,1H),8.09(d,J=2.4Hz,1H),7.68(dd,J=8.6,2.5Hz,1H),6.83(d,J=7.8Hz,1H),6.76(d,J =8.5Hz,1H),4.83(p,J=7.2Hz,1H),3.81(s,3H),3.69–3.61(m,4H),3.41–3.35(m,4H),2.20(s,3H),2.12(s,3H),1.38(d,J=7.1Hz,3H).

[0597] MS (ESI, [M+H] + )m / z:452.3.

[0598] Example 36: Preparation of (S)-N-(1-(6-isopropoxypyridin-3-yl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-amide

[0599] Reaction process:

[0600]

[0601] Step A: Preparation of 1-(6-isopropoxypyridin-3-yl)ethanone

[0602] Add 2.0 g (9.26 mmol) of 2-isopropoxy-5-bromopyridine and 20 mL of THF to a 50 mL three-necked flask. Cool down to -78 °C under nitrogen protection. Then slowly add 0.72 g (2.5 mol / L, 11.24 mmol) of n-butyl lithium. Stir for a while at low temperature after the addition is complete. Dissolve 1.241 g (12.03 mmol) of N-methoxy-N-methylacetamide in 5 ml of THF and slowly add it to the reaction system. After the reaction is completed, add 20 mL of saturated ammonium chloride solution to the reaction solution to quench the reaction. Then pour the reaction solution into 100 mL of purified water. Extract with EA, combine the organic phases, add anhydrous sodium sulfate and dry. Filter and concentrate to obtain 1.59 g of yellow oil.

[0603] MS (ESI, [M+H] + )m / z:180.1.

[0604] Step B: Preparation of (S,Z)-N-(1-(6-isopropoxypyridin-3-yl)ethylidene)-2-methylpropane-2-sulfenamide

[0605] In a 50mL single-mouth bottle, add 1-(6-isopropoxypyridin-3-yl)ethanone 1.59g (8.87mmol), THF 25mL, diethylene glycol dimethyl ether 2.98g (22.18mmol), tetraethyl titanate 5.06g (22.18mmol), (R)-(+)-tert-butylsulfenamide 2.69g (22.28mmol). React at 80°C under nitrogen protection. After the reaction is completed, pour the reaction solution into 100mL purified water, and a large amount of white solid precipitates. After suction filtration, wash the filter cake with EA, combine the organic phases, add anhydrous sodium sulfate and dry. Then filter, concentrate and purify by column chromatography to obtain 1.8g of yellow liquid.

[0606] MS (ESI, [M+H] + )m / z:283.3.

[0607] Step C: Preparation of (S)-N-((S)-1-(6-isopropoxypyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide

[0608] Add (S,Z)-N-(1-(6-isopropoxypyridin-3-yl)ethylidene)-2-methylpropane-2-sulfenamide 1.8g (6.39mmol) and THF 20mL to a 100mL three-necked flask. Cool to -80°C. Then slowly add 2.43g (1mol / L, 12.78mmol) of lithium tri-sec-butylborohydride to the reaction system. After the addition is complete, react at -80°C. After the reaction is complete, add 10mL of methanol to the reaction system to quench the reaction. Then pour the reaction solution into 100mL of ice water, and a large amount of solid precipitates. After suction filtration, wash the filter cake with EA. Combine the organic phases, add anhydrous sodium sulfate to dry, concentrate, and purify by column chromatography to obtain 0.6g of white solid.

[0609] MS (ESI, [M+H] + )m / z:285.2.

[0610] Step D: Preparation of (S)-1-(6-isopropoxypyridin-3-yl)ethylamine hydrochloride

[0611] In a 100mL single-mouth bottle, add (S)-N-((S)-1-(6-isopropoxypyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide 0.672g (2.363mmol), methanol 20mL, and hydrogen chloride dioxane solution 5.9ml (4mol / L, 23.62mmol) in sequence. React at room temperature under nitrogen atmosphere. After the reaction is completed, evaporate the reaction solvent. After adding 20mL EA, a white solid precipitates. After pulping, filter, collect the filter cake, and vacuum dry to obtain 470mg of a white solid.

[0612] MS (ESI, [M+H] + )m / z:181.1.

[0613] Step E: Preparation of (S)-N-(1-(6-isopropoxypyridin-3-yl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0614] Add 0.142g (0.878mmol) of CDI and 10mL of DCM to a 50mL three-necked flask. Cool to 0℃ in an ice-salt bath under nitrogen protection. Take a 10mL test tube and add 0.202g (0.798mmol) of (S)-1-(6-isopropoxypyridin-3-yl)ethylamine hydrochloride, 0.485g (4.79mmol) of triethylamine, and 5mL of DCM, and slowly add the solution to the reaction system. After about 30 minutes of low-temperature reaction, add 5mL of DCM solution containing 0.4g (0.798mmol) of 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-(piperazine-1-yl)pyrimidine-4-amine trifluoroacetate and 0.485g (4.79mmol) of triethylamine to the reaction system. After the reaction is completed, pour the reaction solution into 100mL of purified water and extract with DCM. The combined organic phases were dried over anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography to obtain 120 mg of a white solid.

[0615] 1H NMR(500MHz,DMSO-d6)δ11.86(s,1H),9.25(s,1H),8.07(d,J=2.1Hz,1H),7.6 5(s,2H),7.02(s,1H),6.82(d,J=7.7Hz,1H),6.68(d,J=8.5Hz,1H),5.21(hep t,J=6.2Hz,1H),4.83(p,J=7.0Hz,1H),3.66(t,J=5.0Hz,4H),3.38(t,J=5.0H z, 4H), 2.21 (s, 3H), 2.13 (s, 3H), 1.38 (d, J = 7.0Hz, 3H), 1.27 (d, J = 6.2Hz, 6H).

[0616] MS (ESI, [M+H] + )m / z:480.3.

[0617] Example 37: Preparation of (S)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-N-(1-(6-(pyrrolidin-1-yl)pyridin-3-yl)ethyl)piperazine-1-carboxamide

[0618] Reaction process:

[0619]

[0620] Step A: Preparation of (R)-N-((S)-1-(6-bromopyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide

[0621] In a 250mL three-necked flask, add 1-(6-bromopyridin-3-yl)ethane-1-one (5.26g, 26.3mmol), THF (100mL), tetraethyl titanate (12.00g, 52.6mmol), (R)-(+)-tert-butylsulfenamide (6.37g, 52.6mmol), diethylene glycol dimethyl ether (3.53g, 26.3mmol), replace with nitrogen three times, heat to 75℃, and heat to react for 7h. Cool the reaction system to -78℃, blow off the air with nitrogen, and under nitrogen protection, measure lithium tri-sec-butyl borohydride (15.00g, 79mmol), control the temperature not higher than -70℃ and add it dropwise to the bottle. Control the temperature not higher than -40℃ and react for 4h. The reaction solution was quenched by adding 30 mL of MeOH, poured into 300 mL of ice water and slurried for 30 min, filtered, the filtrate was collected and concentrated, 100 mL of EA was added, and the liquid was shaken and separated. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and spin-dried to obtain 6.86 g of yellow oily liquid.

[0622] MS (ESI, [M+H] +)m / z:305.3.

[0623] Step B: Preparation of (R)-2-methyl-N-((S)-1-(6-(pyrrolidin-1-yl)pyridin-3-yl)ethyl)propane-2-sulfenamide

[0624] Under nitrogen protection, (R)-N-((S)-1-(6-bromopyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide (1000 mg, 3.28 mmol), THF (8 mL), tetrahydropyrrole (500 mg, 7.03 mmol), Davephos (260 mg, 0.661 mmol) were added to the tube in sequence, Pd2(dba)3 (300 mg, 0.328 mmol), LiHMDS (1372 mg, 8.20 mL, 8.20 mmol), nitrogen was purged of air, placed in a microwave reactor, heated to 130 ° C at 100 W for 30 min. 2 mL of 1M saturated ammonium chloride solution was added dropwise under ice bath conditions to quench the reaction, and diluted with 20 mL of ethyl acetate. The organic phase was washed with saturated sodium chloride aqueous solution and dried over anhydrous sodium sulfate. The organic phase was concentrated and the resulting crude product was purified by column chromatography to obtain 135 mg of the target compound as a yellow solid.

[0625] MS (ESI, [M+H] + )m / z:296.1.

[0626] Step C: Preparation of (S)-1-(6-(pyrrolidin-1-yl)pyridin-3-yl)ethan-1-amine hydrochloride

[0627] In a 50 mL round-bottom flask, (R)-2-methyl-N-((S)-1-(6-(pyrrolidin-1-yl)pyridin-3-yl)ethyl)propane-2-sulfenamide (280 mg, 0.948 mmol), MeOH (50 mL), and HCl in Dioxane (346 mg, 0.288 mL, 9.48 mmol) were added in sequence and stirred at room temperature overnight. After the reaction was completed, the reaction solution was concentrated to obtain 0.26 g of a white solid product, which was directly used in the next step without purification.

[0628] MS (ESI, [M+H] + )m / z:192.2.

[0629] Step D: Preparation of (S)-4-(4-methyl-6-(((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-N-(1-(6-(pyrrolidin-1-yl)pyridin-3-yl)ethyl)piperazine-1-carboxamide

[0630] In a 50 mL eggplant-shaped bottle, (S)-1-(6-(pyrrolidin-1-yl)pyridin-3-yl)ethyl-1-amine hydrochloride (225 mg, 0.988 mmol), DCM (10 mL), TEA (1000 mg, 9.88 mmol), and CDI (160 mg, 0.988 mmol) were added in sequence. The mixture was reacted at room temperature for 1 h. In another 25 mL single-mouth bottle, 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-(piperazine-1-yl)pyrimidine-4-amine trifluoroacetate (367 mg, 0.988 mmol), DCM (10 mL), and TEA (1000 mg, 9.88 mmol) were added in sequence. The mixture was stirred evenly until the solid was completely dissolved, and then added to a 50 mL eggplant-shaped bottle and stirred at room temperature overnight. After the reaction was completed, 50 mL of dichloromethane was added to the reaction solution to dilute it and washed with saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography to obtain 290 mg of a white powdery solid.

[0631] 1 H NMR (500MHz, DMSO-d6) δ9.32(s,1H),7.97(d,J=2.4Hz,1H),7.54(dd,J=8.8,2.4Hz,2H),6.75(d,J=7.9Hz,1H),6.47(d,J=8.8Hz,1H) ,4.75(p,J=7.2Hz,1H),3.76–3.58(m,4H),3.06(q,J=7.3Hz,6H),2.20(s,3H),2.13(s,3H),1.95–1.88(m,4H),1.35(d,J=7.0Hz,3H).

[0632] MS (ESI, [M+H] + )m / z:491.4.

[0633] Example 38: Preparation of 4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-N-(3-((4-methylpiperazin-1-yl)methyl)phenyl)piperazine-1-carboxamide

[0634] Reaction process:

[0635]

[0636] Step A: Preparation of 1-methyl-4-(3-nitrobenzyl)piperazine

[0637] In a 100mL single-mouth bottle, add 2g (9.26mmol) of 3-nitrobenzyl bromide, 0.928g (9.26mmol) of N-methylpiperazine, 1.28g (9.26mmol) of potassium carbonate and 15mL of DMF in sequence. Stir and react at room temperature. After the reaction is completed, add 100mL of purified water to the reaction system and extract with EA. Combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate and purify by column chromatography to obtain 2.08g of yellow oil.

[0638] MS (ESI, [M+H] + )m / z:236.1.

[0639] Step B: Preparation of 3-((4-methylpiperazin-1-yl)methyl)aniline

[0640] Add 1 g of 1-methyl-4-(3-nitrobenzyl)piperazine and 0.1 g of palladium carbon (10% m / c) to a 100 mL single-mouth bottle. Stir at room temperature for about 1 hour under a hydrogen atmosphere. After the reaction is complete, filter and separate the palladium carbon, and wash the filter cake with EA.

[0641] The combined organic phases were concentrated to obtain 0.75 g of a yellow oil.

[0642] MS (ESI, [M+H] + )m / z:206.2.

[0643] Step C: Preparation of 4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-N-(3-((4-methylpiperazin-1-yl)methyl)phenyl)piperazine-1-carboxamide

[0644] Dissolve 0.118g (0.399mol) of triphosgene in 3mL of dichloromethane in a 50mL three-necked flask, and cool to 0°C in an ice-salt bath under N2 protection. Add 3mL of dichloromethane solution containing 0.082g (0.399mmol) of 3-((4-methylpiperazine-1-yl)methyl)aniline and 0.242g (2.4mmol) of triethylamine. Stir the reaction solution at 0°C for 5min. Add 3ml of dichloromethane solution containing 0.200g (0.399mmol) of 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-(piperazine-1-yl)pyrimidine-4-amine trifluoroacetate and 0.242g (2.4mmol) of triethylamine. React at room temperature for 30min. After the reaction is completed, add 50mL of dichloromethane to dilute the reaction solution, wash with saturated brine, and collect the organic phase. After drying over anhydrous sodium sulfate, the residue was filtered, concentrated and purified by column chromatography to obtain 57 mg of a white solid.

[0645] 1H NMR (500MHz, DMSO-d6) δ11.88(s,1H),9.27(s,1H),8.58(s,1H),7.42(d,J=9.6Hz,2H),7.17(t,J=7.7Hz,1H),6.86(d,J=7.5Hz,1H), 6.19(d,J=49.0Hz,2H),3.74(t,J=5.1Hz,4H),3.52(t,J=5.1Hz,4H),3.41(s,2H),2.43(s,8H),2.23(d,J=11.9Hz,6H),2.14(s,3H).

[0646] MS (ESI, [M+H] + )m / z:505.3.

[0647] Example 39: Preparation of 4-(4-methyl-6-(((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)piperazine-1-carboxamide

[0648] Reaction process:

[0649]

[0650] The synthesis method is similar to that of step G in Example 1.

[0651] 1 H NMR (500MHz, DMSO-d6): δ11.72(s,1H),9.26(s,1H),8.86(s,1H),7.90(s,1H),7.75(d,J=8.0Hz,1H),7.57(d,J= 8.5Hz,1H),6.20(m,2H),3.75(d,J=5.0Hz,4H),3.53(m,6H),2.38(s,8H),2.21(s,3H),2.17(s,3H),2.14(s,3H).

[0652] MS (ESI, [M+H] + )m / z:573.3.

[0653] Example 40: Preparation of (S)-4-(4-methyl-6-(((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-N-(1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)ethyl)piperazine-1-carboxamide

[0654] Reaction process:

[0655]

[0656] Step A: Preparation of benzyl (S)-(1-((2-amino-5-(trifluoromethyl)phenyl)amino)-1-oxopropan-2-yl)carbamate

[0657] In a 50mL single-mouth bottle, ((benzyloxy)carbonyl)-L-alanine (1g, 4.48mmol), dichloromethane (20mL), 4-(trifluoromethyl)benzene-1,2-diamine (0.789g, 4.48mmol), triethylamine (1.36g, 13.44mmol) and EDCI (0.859g, 4.48mmol) were added in sequence, and the mixture was stirred at room temperature for 1.5h. 20mL of dichloromethane was added to the reaction system for dilution, and washed once with 20mL of saturated brine, the organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain 1.4g of brown oil. No further purification was performed, and the subsequent reaction was continued.

[0658] MS (ESI, [M+H] + )m / z:382.1.

[0659] Step B: Preparation of benzyl (S)-(1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)ethyl)carbamate

[0660] In a 50mL single-mouth bottle, (S)-(1-((2-amino-5-(trifluoromethyl)phenyl)amino)-1-oxopropane-2-yl)carbamic acid benzyl ester (1.4g, 3.67mmol) and glacial acetic acid (15mL) were added in sequence, and the mixture was heated to 70°C and stirred for 1.5h. After the reaction was complete, half of the glacial acetic acid was concentrated under reduced pressure to obtain a brown glacial acetic acid solution. No further purification was performed and the subsequent reaction was continued.

[0661] MS (ESI, [M+H] + )m / z:364.1.

[0662] Step C: Preparation of (S)-1-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)ethan-1-amine hydrobromide

[0663] To the brown glacial acetic acid solution obtained in step B, add 20 mL of 48% HBr aqueous solution, and stir the mixture at room temperature for 24 h. After the reaction is complete, the reaction solution is concentrated under reduced pressure to remove the solvent to obtain a brown oily crude product. 5 mL of water is added to the crude product, the pH is adjusted to about 8 with a saturated sodium carbonate aqueous solution, and extracted with ethyl acetate (30 mL×3), the organic phase is collected, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain 780 mg of white crystals.

[0664] MS (ESI, [M+H] + )m / z:230.1.

[0665] Step D: Preparation of (S)-4-(4-methyl-6-(((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-N-(1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)ethyl)piperazine-1-carboxamide

[0666] The synthesis method is similar to that of step G in Example 1.

[0667] 1 H NMR (500MHz, CDCl3): δ12.52(s,1H),11.87(s,1H),9.26(s,1H),7.84(m,2H),7.47(s,1H),7.10(d,J=5.0Hz ,1H),6.20(m,2H),5.15(m,1H),3.71(s,4H),3.46(s,4H),2.21(s,3H),2.14(s,3H),1.58(d,J=5.0Hz,3H).

[0668] MS (ESI, [M+H] + )m / z:529.3.

[0669] Example 41: Preparation of 2-(4-((6-(dimethylamino)pyridin-3-yl)methyl)piperazin-1-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine

[0670] Reaction process:

[0671]

[0672] Step A: Preparation of 2-(4-((6-chloropyridin-3-yl)methyl)piperazin-1-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine

[0673] Take a 100mL single-mouth bottle and add 1g (1.994mmol) of 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-(piperazine-1-yl)pyrimidine-4-amine trifluoroacetate, dichloromethane (25mL), and 807mg (7.98mmol) of triethylamine. Stir until the solid is completely dissolved and the solution is clear. Then add 282mg (1.994mmol) of 6-chloronicotinaldehyde and 1.268g (5.98mmol) of sodium triacetoxyborohydride. Stir the reaction at room temperature overnight. The reaction solution is evaporated under reduced pressure on a rotary evaporator to remove the solvent, and purified by column chromatography to obtain 1.8g of a white solid product.

[0674] MS (ESI, [M+H] + )m / z:399.2.

[0675] Step B: Preparation of 2-(4-((6-(dimethylamino)pyridin-3-yl)methyl)piperazin-1-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine

[0676] 2-(4-((6-chloropyridin-3-yl)methyl)piperazine-1-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine 500mg (1.253mmol), dimethylamine 565mg (12.53mmol) and N-methylpyrrolidone (10mL) were added to a 30mL sealed tube, and the mixture was placed in a microwave reactor and heated to 180°C at 200 watts for 2h. The reaction solution was directly poured into 50mL of ice water and extracted with ethyl acetate. The organic phase was collected and dried over anhydrous sodium sulfate. The filtrate was concentrated by filtration and purified by column chromatography to obtain 60mg of off-white powdery solid.

[0677] 1 H NMR(500MHz,Chloroform-d)δ8.06(s,1H),7.49(d,J=8.6Hz,1H),6.97(s,1H),6.52(d,J=8.7Hz,1H) ,6.03(d,J=15.4Hz,2H),3.79(s,4H),3.43(s,2H),3.09(s,6H),2.48(s,4H),2.26(d,J=27.7Hz,6H).

[0678] MS (ESI, [M+H] + )m / z:408.4.

[0679] Example 42: Preparation of (S)-N-(Benzo[d][1,3]dioxin-5-ylmethyl)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)piperazine-1-carboxamide

[0680] Reaction process:

[0681]

[0682] The synthesis method is similar to that of Example 19.

[0683] 1H NMR(500MHz,Chloroform-d)δ6.83(s,1H),6.75-6.79(m,2H),6.68(s,1H),6.14(s,1H) ,5.94(s,2H),5.92(s,1H),5.83(s,1H),4.76-4.78(m,1H),4.32-4.40(m,2H),4.17(s,1 H),4.02(d,J=12.2Hz,1H),3.92(d,J=12.7Hz,1H),3.79-3.81(m,1H),3.28-3.33(m,1H) ,3.21-3.24(m,1H),3.00-3.05(m,1H),2.27(s,3H),2.20(s,3H),1.24(d,J=6.8Hz,3H).

[0684] MS (ESI, [M+H] + )m / z:464.3.

[0685] Example 43: Preparation of (S)-N-((2,2-difluorobenzo[d][1,3]dioxin-5-yl)methyl)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)piperazine-1-carboxamide

[0686] Reaction process:

[0687]

[0688] Step A: Preparation of 2,2-difluorobenzo[d][1,3]dioxin-5-carbaldehyde oxime

[0689] In a 50mL eggplant-shaped bottle, 1g (5.37mmol) of 2,2-difluoro-1,3-benzodioxole-5-carboxaldehyde, 373mg (5.37mmol) of hydroxylamine hydrochloride and methanol (10mL) were added in sequence, followed by 1.06g (13.43mmol) of pyridine. The mixture was reacted at room temperature for 2h under N2 protection. The reaction solution was evaporated under reduced pressure by a rotary evaporator to remove the solvent, and purified by column chromatography to obtain 0.6g of a white solid product.

[0690] Step B: Preparation of (2,2-difluorobenzo[d][1,3]dioxin-5-yl)methylamine

[0691] In a 25mL three-necked flask, add 189mg (4.97mmol) of lithium aluminum tetrahydride, add tetrahydrofuran (5mL) under N2 protection, cool the system to 0°C, then dropwise add a solution of 1g (4.97mmol) of 2,2-difluoro-1,3-benzodioxolane-5-carboxaldehyde oxime in tetrahydrofuran (5mL), then transfer the mixture to room temperature for 2h. Add 5mL of saturated aqueous ammonium chloride to the reaction system, then add 30mL*3 of ethyl acetate for extraction, separate the organic phase, dry over anhydrous sodium sulfate, filter, and remove the solvent from the filtrate by rotary evaporator under reduced pressure. Purify by column chromatography to obtain 0.25g of white solid product.

[0692] MS (ESI, [M+H] + )m / z:188.3.

[0693] Step C: Preparation of (S)-N-((2,2-difluoro-1,3-benzodioxolan-5-yl)methyl)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)piperazine-1-carboxamide

[0694] The synthesis method is similar to that of Example 19, Step D.

[0695] 1 H NMR(500MHz,Chloroform-d)δ8.61(s,1H),7.34(d,J=8.3Hz,1H),7.28(s,1H),7.16(t, J=5.7Hz,1H),7.10(d,J=8.3Hz,1H),6.33(s,1H),6.01(s,1H),5.96(s,1H),4.21-4.30 (m,3H),4.10(d,J=12.1Hz,1H),4.01(s,1H),3.82(d,J=12.9Hz,1H),3.06-3.11(m,1H) ,2.96-2.99(m,1H),2.74-2.78(m,1H),2.18(s,3H),2.12(s,3H),1.10(d,J=6.5Hz,3H).

[0696] MS (ESI, [M+H] + )m / z:500.3.

[0697] Example 44: Preparation of (6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)(4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)piperazin-1-yl)methanone

[0698] Reaction process:

[0699]

[0700] Step A: Preparation of 6-(4-fluoro-1H-pyrazol-1-yl)nicotinate

[0701] The synthesis method is as described in Example 1A.

[0702] MS (ESI, [M+H] + )m / z:222.1.

[0703] Step B: Preparation of 6-(4-fluoro-1H-pyrazol-1-yl)nicotinic acid

[0704] In a 50mL reaction bottle, add 6-(4-fluoro-1H-pyrazol-1-yl)nicotinate methyl ester 300mg (1.356mmol) and ethanol (25mL). The system is white suspension. Add 2mL 20% sodium hydroxide aqueous solution to the reaction system and stir at room temperature for 1h. Distill the reaction system under reduced pressure to remove the solvent, add concentrated hydrochloric acid dropwise to adjust the pH to 2, extract with 20mL*5 dichloromethane for multiple times, separate the organic phase, dry over anhydrous sodium sulfate, filter, and distill the filtrate under reduced pressure to remove the solvent to obtain 250mg of white solid.

[0705] MS (ESI, [MH] - )m / z:206.1.

[0706] Step C: Preparation of (6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)(4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)piperazin-1-yl)methanone

[0707] In a 50mL reaction bottle, add 746mg (0.965mmol) of 6-(4-fluoro-1H-pyrazol-1-yl)nicotinic acid, N,N-dimethylformamide (10mL) and dichloromethane (10mL), then add 441mg (1.159mmol) of 2-(1H-benzotriazol L-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate, stir at room temperature for 5 minutes, then add 196mg (1.93mmol) of N-methylmorpholine. Protect with N2 and stir at room temperature for 1h. Slowly dropwise add 746mg (1.931mmol) of 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-(piperazine-1-yl)pyrimidine-4-amine trifluoroacetate and 196mg (1.93mmol) of N,N-dimethylformamide solution to the above reaction system. Protect with N2 and stir at room temperature overnight. The reaction solution was evaporated under reduced pressure on a rotary evaporator to remove the solvent, 50 mL of dichloromethane was added, and the mixture was washed several times with 20 mL*3 saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and the filtrate was purified by column chromatography to obtain 150 mg of a yellow solid product.

[0708] 1 H NMR(500MHz,Chloroform-d)δ8.50(s,1H),8.43(d,J=4.4Hz,1H),8.02(d,J=8.4Hz,1H),7.92(d,J=6.3Hz,1H),7 .63(d,J=4.2Hz,1H),7.06(s,1H),6.16(s,1H),6.04(s,1H),3.85(s,6H),3.56(s,2H),2.30(s,3H),2.25(s,3H).

[0709] MS (ESI, [M+H] + )m / z:463.3.

[0710] Example 45: Preparation of (S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-methyl-4-(4-((5-methyl-1H-pyrazol-3-yl)amino)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl)piperazine-1-carboxamide

[0711] Reaction process:

[0712]

[0713] Step A: Preparation of 6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diol

[0714] In a 50mL three-necked flask, 5g (35.2mmol) of 2-methoxycarbonylcyclopentanone, 4.22g (70.3mmol) of urea and N,N-dimethylformamide (5mL) were added in sequence, and the temperature was lowered to 0℃ under N2 protection. 4.59g (42.2mmol) of trimethylchlorosilane was injected with a syringe, and then the reaction system was warmed to room temperature and reacted overnight. 10ml of water was added to the reaction system to produce a large amount of white solid, which was filtered, and the filter cake was washed with 5ml of water and 5ml of petroleum ether. The filter cake was transferred to an eggplant-shaped bottle and the solvent was distilled off under reduced pressure. 10mL of water was added to the above white solid, and the solid was insoluble. Then 4.22g (106mmol) of sodium hydroxide was added, and the system was heated to 70℃ and stirred for 1h. The reaction system was cooled to 0℃, concentrated hydrochloric acid was added dropwise, and the pH of the system was adjusted to 2. A large amount of white solid precipitated, which was filtered, and the filter cake was washed with 10mL of water. The filter cake was distilled off under reduced pressure to remove water, and 4.6g of white solid was obtained.

[0715] MS (ESI, [MH] - )m / z:151.0.

[0716] Step B: Preparation of 2,4-dichloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine

[0717] In a 50mL three-necked flask, 3g (19.72mmol) of 6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diol and phosphorus oxychloride (15mL) were added in sequence. Under N2 protection, the mixture was heated to 110°C and refluxed for 5h. The reaction system was distilled under reduced pressure to remove the solvent, cooled to 0°C, 50mL of water was added, and the mixture was stirred vigorously. A large amount of yellow solid precipitated, which was filtered and the filter cake was washed with 10mL of water. The filter cake was dried under reduced pressure to remove moisture, and 2.5g of yellow solid was obtained.

[0718] MS (ESI, [M+Na] + )m / z:212.0.

[0719] Step CF: Preparation of (S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-methyl-4-(4-((5-methyl-1H-pyrazol-3-yl)amino)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl)piperazine-1-carboxamide

[0720] The synthesis method is as in Example 1.

[0721] 1 H NMR (500MHz, DMSO-d6) δ11.91(s,1H),8.74(s,1H),8.66(d,J=4.3Hz,1H),8.40(s,1H),7.95(d,J=8.4Hz,1H ),7.90(d,J=4.0Hz,1H),7.86(d,J=8.4Hz,1H),6.88(d,J=7.5Hz,1H),6.36(s,1H),4.92-4.98(m,1H),4.46 (d,J=12.2Hz,1H),4.39(d,J=12.6Hz,1H),4.31(s,1H),3.83(d,J=12.9Hz,1H),2.99-3.04(m,2H),2.81-2. 84(m,1H),2.61-2.67(m,4H),2.22(s,3H),1.91-1.94(m,2H),1.44(d,J=7.0Hz,3H),1.03(d,J=6.4Hz,3H).

[0722] MS (ESI, [M+H] + )m / z:546.4.

[0723] Example 46: Preparation of N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-9-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxamide

[0724] Reaction process:

[0725]

[0726] Step A: Preparation of tert-butyl 9-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate

[0727] 2-Chloro-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-4-amine 70 mg (0.313 mmol), N,N-dimethylformamide (5 mL), 3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylic acid tert-butyl ester 79 mg (0.344 mmol), N,N-diisopropylethylamine 121 mg (0.939 mmol) were added to a 30 mL microwave tube. Heat to 140 ° C under N2 protection and react for 40 hours. The reaction solution was evaporated under reduced pressure on a rotary evaporator to remove the solvent, and 50 mL of dichloromethane was added, and 20 mL*3 saturated brine was washed several times, the organic phase was separated, dried over anhydrous sodium sulfate, filtered, and the filtrate was purified by column chromatography to obtain 100 mg of a yellow oily product.

[0728] MS (ESI, [M+H] + )m / z:416.3.

[0729] Step B: Preparation of 2-(3-oxo-7,9-diazabicyclo[3.3.1]non-9-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine trifluoroacetate

[0730] The synthesis method is similar to that of step F in Example 1.

[0731] Step C: Preparation of N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-9-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxamide

[0732] The synthesis method is similar to that of step G in Example 1.

[0733] MS (ESI, [M+H] +)m / z:548.3.

[0734] Example 47: Preparation of 2-(4-((6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)methyl)piperazin-1-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine

[0735] Reaction process:

[0736]

[0737] Step A: Preparation of 2-(4-((6-bromopyridin-3-yl)methyl)piperazin-1-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine

[0738] In a 100mL single-mouth bottle, add 0.5g (0.997mmol) of 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-(piperazine-1-yl)pyrimidin-4-amine trifluoroacetate, 25mL of dichloromethane, 0.404g (3.99mmol) of triethylamine and 0.185g (0.997mmol) of 2-bromo-5-formylpyridine. React at room temperature. After the reaction is completed, separate the solid and liquid by suction filtration, wash the filter cake with dichloromethane, combine the organic phases, concentrate, and purify by column chromatography to obtain 535mg of white semisolid.

[0739] MS (ESI, [M+H] + )m / z:443.1.

[0740] Step B: Preparation of 2-(4-((6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)methyl)piperazin-1-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine

[0741] In a 30mL microwave tube, 0.661g (2.030mmol) of cesium carbonate, 0.193g (1.015mmol) of cuprous iodide, 10mL of DMF, 0.175g (2.030mmol) of 4-fluoro-1H-pyrazole, 0.3g (0.677mmol) of 2-(4-((6-bromopyridin-3-yl)methyl)piperazine-1-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine, and 0.144g (1.015mmol) of trans-(1R,2R)-N,N'-dimethyl 1,2-cyclohexanediamine were added in sequence. After nitrogen protection, the tube was sealed and reacted under microwave conditions of 150℃ / 200W. After the reaction was completed, the reaction solution was poured into 150mL of purified water, extracted with DCM, and washed with saturated brine. The organic phases were combined and dried over anhydrous sodium sulfate. The residue was then filtered, concentrated and purified by column chromatography to obtain 130 mg of a yellow solid.

[0742] 1 H NMR(500MHz,DMSO-d6)δ11.83(s,1H),9.20(s,1H),8.69(d,J=4.5Hz,1H),8.40(s,1H),8.02–7.84(m,3H ),6.21(s,1H),6.10(s,1H),3.70(t,4H),3.58(s,2H),3.33(s,3H),2.44(t,J=5.0Hz,4H),2.18(s,3H).

[0743] MS (ESI, [M+H] + )m / z:449.2.

[0744] Example 48: Preparation of 2-(4-((6-methoxypyridin-3-yl)methyl)piperazin-1-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine

[0745] Reaction process:

[0746]

[0747] The synthesis method is similar to that of Example 47.

[0748] 1 H NMR (500MHz, DMSO-d6) δ11.88(s,1H),9.29(s,1H),8.12(s,1H),7.70(d,J=7.7Hz,1H),6.83(d,J=8.4Hz,1H),6.24(s,1H),6 .11(s,1H),3.85(s,3H),3.43–3.32(m,4H),3.14–3.04(m,2H),2.54(s,2H),2.19(s,3H),2.12(s,3H),1.18(t,J=7.3Hz,2H).

[0749] MS (ESI, [M+H] + )m / z:395.3.

[0750] Example 49: Preparation of 2-((1R,5S)-8-((6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)methyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine

[0751] Reaction process:

[0752]

[0753] The synthesis method is similar to that of Example 47.

[0754] 1 H NMR (500MHz, DMSO-d6) δ11.83(s,1H),9.19(s,1H),8.68(d,J=4.2Hz,1H),8.45(s,1H),8.03(d,J=8.4Hz,1H),7.91(s,2H),6.17(s,2H),4. 21(d,J=11.7Hz,2H),3.60(s,2H),3.23(s,2H),3.00(d,J=11.9Hz,2H),2.18(s,3H),2.10(s,3H),1.99–1.94(m,2H),1.54(d,J=7.5Hz,2H).

[0755] MS (ESI, [M+H] + )m / z:475.3.

[0756] Example 50: Preparation of 2-(6-((6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine

[0757] Reaction process:

[0758]

[0759] The synthesis method is similar to that of Example 47.

[0760] 1 H NMR (500MHz, DMSO-d6) δ11.88(s,1H),9.33(s,1H),8.66(s,1H),8.41(s,1H),7.97(d,J=7.4Hz,1H),7.91(s,1H),7.88(s, 1H),6.38(s,1H),6.23(s,1H),3.77(s,2H),3.73(s,2H),3.51(s,2H),2.27(s,3H),2.18(s,2H),2.16(s,3H),1.23(s,2H).

[0761] MS (ESI, [M+H] + )m / z:461.3.

[0762] Example 51: Preparation of 4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-N-((S)-1-(6-(((S)-pentan-2-yl)oxy)pyridin-3-yl)ethyl)piperazine-1-amide

[0763] Reaction process:

[0764]

[0765] The synthesis method is similar to that of Example 36.

[0766] 1 H NMR(500MHz,DMSO-d6)δ11.87(s,1H),9.26(s,1H),8.06(d,J=2.4Hz,1H),7.65(s,1H),6.8 2(d,J=7.8Hz,1H),6.69(d,J=8.5Hz,1H),6.14(s,2H),5.18–5.10(m,1H),4.83(p,J=7.0Hz, 1H),3.67(t,J=5.0Hz,4H),3.39(t,J=5.0Hz,4H),2.21(s,3H),2.13(s,3H),1.68–1.47(m, 2H),1.38(d,J=7.1Hz,3H),1.37–1.28(m,2H),1.23(d,J=6.1Hz,3H),0.88(t,J=7.4Hz,3H).

[0767] MS (ESI, [M+H] + )m / z:508.3.

[0768] Example 52: Preparation of (S)-N-(chroman-6-ylmethyl)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)piperazine-1-amide

[0769] Reaction process:

[0770]

[0771] The synthesis method is similar to that of Example 19.

[0772] 1H NMR(500MHz,DMSO-d6)δ11.62(s,1H),8.55(s,1H),6.94(s,3H),6.65(s,1H),6.35(s,1H),6.01(s,1H),5.95(s,1H),4.26(s,2H),4.08 (s,4H),3.81(s,1H),3.02(d,J=46.5Hz,2H),2.69(s,2H),2.17(s,3H),2.11(s,3H),1.89(s,2H),1.29(d,J=59.9Hz,2H),1.09(s,3H).

[0773] MS (ESI, [M+H] + )m / z:476.3.

[0774] Example 53: Preparation of (1R,5S)-N-((R)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-(6-((5-methyl-1H-pyrazol-3-yl)amino)-4-(trifluoromethyl)pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-amide

[0775] Reaction process:

[0776]

[0777] Step A: Preparation of 6-(4-fluoro-1H-pyrazol-1-yl)pyridine-3-ethanone

[0778] Add 3g (15mmol) of 5-acetyl-2-bromopyridine, 1.549g (18mmol) of 4-fluoro-1H-pyrazole, 4.15g (30mmol) of potassium carbonate, and 25mL of DMF to a 250mL single-mouth bottle. Heat the reaction at 100°C under a nitrogen atmosphere for about 5h. After the reaction is completed, add 100mL of purified water to the reaction solution, at which time a large amount of solid precipitates. Wash the filter cake with purified water several times, collect the solid, dry it, and then add an appropriate amount of PE for pulping. After filtering and drying, 2.45g of brown solid product is obtained.

[0779] MS (ESI, [M+H] + )m / z:206.1.

[0780] Step B: Preparation of (S,E)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethylidene)-2-methylpropane-2-sulfenamide

[0781] Add 2.45 g (11.94 mmol) of 6-(4-fluoro-1H-pyrazol-1-yl)pyridine-3-ethanone, 50 mL of THF, 3.20 g (23.88 mmol) of diethylene glycol dimethyl ether, 5.45 g (23.88 mmol) of ethyl titanate, and 2.89 g (23.88 mmol) of S-tert-butylsulfenamide to a 250 mL single-mouth bottle. Heat the mixture at 80 ° C for about 3 hours under a nitrogen atmosphere. After the reaction is completed, the reaction solution is not treated and the next step is directly carried out.

[0782] Step C: Preparation of (S)-N-((R)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide

[0783] The reaction system in the previous step was placed in a nitrogen atmosphere and cooled to -80°C. 5.45 g (1 mol / L; 28.7 mL; 28.7 mmol) of lithium tri-sec-butyl borohydride was slowly added dropwise to the system using a syringe. After the addition was complete, the reaction was maintained at -80°C. After the reaction was completed, the reaction solution was poured into 150 mL of purified water, at which time a large amount of solid precipitated. After suction filtration, the filter cake was washed with EA, and the organic phases were combined and concentrated under reduced pressure to obtain 9.7 g of a yellow oily crude product. The crude product was not further purified and directly subjected to the next step of reaction.

[0784] Step D: Preparation of (R)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethylamine hydrochloride

[0785] In a 250 mL single-mouth bottle, add 3.54 g (11.40 mmol) of (S)-N-((R)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide, 50 mL of methanol, and 4.2 g (4 mol / L; 28.8 mL; 115 mmol) of hydrochloric acid. The reaction was carried out at room temperature under a nitrogen atmosphere. After the reaction was completed, the solvent was removed under reduced pressure, and 50 mL of EA was added for pulping. After suction filtration, the mixture was washed with EA. The filter cake was vacuum dried to obtain 3.19 g of a yellow-white solid product.

[0786] MS (ESI, [M+H] + )m / z:207.14.

[0787] Step E: Preparation of tert-butyl (1R,5S)-3-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0788] Add 0.6 g (2.78 mmol) of 2,6-dichloro-4-trifluoromethylpyridine, 5 mL of DMF, 0.637 g (3.00 mmol) of 8-BOC-3,8-diazabicyclo[3.2.1]octane, and 0.718 g (0.970 mL; 5.56 mmol) of DIPEA to a 50 mL single-mouth bottle. Heat the mixture to 110 °C and react for about 5 hours. After the reaction is completed, add 50 mL of EA to dilute the reaction solution, and wash the organic phase with saturated brine. Collect the organic phase, dry it with anhydrous sodium sulfate, filter it, concentrate it, and purify it with column chromatography to obtain 0.4 g of a white solid product.

[0789] Step F: Preparation of tert-butyl (1R,5S)-3-(6-((5-methyl-1H-pyrazol-3-yl)amino)-4-(trifluoromethyl)pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0790] Add 660 mg (1.684 mmol) of (1R, 5S)-3-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 15 mL of THF, 180 mg (1.853 mmol) of 3-amino-5-methylpyrazole, 154 mg (0.168 mmol) of tris(dibenzylideneacetone)dipalladium, 133 mg (0.337 mmol) of 2-dicyclohexylphosphino-2'-(N,N-dimethylamine)-biphenyl, and 730 mg (4.36 mmol) of lithium bis(trimethylsilylamide) into a 35 mL microwave tube. Place the reaction mixture in a CEM microwave reactor under a nitrogen atmosphere and set the reaction temperature to 130 ° C and 100 W for 30 min. After the reaction is completed, add 50 mL of EA to dilute the reaction solution and wash the organic phase with saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography to obtain 480 mg of a brown solid product.

[0791] MS (ESI, [M+H] + )m / z:453.2.

[0792] Step G: Preparation of 6-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-N-(5-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)pyridin-2-amine trifluoroacetate

[0793] 0.48 g (1.061 mmol) of (1R, 5S)-3-(6-((5-methyl-1H-pyrazol-3-yl)amino)-4-(trifluoromethyl)pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester, 20 mL of DCM, and 0.605 g (5.30 mmol) of trifluoroacetic acid were added to a 250 mL single-mouth bottle. The reaction was carried out at room temperature for about 5 hours. After the reaction was completed, the reaction solvent and excess trifluoroacetic acid were directly removed under reduced pressure, and the mixture was slurried with DCM and filtered and dried to obtain 0.4 g of an off-white solid.

[0794] MS (ESI, [M+H] + )m / z:353.2.

[0795] Step H: Preparation of (1R,5S)-N-((R)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-(6-((5-methyl-1H-pyrazol-3-yl)amino)-4-(trifluoromethyl)pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-amide

[0796] Add 0.073 g (0.246 mmol) of solid triphosgene and 5 mL of DCM to a 25 mL three-necked flask. Cool to 0°C in an ice-salt bath under nitrogen protection. Take a 15 mL test tube and add 0.063 g (0.224 mmol) of (R)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethylamine hydrochloride, 0.136 g (1.344 mmol) of triethylamine, and 5 mL of DCM, and slowly add the solution to the reaction system. After about 30 minutes of low temperature reaction, 5 mL of DCM solution containing 0.13 g (0.224 mmol) of 6-((1R, 5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-N-(5-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)pyridine-2-amine trifluoroacetate and 0.136 g (1.344 mmol) of triethylamine was added to the reaction system. After the addition, the reaction was carried out at 0°C in an ice bath for about 30 minutes. After the reaction was completed, the reaction solution was poured into 100 mL of purified water and extracted with DCM. The organic phases were combined and dried over anhydrous sodium sulfate. Subsequently, the product was filtered, concentrated, and purified by column chromatography to obtain 67 mg of a yellow-white solid product.

[0797] 1H NMR (500MHz, DMSO-d6) δ11.81(s,1H),9.18(s,1H),8.66(d,J=4.3Hz,1H),8.41(s,1H),7.95( d,J=8.3Hz,1H),7.90(s,1H),7.86(s,1H),7.14(d,J=7.6Hz,1H),6.82(s,1H),6.21(s,1H),6. 03(s,1H),4.95(p,J=6.7Hz,1H),4.45(d,J=13.9Hz,2H),3.95(d,J=6.1Hz,2H),3.51(s,1H),2 .98(d,J=11.6Hz,2H),2.20(s,3H),1.79(s,1H),1.66(d,J=7.8Hz,2H),1.45(d,J=6.9Hz,3H).

[0798] MS (ESI, [M+H] + )m / z:585.3.

[0799] Example 54: Preparation of (1R, 5S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-8-(6-((5-methyl-1H-pyrazol-3-yl)amino)-4-(trifluoromethyl)pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octane-3-amide

[0800] Reaction process:

[0801]

[0802] The synthesis method is similar to that of Example 53.

[0803] 1 H NMR(500MHz,DMSO-d6)δ11.85(s,1H),9.28(s,1H),8.68(s,1H),8.39(s,1H),7.93 (d,J=9.1Hz,1H),7.91(s,1H),7.86(d,J=8.2Hz,1H),6.90–6.69(m,2H),6.34(s,1 H),6.05(s,1H),4.90(p,J=7.7Hz,1H),4.62(s,2H),3.72(s,1H),3.70(s,1H),3.0 3(d,J=11.9Hz,2H),2.21(s,3H),1.90(s,2H),1.72(s,2H),1.41(d,J=6.1Hz,3H).

[0804] MS (ESI, [M+H] +)m / z:585.3.

[0805] Example 55: Preparation of (R)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-2-methyl-4-(6-((5-methyl-1H-pyrazol-3-yl)amino)-4-(trifluoromethyl)pyridin-2-yl)piperazine-1-amide

[0806] Reaction process:

[0807]

[0808] The synthesis method is similar to that of Example 53.

[0809] 1 H NMR(500MHz,DMSO-d6)δ11.83(s,1H),9.21(s,1H),8.68(d,J=4.4Hz,1H),8.42(s,1H),8.00– 7.84(m,3H),6.96(d,J=7.4Hz,1H),6.85(s,1H),6.32(s,1H),6.03(s,1H),4.95(p,J=6.9Hz, 1H),4.31(s,1H),4.21(d,J=12.2Hz,1H),4.13(d,J=12.7Hz,1H),3.88(d,J=13.0Hz,1H),3.1 7–3.01(m,2H),2.97–2.85(m,1H),2.21(s,3H),1.45(d,J=7.1Hz,3H),1.09(d,J=6.5Hz,3H).

[0810] MS (ESI, [M+H] + )m / z:573.3.

[0811] Example 56: Preparation of (S)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-4-(6-((5-methyl-1H-pyrazol-3-yl)amino)-4-(trifluoromethyl)pyridin-2-yl)piperazine-1-amide

[0812] Reaction process:

[0813]

[0814] The synthesis method is similar to that of Example 53.

[0815] 1H NMR(500MHz,DMSO-d6)δ11.83(s,1H),9.22(s,1H),8.67(d,J=4.5Hz,1H),8 .42(d,J=1.8Hz,1H),7.99–7.94(m,1H),7.93–7.85(m,2H),7.03(d,J=7.5H z,1H),6.88(s,1H),6.33(s,1H),6.03(s,1H),4.94(p,J=7.0Hz,1H),3.54( d,J=5.2Hz,4H),3.47(d,J=5.1Hz,4H),2.21(s,3H),1.45(d,J=7.1Hz,3H).

[0816] MS (ESI, [M+H] + )m / z:559.4.

[0817] Example 57: Preparation of (S)-N-(1-(4-(4-fluoro-1H-pyrazol-1-yl)phenyl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0818] Reaction process:

[0819]

[0820] Step A: Preparation of (S)-N-(1-(4-bromophenyl)ethyl)-2,2,2-trifluoroacetamide

[0821] In a 50mL three-necked flask, (R)-1-(4-bromophenyl)ethyl-1-amine (1g, 5.00mmol) was dissolved in 10mL of dichloromethane. The reaction system was cooled to 0°C in an ice-salt bath. Trifluoroacetic anhydride (1.260g, 0.847mL, 6.00mmol) was slowly added dropwise to the above reaction system through a syringe over 3min. The mixture was stirred at 0°C for 1h, naturally heated, and stirred at room temperature overnight. After the reaction was completed, 40mL of dichloromethane and 10mL of water were added to the reaction system, extracted, and the organic phase was collected. The organic phase was washed with 1M sodium bisulfate aqueous solution (20mL) and saturated sodium bicarbonate (20mL) in turn. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain 1.45g of a white powdery solid.

[0822] MS (ESI, [MH] - )m / z:294.1.

[0823] Step B: Preparation of (S)-2,2,2-trifluoro-N-(1-(4-(4-fluoro-1H-pyrazol-1-yl)phenyl)ethyl)acetamide

[0824] In a 35mL microwave tube, (R)-N-(1-(4-bromophenyl)ethyl)-2,2,2-trifluoroacetamide (1.2g, 4.05mmol), N,N-dimethylacetamide (15ml), 4-fluoro-1H-pyrazole (0.419g, 4.86mmol), copper iodide (0.154g, 0.811mmol), 1,10-phenanthroline (0.292g, 1.621mmol) and Cs2CO3 (2.64g, 8.11mmol) were added in sequence, and the reaction system was transferred to a microwave reactor. The microwave conditions were: 160°C, 3h. After the reaction was completed, 40mL of ethyl acetate was added to the reaction system, and diatomaceous earth was filtered. The filtrate was washed three times with 30mL of saturated brine. Drying over anhydrous sodium sulfate, filtration and concentration, and column chromatography were used to purify to obtain 200mg of brown oil.

[0825] MS (ESI, [M+H] + )m / z:302.1.

[0826] Step C: Preparation of (S)-1-(4-(4-(4-fluoro-1H-pyrazol-1-yl)phenyl)ethan-1-amine

[0827] In a 25mL single-mouth bottle, (R)-2,2,2-trifluoro-N-(1-(4-(4-fluoro-1H-pyrazol-1-yl)phenyl)ethyl)acetamide (0.03g, 0.100mmol), methanol (5mL), 1M LiOH aqueous solution (5mL) were added in sequence, and the mixture was stirred at room temperature overnight. When the reaction was complete, 40mL of ethyl acetate and 10mL of water were added to the reaction system. Extraction, the organic phase was washed twice with 10mL of saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain 10mg of a light yellow oil.

[0828] Step D: Preparation of (S)-N-(1-(4-(4-fluoro-1H-pyrazol-1-yl)phenyl)ethyl)-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperazine-1-carboxamide

[0829] Step D refers to Step D of Example 19.

[0830] 1H NMR (500MHz, CDCl3): δ12.37(s,1H),12.35(s,1H),8.64(d,J=4.5Hz,1H),7.80(d,J=4.0Hz,1H),7.71(d,J=8.5Hz,2H),7.46(d,J=8. 5Hz,2H),7.01(d,J=7.5Hz,1H),6.30(m,2H),4.90(m,1H),3.82(s,4H),3.53(s,4H),2.36(s,3H),2.25(s,3H),1.42(d,J=7.0Hz,3H). MS(ESI,[M+H] + )m / z:505.2.

[0831] Example 58: Preparation of 1-(6-(2-cyanopropane-2-yl)pyridin-3-yl)-3-(1-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperidin-4-ylurea

[0832] Reaction process:

[0833]

[0834] The synthesis method is as in Example 1.

[0835] 1 H NMR (500MHz, DMSO-d6): δ11.85(s,1H),9.19(s,1H),8.65(s,1H),8.55(d,J=2.5Hz,1H),7.61(m,1H),7.56(d,J=9.0Hz,1H),6.78(d,J=8H z,1H),6.22(s,1H),6.10(s,1H),3.76(m,1H),3.07(m,2H),2.51(m,2H),2.20(s,3H),2.12(s,3H),1.89(m,2H),1.67(s,6H),1.37(m,2H).

[0836] MS (ESI, [M+H] + )m / z:475.3.

[0837] Example 59: Preparation of (1R,5S)-3-(5-chloro-4-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-N-((S)-1-(4-(4-fluoro-1H-pyrazol-1-yl)phenyl)ethyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide

[0838] Reaction process:

[0839]

[0840] The synthesis method is as in Example 1.

[0841] 1 H NMR (500MHz, DMSO-d6): δ12.07(s,1H),8.62(d,J=4.5Hz,2H),8.00(s,1H),7.79(d ,J=4.0Hz,1H),7.71(d,J=8.5Hz,2H),7.44(d,J=8.5Hz,2H),7.01(d,J=8.0Hz,1H) ,6.29(s,1H),4.91(t,J=7.0Hz,1H),4.42(m,2H),4.18(s,2H),3.02(d,J=12Hz,2H ), 2.24 (s, 3H), 1.76 (t, J = 4.5Hz, 2H), 1.57 (d, J = 8.5Hz, 2H), 1.41 (d, J = 7.0Hz, 3H).

[0842] MS (ESI, [M+H] + )m / z:551.3.

[0843] Example 60: Preparation of (1R,5S)-N-((S)-1-(4-(4-fluoro-1H-pyrazol-1-yl)phenyl)ethyl)-3-(5-fluoro-4-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide

[0844] Reaction process:

[0845]

[0846] The synthesis method is as in Example 1.

[0847] 1H NMR (500MHz, DMSO-d6): δ12.03(s,1H),9.44(s,1H),8.62(d,J=4.5Hz,1H),7.92(d,J=3. 5Hz,1H),7.79(d,J=4.0Hz,1H),7.71(d,J=8.5Hz,2H),7.44(d,J=8.5Hz,2H),7.02(d,J=8 .0Hz,1H),6.33(s,1H),4.91(t,J=7.0Hz,1H),4.42(m,2H),4.14(m,2H),3.01(d,J=12.5 Hz, 2H), 2.24 (s, 3H), 1.76 (t, J = 4.0Hz, 2H), 1.59 (d, J = 8.0Hz, 2H), 1.41 (d, J = 7.0Hz, 3H).

[0848] MS (ESI, [M+H] + )m / z:535.3.

[0849] Example 61: Preparation of (1R,5S)-N-((S)-1-(4-(4-fluoro-1H-pyrazol-1-yl)phenyl)ethyl)-3-(6-((5-methyl-1H-pyrazol-3-yl)amino)-4-(trifluoromethyl)pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide

[0850] Reaction process:

[0851]

[0852] The synthesis method is similar to that of Example 27.

[0853] 1 H NMR (500MHz, DMSO-d6): δ11.80(s,1H),9.16(s,1H),8.62(d,J=4.5Hz,1H),7.79(d,J =4.0Hz,1H),7.71(d,J=8.5Hz,2H),7.45(d,J=8.5Hz,2H),7.06(d,J=8.0Hz,1H),6.8 3(s,1H),6.21(s,1H),6.03(s,1H),4.92(m,1H),4.46(m,2H),3.94(m,2H),3.00(m,2 H), 2.21 (s, 3H), 1.79 (d, J = 4.5Hz, 2H), 1.67 (d, J = 8.0Hz, 2H), 1.41 (d, J = 7.0Hz, 3H).

[0854] MS (ESI, [M+H] + )m / z:584.4.

[0855] Example 62: Preparation of 2-(1-(4-methyl-6-(((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)piperidin-4-yl)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)acetamide

[0856] Reaction process:

[0857]

[0858] The synthesis method is similar to that of Example 15.

[0859] 1 H NMR (500MHz, DMSO-d6): δ11.85(d,J=5.0Hz,1H),9.88(s,1H),9.21(s,1H) ,7.54(d,J=5.0Hz,2H),7.19(d,J=8.5Hz,2H),6.11(s,2H),4.64(m,2H),2. 80(m,2H),2.31(m,5H),2.24(d,J=7.5Hz,3H),2.18(s,3H),2.15(s,3H),2 .10(s,3H),2.02(m,2H),1.70(d,J=11.0Hz,2H),1.35(s,1H),1.14(m,4H).

[0860] MS (ESI, [M+H] + )m / z:518.5.

[0861] Example 63: Preparation of N-(6-(2-cyanopropane-2-yl)pyridin-3-yl)-2-(1-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-ylpiperidin-4-ylacetamide

[0862] Reaction process:

[0863]

[0864] The synthesis method is similar to that of Example 15.

[0865] 1H NMR (500MHz, DMSO-d6): δ11.85(s,1H),10.25(s,1H),9.21(s,1H),8.72(d,J=2.0Hz,1H),8.14(m,1H),7.55(d,J=8.5Hz,1H),6.11(m ,2H),4.65(m,2H),2.80(m,2H),2.30(d,J=7.0Hz,2H),2.19(s,3H),2.11(s,3H),1.99(s,1H),1.72(m,2H),1.68(s,6H),1.17(m,2H).

[0866] MS (ESI, [M+H] + )m / z:474.4.

[0867] Example 64: Preparation of (S)-N-((S)-1-(6-((R)-3-fluoropyrrolidin-1-yl)pyridin-3-yl)ethyl)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-ylpiperazine-1-carboxamide

[0868] Reaction process:

[0869]

[0870] Step A: Preparation of (S)-N-((S)-1-(6-bromopyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide

[0871] 80 mL of anhydrous tetrahydrofuran, 1-(6-bromopyridin-3-yl)ethane-1-one (6 g, 66.7 mmol), R-tert-butylsulfenamide (7.27 g, 60.0 mmol), diethylene glycol dimethyl ether (4.02 g, 30.0 mmol) and tetraethyl titanate (13.68 g, 60.0 mmol) were added to a 250 mL three-necked round-bottom flask in sequence. The reaction system was protected by nitrogen and the reaction solution was heated under reflux for 5 h. The reaction solution was cooled to -78 °C and 1 M lithium tri-sec-butylborohydride tetrahydrofuran solution (90 mL, 90 mmol) was slowly added dropwise under nitrogen protection. The temperature was controlled not to be higher than -70 °C. After the addition was completed, the reaction was continued to stir at -78 °C for 40 min. 40 mL of methanol was added dropwise to quench the reaction. The reaction solution was naturally heated to 0 °C and poured into 500 mL of water and stirred. Filtered and the filter cake was washed with ethyl acetate. The organic phase was separated and the aqueous phase was extracted with ethyl acetate. The organic phases were combined and dried over anhydrous sodium sulfate and concentrated to obtain a yellow solid. 50 mL of a mixed solution of petroleum ether:ethyl acetate = 5:1 was added to the crude product and stirred at room temperature for 2 h, filtered, and the filter cake was washed with petroleum ether to obtain 5.6 g of a white powdery solid.

[0872] Step B: Preparation of (S)-N-((S)-1-(6-((R)-3-fluoropyrrolidin-1-yl)pyridin-3-yl)ethyl)-2-methylpropane-2-sulfenamide

[0873] In a 35mL microwave tube, (R)-N-((S)-1-(6-bromopyridin-3-yl)ethyl)-2-methylpropane-2-sulfinamide (300mg, 0.983mmol), THF (10mL), (R)-3-fluoropyrrolidine hydrochloride (123mg, 0.983mmol), davephos (26mg, 0.066mmol), Pd2(dba)3 (30mg, 0.033mmol), 1M LiHMDS (0.825mL, 0.825mmol) were added in sequence, and the mixture was placed in a microwave reactor under nitrogen protection. The microwave conditions were: 130°C, 30min. After the reaction was complete, 50mL of dichloromethane diluted solution was added to the reaction system, and the reaction solution was washed three times with 20mL of saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography was used to purify the mixture to obtain 0.14g of brown oil.

[0874] MS (ESI, [M+H] + )m / z:314.2.

[0875] Step C: Preparation of (S)-1-(6-((R)-3-fluoropyrrolidin-1-yl)pyridin-3-yl)ethan-1-amine dihydrochloride

[0876] In a 50mL single-mouth bottle, (S)-N-((S)-1-(6-((R)-3-fluoropyrrolidin-1-yl)pyridin-3-yl)ethyl)-2-methylpropane-2-sulfinamide (0.14g, 0.447mmol), methanol (10mL), 1M dilute hydrochloric acid (4mL, 4.02mmol) were added in sequence, and the mixture was stirred at room temperature for 3h. The reaction solution was concentrated under reduced pressure to obtain a brown solid, which was slurried for 2h with 20mL of ethyl acetate, filtered, and the filter cake was collected to obtain 0.07g of a gray solid.

[0877] Step D: Preparation of (S)-N-((S)-1-(6-((R)-3-fluoropyrrolidin-1-yl)pyridin-3-yl)ethyl)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-ylpiperazine-1-carboxamide

[0878] The synthesis method is similar to that of step G in Example 1.

[0879] 1H NMR (500MHz, DMSO-d6): δ11.77(s,1H),8.67(s,1H),8.01(d,J=2.0Hz,1H),7.55(d,J=7.5 Hz,1H),6.71(d,J=8.0Hz,1H),6.50(d,J=9.0Hz,1H),6.32(s,1H),6.01(m,2H),4.79(m,1 H),4.28(t,J=3.0Hz,1H),4.05(m,2H),3.82(m,1H),3.60(m,3H),3.03(m,2H),2.72(m,1H ),2.24(m,2H),2.18(s,3H),2.12(s,3H),1.36(m,3H),1.22(m,2H),1.07(d,J=6.0Hz,3H).

[0880] MS (ESI, [M+H] + )m / z:522.3.

[0881] Example 65: Preparation of (2S)-N-(((1S)-1-(6-(3-azabicyclo[3.1.0]]hex-3-yl)pyridin-3-yl)ethyl)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-ylpiperazine-1-carboxamide

[0882] Reaction process:

[0883]

[0884] The synthesis method is described in Example 64.

[0885] 1 H NMR (500MHz, DMSO-d6): δ11.71(s,1H),8.62(s,1H),7.97(d,J=2.0Hz,1H),7.46(m,1H),6.66 (d,J=8.0Hz,1H),6.40(m,2H),6.01(m,2H),4.76(m,1H),4.27(t,J=3.0Hz,1H),4.06(m,2H), 3.81(m,1H),3.61(m,2H),3.28(d,J=9.0Hz,2H),3.01(m,2H),2.71(m,1H),2.18(s,3H),2.11 (s,3H),1.65(m,2H),1.34(d,J=7.5Hz,3H),1.06(d,J=8.0Hz,3H),0.85(m,1H),0.70(m,1H).

[0886] MS (ESI, [M+H]+ )m / z:516.4.

[0887] Example 66: Preparation of (S)-N-((S)-1-(6-(azetidin-1-yl)pyridin-3-yl)ethyl)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)piperazine-1-carboxamide

[0888] Reaction process:

[0889]

[0890] The synthesis method is described in Example 64.

[0891] 1 H NMR (500MHz, DMSO-d6): δ11.77(d,J=5.0Hz,1H),8.66(s,1H),7.97(d,J=3.0Hz,1H), 7.55(d,J=3.5Hz,1H),6.71(d,J=7.5Hz,1H),6.36(m,2H),6.01(m,2H),4.76(m,1H),4 .28(d,J=3.0Hz,1H),4.05(m,2H),3.91(m,4H),3.81(m,1H),2.96(m,2H),2.72(m,1H) ,2.30(d,J=7.5Hz,2H),2.17(s,3H),2.11(s,3H),1.34(m,3H),1.06(d,J=6.5Hz,3H).

[0892] MS (ESI, [M+H] + )m / z:490.4.

[0893] Example 67: Preparation of (S)-N-((S)-1-(6-((S)-3-fluoropyrrolidin-1-yl)pyridin-3-yl)ethyl)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-ylpiperazine-1-carboxamide

[0894] Reaction process:

[0895]

[0896] The synthesis method is described in Example 64.

[0897] 1H NMR (500MHz, DMSO-d6): δ11.73(s,1H),8.65(s,1H),8.01(s,1H),7.53(d,J=7.5Hz,1H),6 .70(d,J=8.0Hz,1H),6.48(d,J=8.5Hz,1H),6.32(s,1H),6.00(m,2H),4.78(m,1H),4.29( s,1H),4.06(m,2H),3.81(m,1H),3.61(m,3H),3.03(m,2H),2.93(d,J=9.5Hz,1H),2.72(m ,2H),2.18(s,3H),2.12(s,3H),1.36(d,J=7.0Hz,3H),1.23(s,2H),1.07(d,J=6.0Hz,3H).

[0898] MS (ESI, [M+H] + )m / z:522.4.

[0899] Example 68: Preparation of (S)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-4-(6-((5-methyl-1H-pyrazol-3-yl)amino)pyrazin-2-yl)piperazine-1-carboxamide

[0900] Reaction process:

[0901]

[0902] The synthesis method is similar to that of Example 27.

[0903] 1 H NMR (500MHz, DMSO-d6): δ11.83(s,1H),9.19(s,1H),8.66(d,J=4.0Hz,1H),8.41(s,1H),7.89(m,3H),7.78( s,1H),7.55(s,1H),7.01(d,J=7.5Hz,1H),6.11(s,1H),4.93(m,1H),3.48(m,8H),2.51(s,3H),2.20(s,3H).

[0904] MS (ESI, [M+H] + )m / z:492.3.

[0905] Example 69: Preparation of (S)-N-((S)-1-(6-(3-fluoroazetidin-1-yl)pyridin-3-yl)ethyl)-2-methyl-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)piperazine-1-carboxamide

[0906] Reaction process:

[0907]

[0908] The synthesis method is described in Example 64.

[0909] 1 H NMR (500MHz, CDCl3): δ11.66(s,1H),8.63(s,1H),8.04(s,1H),7.54(d,J=8.0Hz,1H),6.72 (d,J=7.5Hz,1H),6.43(d,J=8.5Hz,1H),6.32(s,1H),6.02(s,1H),5.95(s,1H),5.48(m,1H) ,4.79(m,1H),4.23(m,3H),3.75(m,4H),3.81(m,1H),3.08(t,J=11Hz,1H),2.92(d,J=10.5 Hz,1H),2.71(t,J=11Hz,1H),2.18(s,3H),2.12(s,3H),1.36(d,J=6.0Hz,3H),1.07(m,3H).

[0910] MS (ESI, [M+H] + )m / z:508.3.

[0911] Example 70: Preparation of (S)-4-(4-(difluoromethyl)-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethylpiperazine-1-carboxamide

[0912] Reaction process:

[0913]

[0914] Step A: Preparation of 2,6-dichloro-4-(difluoromethyl)pyridine

[0915] In a 50mL three-necked flask, add cuprous chloride (1.301g, 13.14mmol) and potassium tert-butoxide (2.95g, 26.3mmol), under nitrogen protection, add 20mL of anhydrous DMF to the reaction system, stir the reaction system at room temperature for 15min, slowly add (difluoromethyl)trimethylsilane (2.041g, 16.43mmol) to the reaction system, add it in 5min, and continue to stir the reaction system at room temperature for 5min. Dissolve 1,10-phenanthroline (2.369g, 13.14mmol) in 5mL of anhydrous DMF and add it to the above reaction system at once, and continue to stir the reaction system at room temperature for 20min. Dissolve 2,6-dichloro-4-iodopyridine (3g, 10.95mmol) in 15mL of anhydrous DMF and add it to the above system at once, and stir at room temperature overnight. When the reaction is complete, add 20mL of water and 50mL of ethyl acetate to the reaction system, and collect the organic phase. The organic phase was washed three times with 20 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain 1.0 g of a colorless oil.

[0916] Step B: Synthesis of tert-butyl 4-(6-chloro-4-(difluoromethyl)pyridin-2-yl)piperazine-1-carboxylate

[0917] 2,6-dichloro-4-(difluoromethyl)pyridine (0.4 mg, 2.02 mmol), N,N-dimethylformamide (10 mL), N-Boc-piperazine (0.75 g, 4.04 mmol), diisopropylethylamine (0.78 g, 6.06 mmol) were added to a 50 mL single-mouth bottle in sequence, and the mixture was heated to 120 ° C for 4 hours. 30 mL of ethyl acetate and 10 mL of water were added to the reaction solution, and the organic phase was extracted and collected. The organic phase was then washed three times with 10 mL of saturated brine, the organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and purified by column chromatography to obtain 0.4 g of light yellow oil.

[0918] MS (ESI, [M-Boc+H] + )m / z:248.1.

[0919] Step C: Synthesis of tert-butyl 4-(4-(difluoromethyl)-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)piperazine-1-carboxylate

[0920] In a 35mL microwave tube, add tert-butyl 4-(6-chloro-4-(difluoromethyl)pyridin-2-yl)piperazine-1-carboxylate (0.4g, 1.150mmol), tetrahydrofuran (10mL), 5-methyl-1H-pyrazol-3-amine (0.117g, 1.208mmol), 2'-(dicyclohexylphosphino)-N,N-dimethyl-[1,1'-biphenyl]-2-amine (0.045g, 0.115mmol), 1M lithium bis(trimethylsilyl)amide (5.2mL, 5.18mmol), Pd2(dba)3 (0.053g, 0.058mmol). Remove air with nitrogen gas, put into a microwave reactor, heat to 130℃ at 400W for 30 minutes. Add 5mL of 1M saturated ammonium chloride solution dropwise under ice bath to quench the reaction, and dilute with 20mL of ethyl acetate. The organic phase was washed with a saturated sodium chloride aqueous solution and dried over anhydrous sodium sulfate. The organic phase was concentrated and the resulting crude product was purified by column chromatography to obtain 0.18 g of a light yellow oil.

[0921] MS (ESI, [M+H] + )m / z:409.2.

[0922] Step D: Synthesis of trifluoroacetate salt of 4-(difluoromethyl)-N-(5-methyl-1H-pyrazol-3-yl)-6-(piperazin-1-yl)pyridin-2-amine (1:2)

[0923] In a 50 mL round-bottom flask, tert-butyl 4-(4-(difluoromethyl)-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)piperazine-1-carboxylate (0.18 g, 0.441 mmol), dichloromethane (10 mL) and trifluoroacetic acid (0.251 g, 2.203 mmol) were added in sequence and stirred at room temperature overnight. After the reaction was completed, the reaction solution was concentrated to obtain 0.18 g of a brown solid product, which was used for the next step without purification.

[0924] MS (ESI, [M+H] + )m / z:309.1.

[0925] Step E: Synthesis of (S)-4-(4-(difluoromethyl)-6-(((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)-N-(1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethylpiperazine-1-carboxamide

[0926] Dissolve triphosgene (0.053 g, 0.178 mmol) in 5 mL of dichloromethane, cool to 0°C under nitrogen protection in an ice-salt bath, and add dropwise 5 mL of a dichloromethane solution containing (S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethylamine dihydrochloride (0.056 g, 0.198 mmol) and triethylamine (0.17 g, 1.584 mmol). After the reaction solution was stirred at 0°C for 5 min, 4-(difluoromethyl)-N-(5-methyl-1H-pyrazol-3-yl)-6-(piperazin-1-yl)pyridin-2-amine trifluoroacetate (0.1 g, 0.198 mmol) and triethylamine (0.09 g, 0.792 mmol) were added, and stirred at room temperature for 20 min. After the reaction was completed, 50 mL of dichloromethane was added to the reaction solution for dilution, and the mixture was washed with 20 mL of saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated, and the crude product was purified by column chromatography to obtain 47 mg of the target compound as a white powdery solid.

[0927] 1 H NMR (500MHz, DMSO-d6): δ11.76(s,1H),9.02(s,1H),8.67(d,J=3.5Hz,1H),8.42(s,1H),7.88(m,3H),7.02(d,J=6.5Hz,1H), 6.88(m,1H),6.15(d,J=6.5Hz,1H),6.23(s,1H),6.02(s,1H),4.94(m,1H),3.47(m,8H),2.20(s,3H),1.44(d,J=6.5Hz,3H).

[0928] MS (ESI, [M+H] + )m / z:541.2.

[0929] Example 71: Preparation of (1R,5S)-8-(4-(difluoromethyl)-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3,8-diazabicyclo[3.2.1]octane-3-carboxamide

[0930] Reaction process:

[0931]

[0932] The synthesis method refers to Example 70.

[0933] 1H NMR (500MHz, DMSO-d6): δ11.75(s,1H),9.04(s,1H),8.67(d,J=5.0Hz,1H),8.38(s,1H),7.90(m,3H),6.85(m, 3H),6.21(s,1H),6.04(s,1H),4.89(t,J=5.0Hz,1H),4.54(s,2H),3.69(m,2H),3.03(m,2H),2.20(s,3H),1.8 9(s,2H),1.73(m,2H),1.41(d,J=7.0Hz,3H).

[0934] Example 72: Preparation of 2-(4-((6-isopropoxypyridin-3-yl)methyl)piperazin-1-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine

[0935] Reaction process:

[0936]

[0937] In a 100 mL single-mouth bottle, add 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-(piperazine-1-yl)pyrimidine-4-amine trifluoroacetate (500 mg, 1.065 mmol), DCM (20 mL), TEA (431 mg, 0.594 mL, 4.26 mmol), 6-(1-methylethoxy)-3-pyridinecarboxaldehyde (194 mg, 1.172 mmol), sodium triacetoxyborohydride (677 mg, 3.20 mmol) in sequence, and stir at room temperature overnight. Filter, collect the filtrate and concentrate, add 20 mL DCM and 60 mL H2O, shake well, dry over anhydrous sodium sulfate, filter, and concentrate. The crude product is purified by column chromatography to obtain 427 mg of a white solid.

[0938] 1 H NMR (500MHz, DMSO-d6) δ9.57(s,1H),8.22(s,1H),7.84–7.70(m,1H),6.80(d,J=8.5Hz,1H),6.21(d,J=96.4Hz,2H),5.26(p,J=6.2 Hz,1H),4.18(s,2H),3.09(q,J=7.0Hz,4H),2.18(d,J=18.5Hz,6H),1.29(d,J=6.2Hz,6H),1.19(s,1H),1.18(s,2H),1.16(s,1H).

[0939] MS (ESI, [M+H] + )m / z:423.3.

[0940] Example 73: Preparation of (1R,5S)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-3-(6-((5-methyl-1H-pyrazol-3-yl)amino)-4-(trifluoromethyl)pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxamide

[0941] Reaction process:

[0942]

[0943] The synthesis method is similar to that of Example 53.

[0944] 1 H NMR(500MHz,DMSO-d6)δ11.80(s,1H),9.16(s,1H),8.69–8.61(m,1H),8.40(d, J=2.2Hz,1H),7.97–7.84(m,3H),7.13(d,J=7.7Hz,1H),6.82(s,1H),6.20(s,1 H),6.02(s,1H),4.94(p,J=7.1Hz,1H),4.44(d,J=15.3Hz,2H),3.94(d,J=5.9H z,2H),2.97(d,J=12.2Hz,2H),2.19(s,3H),1.44(d,J=7.1Hz,3H),1.23(s,4H).

[0945] MS (ESI, [M+H] + )m / z:585.3.

[0946] Experimental Example 1: Inhibition of the activity of in vitro kinases RET, RET(M918T), RET(Y791F), RET(V804L), RET(V804M), and KDR

[0947] 1.1 RET inhibitory activity screening

[0948] 50 ng / μL RET stock solution was diluted with kinase buffer (50 mM HEPES, 10 mM MgCl2, 2 mM DTT, 1 mM EGTA, 0.01% Tween 20), and 6 μL of 1.67× 0.000334 ng / μL working solution was added to each well (final concentration was 0.0002 ng / μL). Different compounds dissolved in DMSO were added to the wells using a nanoliter pipette to make the final concentration of the compound be 1000 nM-0.24 nM, with a 4-fold gradient and a total of 7 concentrations. At the same time, blank control wells (without enzyme) and negative control wells (with enzyme, with solvent DMSO) were set up, and 2 replicate wells were set up. After the enzyme reacted with the compound or solvent for 30 minutes, 5× 50μM ATP (final concentration of 10μM) and 5× 0.5μM substrate (final concentration of 0.1μM, ULight-poly GT) prepared with kinase buffer were mixed at a ratio of 1:1 and added to each well at a rate of 4μL; after sealing the plate with a sealing film and reacting at room temperature for 2h, 5μL 4× 40mM EDTA (final concentration of 10mM) was added to each well, and incubated at room temperature for 5min, and then 5μL 4× 8nM detection reagent (final concentration of 2nM, Eu-anti-phospho-tyrosine antibody) was added to each well, and incubated at room temperature for 1h; the plate was read using a PE Envision multifunctional microplate reader (excitation 320nm, emission 665nm), and IC was calculated using four-parameter fitting. 50 .

[0949] 1.2 Screening of RET(M918T) inhibitory activity

[0950] 50 ng / μL RET (M918T) stock solution was diluted with kinase buffer (50 mM HEPES, 10 mM MgCl2, 2 mM DTT, 1 mM EGTA, 0.01% Tween 20), and 6 μl of 1.67× 0.000835 ng / μL working solution was added to each well (final concentration was 0.0005 ng / μL). Different compounds dissolved in DMSO were added to the wells using a nanoliter pipette to make the final concentration of the compound 1000 nM-0.24 nM, with a 4-fold gradient and a total of 7 concentrations. At the same time, blank control wells (without enzyme) and negative control wells (with enzyme, with solvent DMSO) were set up, and 2 replicate wells were set up. After the enzyme reacted with the compound or solvent for 30 minutes, 5× 50μM ATP (final concentration of 10μM) and 5× 0.5μM substrate (final concentration of 0.1μM, ULight-poly GT) prepared with kinase buffer were mixed at a ratio of 1:1 and added to each well at a rate of 4μL; after sealing the plate with a sealing film and reacting at room temperature for 2h, 5μL 4× 40mM EDTA (final concentration of 10mM) was added to each well, and incubated at room temperature for 5min, and then 5μL 4× 8nM detection reagent (final concentration of 2nM, Eu-anti-phospho-tyrosine antibody) was added to each well, and incubated at room temperature for 1h; the plate was read using a PE Envision multifunctional microplate reader (excitation 320nm, emission 665nm), and IC was calculated using four-parameter fitting. 50 .

[0951] 1.3 RET(Y791F) inhibitory activity screening

[0952] 50 ng / μL RET (Y791F) stock solution was diluted with kinase buffer (50 mM HEPES, 10 mM MgCl2, 2 mM DTT, 1 mM EGTA, 0.01% Tween 20), and 6 μL of 1.67× 0.000835 ng / μL working solution was added to each well (final concentration was 0.0005 ng / μL). Different compounds dissolved in DMSO were added to the wells using a nanoliter pipette to make the final concentration of the compound 1000 nM-0.24 nM, with a 4-fold gradient and a total of 7 concentrations. At the same time, blank control wells (without enzyme) and negative control wells (with enzyme, with solvent DMSO) were set up, and 2 replicate wells were set up. After the enzyme reacted with the compound or solvent for 30 minutes, 5× 50μM ATP (final concentration of 10μM) and 5× 0.5μM substrate (final concentration of 0.1μM, ULight-poly GT) prepared with kinase buffer were mixed at a ratio of 1:1 and added to each well at a rate of 4μL; after sealing the plate with a sealing film and reacting at room temperature for 2h, 5μL 4× 40mM EDTA (final concentration of 10mM) was added to each well, and incubated at room temperature for 5min, and then 5μL 4× 8nM detection reagent (final concentration of 2nM, Eu-anti-phospho-tyrosine antibody) was added to each well, and incubated at room temperature for 1h; the plate was read using a PE Envision multifunctional microplate reader (excitation 320nm, emission 665nm), and IC was calculated using four-parameter fitting. 50 .

[0953] 1.4 RET(V804L) inhibitory activity screening

[0954] 50 ng / μL RET (V804L) stock solution was diluted with kinase buffer (50 mM HEPES, 10 mM MgCl2, 2 mM DTT, 1 mM EGTA, 0.01% Tween 20), and 6 μL of 1.67× 0.000334 ng / μL working solution was added to each well (final concentration was 0.0002 ng / μL). Different compounds dissolved in DMSO were added to the wells using a nanoliter pipette to make the final concentration of the compound be 1000 nM-0.24 nM, with a 4-fold gradient and a total of 7 concentrations. At the same time, blank control wells (without enzyme) and negative control wells (with enzyme, with solvent DMSO) were set up, and 2 replicate wells were set up. After the enzyme reacted with the compound or solvent for 30 minutes, 5× 50μM ATP (final concentration of 10μM) and 5× 0.5μM substrate (final concentration of 0.1μM, ULight-poly GT) prepared with kinase buffer were mixed at a ratio of 1:1 and added to each well at a rate of 4μL; after sealing the plate with a sealing film and reacting at room temperature for 2h, 5μL 4× 40mM EDTA (final concentration of 10mM) was added to each well, and incubated at room temperature for 5min, and then 5μL 4× 8nM detection reagent (final concentration of 2nM, Eu-anti-phospho-tyrosine antibody) was added to each well, and incubated at room temperature for 1h; the plate was read using a PE Envision multifunctional microplate reader (excitation 320nm, emission 665nm), and IC was calculated using four-parameter fitting. 50 .

[0955] 1.5 Screening of RET(V804M) inhibitory activity

[0956] 50 ng / μL RET (V804M) stock solution was diluted with kinase buffer (50 mM HEPES, 10 mM MgCl2, 2 mM DTT, 1 mM EGTA, 0.01% Tween 20), and 6 μL of 1.67× 0.0835 ng / μL working solution was added to each well (final concentration was 0.05 ng / μL). Different compounds dissolved in DMSO were added to the wells using a nanoliter pipette to make the final concentration of the compound 1000 nM-0.24 nM, with a 4-fold gradient and a total of 7 concentrations. At the same time, blank control wells (without enzyme) and negative control wells (with enzyme, with solvent DMSO) were set up, and 2 replicate wells were set up. After the enzyme reacted with the compound or solvent for 30 minutes, 5× 50μM ATP (final concentration of 10μM) and 5× 0.5μM substrate (final concentration of 0.1μM, ULight-poly GT) prepared with kinase buffer were mixed at a ratio of 1:1 and added to each well at a rate of 4μL; after sealing the plate with a sealing film and reacting at room temperature for 2h, 5μL 4× 40mM EDTA (final concentration of 10mM) was added to each well, and incubated at room temperature for 5min, and then 5μL 4× 8nM detection reagent (final concentration of 2nM, Eu-anti-phospho-tyrosine antibody) was added to each well, and incubated at room temperature for 1h; the plate was read using a PE Envision multifunctional microplate reader (excitation 320nm, emission 665nm), and IC was calculated using four-parameter fitting. 50 .

[0957] 1.5 KDR inhibitory activity screening

[0958] 50 ng / μL of KDR stock solution was diluted with kinase buffer (50 mM HEPES, 10 mM MgCl2, 2 mM DTT, 1 mM EGTA, 0.01% Tween 20), and 6 μL of 1.67× 0.1336 ng / μL working solution was added to each well (final concentration was 0.08 ng / μL). Different compounds dissolved in DMSO were added to the wells using a nanoliter pipette to make the final concentration of the compound 1000 nM-0.24 nM, 4-fold gradient, a total of 7 concentrations. At the same time, blank control wells (without enzyme) and negative control wells (with enzyme, solvent DMSO) were set up, and 2 replicate wells were set up. After the enzyme reacted with the compound or solvent for 30 minutes, 5× 25μM ATP (final concentration of 5μM) and 5× 0.5μM substrate (final concentration of 0.1μM, ULight-poly GT) prepared with kinase buffer were mixed at a ratio of 1:1 and added to each well at a rate of 4μL; after sealing the plate with a sealing film and reacting at room temperature for 2h, 5μL 4× 40mM EDTA (final concentration of 10mM) was added to each well, and incubated at room temperature for 5min, and then 5μL 4× 8nM detection reagent (final concentration of 2nM, Eu-anti-phospho-tyrosine antibody) was added to each well, and incubated at room temperature for 1h; the plate was read using a PE Envision multifunctional microplate reader (excitation 320nm, emission 665nm), and IC was calculated using four-parameter fitting. 50 .

[0959] 1.6 The activity results of in vitro kinases RET, RET(M918T), RET(Y791F), RET(V804L), RET(V804M), and KDR are shown in Table 1.

[0960] Table 1

[0961]

[0962]

[0963] “--” means not detected.

Claims

1. A compound represented by formula (I), its stereoisomers and pharmaceutically acceptable salts thereof, in, X is selected from NH; U is CH, V is N, and W is N; or, U is CH, V is CH, and W is N; Q is selected from C(R 2 ); Selected from Ring B is a pyridine ring; -L 1 - is selected from single bonds; Ring AL 2 - Ring B is selected from the ring AC(O)-NH-CH(CH 3 )-Ring B or Ring AC(S)-NH-CH(CH 3 )-Ring B; R 2 and R 5 Each independently selected from H or C 1-4 Alkyl; the C 1-4 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino; R 3 Selected from C 1-4 Alkyl, the C 1-4 The alkyl group may be optionally substituted with one, two or three substituents selected from halogen, hydroxy, cyano or amino; R 4 is selected from pyrazolyl, wherein the pyrazolyl is substituted by one, two or three substituents selected from halogen, hydroxyl, amino, cyano, COOH, nitro; n is 0 or 1; p is 1; And formula (I) is not:

2. The compound of formula (I) according to claim 1, its stereoisomers and pharmaceutically acceptable salts thereof, in, R 2 is selected from H, methyl, ethyl, isopropyl or tert-butyl, said methyl, ethyl, isopropyl or tert-butyl being optionally substituted with one, two or three substituents selected from halogen.

3. The compound of formula (I) according to claim 1, its stereoisomers and pharmaceutically acceptable salts thereof, in, R 2 is selected from H, methyl, difluoromethyl or trifluoromethyl.

4. The compound of formula (I) according to claim 1, its stereoisomers and pharmaceutically acceptable salts thereof, in, R 3 Independently selected from methyl, ethyl, isopropyl or tert-butyl.

5. The compound of formula (I) according to claim 1, its stereoisomers and pharmaceutically acceptable salts thereof, in, R 3 Selected from methyl.

6. The compound of formula (I) according to claim 1, its stereoisomers and pharmaceutically acceptable salts thereof, in, Ring AL 2 - Ring B is selected from the ring AC(O)-NH-CH(CH 3 )-Ring B.

7. The compound of formula (I) according to claim 1, its stereoisomers and pharmaceutically acceptable salts thereof, in, Ring B is 8. The compound of formula (I) according to claim 1, its stereoisomers and pharmaceutically acceptable salts thereof, in, for 9. The compound of formula (I) according to claim 1, its stereoisomers and pharmaceutically acceptable salts thereof, in, R 5 Selected from H.

10. The compound of formula (I) according to claim 1, its stereoisomers and pharmaceutically acceptable salts thereof, in, R 4 Selected from 11. The compound of formula (I) according to claim 1, its stereoisomers and pharmaceutically acceptable salts thereof, in, n is 0.

12. The compound of formula (I) according to claim 1 has a structure shown in formula (IV-a), in, R 3 , R 4 , R 5 , Ring A, Ring B, n, and p are as defined in claim 1.

13. The following compounds, their stereoisomers and pharmaceutically acceptable salts thereof:

14. A pharmaceutical composition comprising the compound according to any one of claims 1 to 13, its stereoisomers and pharmaceutically acceptable salts thereof.

15. Use of the compound according to any one of claims 1 to 13, its stereoisomers and pharmaceutically acceptable salts thereof, or the pharmaceutical composition according to claim 14 in the preparation of a medicament for preventing or treating a disease mediated by abnormal RET activity.